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Nystagmus is a disorder of eye movement characterised by irregular, uncontrolled and 
repetitive eye movements. It can occur in a broad spectrum of clinical situations and 
diseases or it may occur in isolation and an inherited disorder. Surprisingly little is 
known about the underlying mechanisms of ocular-motor control. Similarly, the 
pathophysiological mechanisms underpinning nystagmus is also poorly understood. By 
studying pedigrees in whom nystagmus seems to be inherited as an isolated trait 
(Congenital Idiopathic Nystagmus), it may be possible to identify some of the genetic 
causes of this disorder and subsequently understand the pathophysiology.  
This thesis describes a molecular genetic study of congenital nystagmus. A clinical 
phenotyping study is followed by linkage analysis and positional cloning. A novel 
nystagmus gene is investigated in a large cohort of Congenital Idiopathic Nystagmus 
(CIN) patients and X-inactivation studies are performed. Subsequently, cell culture and 
RT-PCR work is performed to study expression of this gene. Additionally a pedigree with 
an atypical congenital nystagmus disorder is investigated and a new mutation within a 
known cerebellar disease gene is identified. 
This work contributed to the identification of the first gene for Congenital Idiopathic 
Nystagmus (CIN). The first detailed temporal expression study of the FRMD7 nystagmus 
gene was also performed in this study which has directed further studies into the 
pathogenesis of CIN. Identification of a new mutation in the CACNA1A gene in a 
pedigree with nystagmus and subtle cerebellar signs has lead to the consideration of 
this gene in patients who present to hospital with isolated atypical nystagmus.  
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1 CHAPTER ONE – Introduction
1.1 The unique X chromosome
1.1.1Introduction
The X chromosome holds a unique place in the history of medical genetics. 
Identification of X-linked diseases is enhanced by the relative ease of recognizing this 
mode of inheritance. Furthermore, a disproportionately large number of disease 
conditions have been associated with the X chromosome because of the phenotypic 
consequence of a recessive mutation which is revealed directly in males. This occurs 
because all males are constitutionally hemizygous for any gene that has no active 
counterpart on the Y chromosome. Thus, although the X chromosome contains only 4% 
of all human genes, almost 10% of diseases with a mendelian pattern of inheritance 
have been assigned to the X chromosome (307 out of 3,199; information obtained from 
the OMIM2TM  repository (Online Mendelian Inheritance in Man). These aspects of the 
medical genetics of the X chromosome have greatly stimulated progress in the 
positional cloning of many genes associated with human disease. 
Identifying genes involved in rare conditions yields important biological insights. 
For example, discovery of mutations in the SH2D1A gene
1 (involved in X-linked 
lymphoproliferative disease (XLP, OMIM 308240)) led to identification of a new 
mediator of signal transduction between T and NK cells, and a novel family of proteins 
involved in the regulation of the immune response. Discovering the genes for these and 
other rare, monogenic disorders is of critical value in extending our understanding of 
fundamental new processes in human biology, and the annotated X chromosome will 
further facilitate this process
2.
1.1.2X-inactivation
One of two X chromosomes is randomly inactivated in each cell early in female 
embryonic development
3, so that it becomes transcriptionally inactive and thereby 
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equalizes the dosage of X-linked genes between males and females. Each daughter cell 
then inactivates the same X chromosome as its parent such that cells are clonally 
expanded with a particular X chromosome inactivated. After this period, techniques able 
to distinguish between the two X chromosomes can be used to track the fate of the 
two different cellular populations. Initially, distinction was achieved using polymorphic 
enzyme variants
4, but, more recently, the fact that placental mammals methylate the 
inactive X chromosome and certain restriction enzymes selectively cut the 
unmethylated allele, has allowed more widespread application
5. In particular, the 
human androgen receptor locus has been found to be useful due to its high degree of 
heterozygosity (about 90%) 
6. Interestingly, many tumours, including leukaemias, 
myelodysplasia, and myeloproliferative disorders, have been shown in this way to 
express only one X chromosome, implying derivation from a single cell
7-10. 
The process of X-inactivation is complex and poorly understood. In humans the 
process involves methylation and modification of the chromatin structure of the 
inactivated X chromosome resulting in a condensed, hyper-chromatinized structure 
called the Barr body. This process occurs before the gastrula stage of embryonic 
development and probably at the late blastula stage when cells are differentiating from 
pluripotent and totipotent lineages
11. The process is thought to be controlled by 2 
important genes and their regulatory elements: the X inactive specific transcript gene 
(XIST) and its antisense partner, the X-inactivation-Specific Transcript-Antisense gene 
(TSIX)
12-15. These genes are located within a region of the X chromosome called the X-
inactivation centre (XIC/Xic). It is believed that the two X chromosomes within a cell 
physically interact (observed using fluorescence in situ hybridization (FISH)) at which 
time the XIC from each chromosome are in direct contact. Following this, the TSIX mRNA 
levels on the chromosome to be inactivated, rapidly plummet for unknown reasons. This 
reduction in TSIX causes alterations in the chromatin structure of the DNA at the XIC 
region resulting in a closed, hetero-chromatinized structure. Paradoxically, this causes 
the XIST gene in this region to increase expression and XIST mRNA then coats the X 
chromosome to be inactivated, rendering it inactive. TSIX also interacts with a molecule 
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that attaches methyl groups to the XIST promoter, which inactivates it. This possibly 
represents a secondary mechanism for ensuring the XIST gene is inactivated on the 
active X chromosome. The X-inactivation that ensues is believed to be random as to 
whether the maternal or paternal X is inactivated. X-inactivation ratios in tissues then 
follow a binomial distribution. This phenomenon has been used to explain the 
observation of manifesting female carriers of X-linked recessive diseases due to variable 
degrees of silencing the X chromosome harbouring the disease gene. However, some 
tissues have been shown to exhibit skewed X-inactivation such that its constituent cells 
tend to show inactivation of one or other X chromosomes to a greater degree than 
would be expected by chance. Again this phenomenon has been used to explain 
manifesting female carriers of X-linked recessive diseases where females have a 
phenotype which is equally as severe as affected males suggesting near total silencing of 
the ‘normal’ X chromosome. Mechanisms underlying skewed X-inactivation have been 
proposed and comprise both stochastic and non-stochastic processes. Firstly, a 
"selective advantage" of one X chromosome over the other is a well-described 
phenomenon in the extreme case where one X chromosome is known to carry a disease 
gene and appears to be selected against
16;17. That this mechanism can operate in the 
absence of an obviously deleterious phenotype has also been shown in cats, where the 
X chromosome of the Geoffroy cat has a selective advantage over that of the domestic 
cat
18. Secondly, because it is believed that stem cell division may stochastically result in 
zero, 1, or 2 daughter stem cells, certain stem cells may become overrepresented or 
correspondingly underrepresented by chance
19-21. Thirdly, expansion of a clone derived 
from a single stem cell or stem cell precursor may occur with a proliferate advantage 
(cell selection)
21;22 and therefore by overrepresented. Fourthly, mutations or 
polymorphisms affecting the control of X-inactivation such as those occurring at the X-
inactivation centre or the X inactive specific transcript gene may skew inactivation ratios 
16;23. All of these proposed mechanisms lead to a somewhat confusing picture. 
To prove definitively that X-inactivation is responsible for an observed 
phenotype would be difficult and would require some knowledge of how a phenotype is 
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caused (including which cell population or tissue is responsible), whether the abnormal 
phenotype causes cell selection and what the tolerance to abnormal gene product levels 
are. Similarly, it would be necessary to show that the tissue sampled, is indeed 
responsible for the phenotype. This is because of the observation that although in 
normal females X-inactivation ratios are often similar between tissues
24, for certain X-
linked conditions complete skewing may be restricted to specific cell lineages and 
different patterns of X-inactivation are seen in all other tissues
25. Furthermore, 
approximately 15% of X-linked genes escape X-inactivation to some degree, and this 
proportion of genes differs dramatically between different regions of the X 
chromosome
26;27 reflecting the evolutionary history of the sex chromosomes. An 
additional 10% of X-linked genes show variable patterns of inactivation and are 
expressed to different extents from some inactive X chromosomes
27. 
Therefore, the degree of X-linked gene expression heterogeneity among females 
is great and complex. Methods of assessing X-inactivation and its contribution to 
phenotype are therefore accompanied by an array of important caveats.
1.2 Eye movements
Eye movements have evolved to subserve the specific visual requirements of 
particular organisms. For example, afoveate animals such as the rabbit (who lack a 
fovea; an area of the retina with the best visual discriminatory function) need eye 
movements primarily to stabilize the eyes in space during head movement. To this end, 
two distinct mechanisms evolved to stabilize images on the retina during such head 
perturbations. The first comprises the Vestibulo-Ocular Reflexes (VOR), which depend 
on the ability of the labyrinthine mechanoreceptors to sense head accelerations. The 
second consists of visually mediated reflexes (Optokinetic and Smooth-pursuit tracking), 
which depend on the ability of the brain to determine the speed of image drift on the 
retina. Together, these reflexes stabilize the angle of gaze and eyes remain pointed at 
the object of regard whenever the head is moving
28. 
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With the development of the fovea it became necessary to change the line of 
sight independently of head movements. Eye movement subsystems evolved both to 
bring eccentric targets onto the fovea (foveation) and keep it there
28. Saccades are fast 
foveating eye movements that bring the object of interest onto the fovea. This function 
was described elegantly as early as the late nineteenth century by the American 
Ophthalmologist William James who said; 
“The peripheral retina is like a Sentinel and when an object of regard falls upon 
it, it shouts ‘hark, who goes there’ and calls the fovea to the spot.”
29 
However, it is also necessary to hold even stationary objects on the fovea and for 
this purpose a gaze-holding system evolved which constantly holds the object of regard 
on the fovea and prevents the gaze from drifting off target.
With the evolution of frontal vision and binocularity came a requirement to place 
an object of interest on the fovea of both eyes simultaneously. Vergence movements 
are binocular movements which achieve this aim by moving the eyes simultaneously in 
opposite directions such as adduction of one eye and abduction of the other.
Therefore, it can be seen that for foveate primates such as humans, the ocular 
motor system consists of several subsystems that generate different types of eye 
movements in response to different stimuli
30.
Mr Jay Self 2008  Page 18 of 220Chapter One - Literature review
1.3 Nystagmus
‘Never write about nystagmus, it will lead you nowhere’. (Wilbrand 1921
31)
1.3.1Introduction
Nystagmus is a disorder of eye movement which can be defined as “a repetitive, 
to-and-fro movement of the eyes that is initiated by slow phases”
30. 
The word nystagmus is derived from a Greek word ‘nustagmos’ meaning nodding 
of the head or drowsiness. The word is thought to have evolved due to a comparison 
with slow downward drift and sudden upward jerk of the head during drowsiness
32.
In humans, there are three main control mechanisms for maintaining steady 
gaze; the fixation movements, the vestibulo-ocular reflex; and the gaze-holding 
system
30. Failure of any of these control systems will bring about a disruption of steady 
fixation. Two types of abnormal fixation can result; nystagmus and saccadic 
intrusions/oscillations. The difference between them lies in the initial movement that 
takes the line of sight away from the object of regard. The initial anomalous movement 
in saccadic intrusions/oscillations is a fast saccadic movement. In the case of nystagmus, 
it is a slow drift or ‘slow phase’ away from the target
30 such that the corrective saccade 
(quick phase) is a normal compensatory movement. It has been suggested that that 
nystagmus results from an anomaly within the gaze-holding pathways or the tissues 
comprising the brainstem mechanism that generates the tonic innervation needed to 
maintain lateral gaze (neural integrator) 
30;33;34.
1.3.2Early descriptions
One of the first known descriptions of nystagmus is that found in case 99, picture 
855 of the Ebers Papyri (c. 1500 BC)
35;36.  These are a collection of medical papyri 
comprising 250 pictures and 887 paragraphs depicting and describing medical scenes. It 
has been suggested that these may be copies of even earlier work by Imhotep the vizier, 
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physician, architect and high priest of Heliopolis in the 3rd dynasty of ancient Egypt. In 
either case, these probably represent the first recorded descriptions of nystagmoid eye 
movements and may date back to as early as c.2800 BC.  
1.3.3Significance
Many different forms of nystagmus exist and it occurs in a wide variety of 
pathological and non-pathological situations. For example it occurs as a normal finding 
on extreme eccentric gaze (end-point nystagmus) or when viewing passing objects from 
a moving train (opto-kinetic nystagmus). Conversely, very similar eye movements may 
herald the onset of significant neurological disease or represent the earliest neurological 
sign in an infant with a devastating visual or neurological condition
37. Little is understood 
about which tissues malfunction to cause nystagmus or indeed which tissues 
communicate to allow eye movement control in healthy subjects
38. Consequently, with 
such complexity and ambiguity surrounding the significance of its presence, physicians 
have attempted to understand nystagmus by classification since its earliest descriptions.
1.3.4Classification of Nystagmus
Nystagmus forms part of a larger group of eye movement disorders called 
fixation instabilities. It differs from other fixation instabilities such as Saccadic intrusions 
and Saccadic oscillations as it is thought to arise primarily from an abnormality in the 
slow pursuit eye movement system or the system which holds eccentric gaze rather 
than being a disorder of the saccades
30.
Over 40 different named types of nystagmus are described and the 
nomenclature is exceptionally inconsistent, with some types being identified by an 
eponym (for example, Bruns’ nystagmus), by behaviour (gaze-evoked nystagmus), by 
direction (downbeat nystagmus) or by age of onset (early onset nystagmus)
39. It is likely 
that this has arisen due to a number of factors including a lack of knowledge of; its 
aetiology, its underlying anatomical basis, the significance of minute features of the 
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specific phenotype, the ever increasing number of clinical situations in which it forms a 
part and the fact that nystagmus is relatively common. Consequently, many complex 
classifications and descriptions have arisen all of which were designed for, and are 
therefore biased in favour of, a specific use. 
1.3.4.1 Ophthalmologists classification of nystagmus in 
infancy
Nystagmus before six months of age can be defined as early onset nystagmus
37. 
It may be divided into three categories: sensory defect nystagmus (SDN) in which there 
is a proven sensory impairment, congenital idiopathic nystagmus (CIN) also known as 
“motor nystagmus” in which no visual or neurological impairment can be found and 
neurological nystagmus (NN) which is associated with neurological disease
37. The 
sensory type occurs as a result of aberrant visual stimulation and most commonly with 
recognisable genetic ocular diseases such as albinism, X-linked congenital stationary 
night blindness and Leber congenital amaurosis
37. In the case of CIN, visual acuity may 
be decreased by the decreased foveation time but is usually well preserved. It is 
presumed that this form of nystagmus represents a primary defect in the parts of the 
brain responsible for ocular motor control although as yet its pathophysiological 
aetiology is unknown
37. 
This classification system for nystagmus is often used in conjunction with other 
methods such as description by phenotype.
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Figure 1 Classification of Early Onset Nystagmus (EON) by Casteels et al
1.3.4.2 Classifying nystagmus by phenotype:
Classifying Nystagmus by its detailed clinical features is complex and few 
features are pathognomic of any particular underlying aetiology. However, some 
features can be indicative of specific aetiologies when used in conjunction with other 
clinical information. 
1.3.4.2.1 Slow - phase characteristics
The broadest classification of nystagmus by phenotype is into either jerk or 
pendular waveform. Jerk nystagmus refers to an abnormal slow movement followed by 
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a corresponding fast movement in the opposite direction. Pendular nystagmus refers to 
a slow movement followed by a similar slow movement in the opposite direction. Jerk 
nystagmus can be further subdivided by the morphology of the slow phases into 
accelerating, linear or decelerating slow phase
37 
Figure 2 Basic Nystagmus waveforms. 
* adapted from Abadi et al 2002.
A schematic illustration of nystagmus waveforms. (A) pendular nystagmus, (B) an accelerating 
velocity exponential slow phase jerk nystagmus (CIN), (C) a decelerating exponential slow phase 
jerk nystagmus (MLN), (D) a linear or constant velocity slow phase jerk nystagmus (MLN). In (A) a 
slow phase is followed by a slow phase while in (B)–(D) a slow phase is followed by a fast phase.
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1.3.4.2.1.1 Accelerating slow phase
Typically, infants with CIN are thought to have waveforms with characteristic 
features including uni-planar jerk nystagmus with accelerating slow phases
37. Indeed 
Jerk nystagmus with accelerating slow phases when horizontal, has been described as 
pathognomic for CIN
37 (although it has also been seen in the vertical plane in downbeat 
nystagmus associated with an Arnold-Chiari malformation). However, there is increasing 
evidence that jerk nystagmus with accelerating slow phases does not distinguish CIN 
from SDN
37. Eye movement recordings have revealed at least 12 distinct waveforms 
associated with SDN and CIN
37 consisting of variants of pendular, jerk and mixed types, 
with no correlation between waveform and aetiology
37;40;41 and even affected 
monozygotic twins can have different waveforms
42;43. Acquired accelerating slow phase 
jerk nystagmus, caused by a cerebellar lesion in an adult has also been described
44.
1.3.4.2.1.2 Linear and decelerating slow phase
Jerk nystagmus with a linear slow phases has been reported in CIN, SDN and 
NN
40;45. Jerk nystagmus with decelerating slow phases is usually associated with latent 
nystagmus or NN but sometimes CIN or SDN
37. It is most often seen when the neural 
integrator is defective and thereby allows the eyes to drift back towards the primary 
position
39. Because this form of nystagmus, when acquired, occurs in lateral gaze 
positions that bring out the inadequacy of the integrator mechanism, such nystagmus is 
often known as gaze-evoked nystagmus. It is rarely the predominant waveform in CIN 
but may be seen in instances of damage to the cerebellum
37; it also arises when gaze 
maintenance is affected by drugs, such as alcohol
46;47. 
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1.3.4.2.1.3 Pendular waveform
If nystagmus is always pendular, clinical context is crucial in determining whether 
such an oscillation is acquired or congenital, although eye movement recordings may be 
useful in many cases. For example a pendular congenital nystagmus often contains small 
saccades that arrest the eyes at one side of the oscillation
37 or becomes jerk nystagmus 
in extreme gaze
39. However, in most cases and when eye movement recordings are not 
possible, pendular nystagmus with no quick phase is not diagnostically useful as it can 




Nystagmus waveform can also be broadly classified by direction into horizontal, 
vertical, cyclorotational (torsional/circular) or a mixture of any of these types e.g 
oblique. Other patterns exist including ‘Gaze evoked nystagmus’ but are not included 
here.
1.3.4.2.1.5 Differences between CIN and SDN nystagmus direction
Although vertical, oblique and rotational congenital nystagmus have been 
reported, the great majority of CIN patients have a mainly horizontal nystagmus, albeit 
sometimes with a minor torsional component
37. Patients with SDN however, are more 
likely to have complex and multidirectional nystagmus and more often have a torsional 
component
37. One of the striking features of typical CIN is that this horizontal oscillation 
often remains horizontal, even in vertical or oblique directions of gaze
37. 
1.3.4.2.1.6 Vertical nystagmus
Vertical nystagmus may be present as part of gaze evoked nystagmus in which 
the nystagmus direction varies with the position of gaze and does not remain vertical
30.  
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Up beating nystagmus has been reported in association with Wernicke's 
encephalopathy, multiple sclerosis, brainstem infarction and other lesions. It is thought 
to be caused by lesions of the medulla, the ventral tegmentum, the anterior vermis of 
the cerebellum, and the adjacent brachium conjunctivum and midbrain. It is also found 
in smokers as a side effect of nicotine, and as a side effect of other medications
49;50.
Down beating nystagmus is classically attributed to the Chiari malformation. 
Numerous large studies have been published, largely concluding that while the Chiari 
malformation may contribute as many as 1/3 of cases, cerebellar degenerations, 
demyelinating disease, drug toxicity, neoplasia, and "idiopathic" are other common 
causes
30.
Early onset vertical nystagmus is often associated with toxic causes
37, intracranial 
space-occupying lesions or demyelinating disorders
51, though it can sometimes be 
idiopathic
52 or associated with familial vestibulo-cerebellar disorders
53.
1.3.4.2.1.7 See-saw nystagmus
See-saw nystagmus (SSN) is a very characteristic eye movement comprising 
intorsion and elevation of one eye, with synchronous extorsion and depression of the 
other
54. If the underlying waveform is pendular this is described as classical SSN but if it 
is jerk, in which case the slow phase corresponds to one half-cycle, this is described as 
hemi-seesaw nystagmus
54. Acquired SSN most often occurs with parasellar or chiasmal 
mass lesions
55-57. However, a seesaw component has been reported in association with a 
variety of disorders
58-60 some of which present as forms of congenital nystagmus
55;61;62. 
Interestingly, SSN has also been reported with visual loss due to cone-rod 
dystrophy
63 and a patient who progressively lost vision due to retinitis pigmentosa
64.
One theory suggests that the two variants of seesaw nystagmus probably arise 
from either imbalance or miscalibration of vestibular responses that normally function 
to optimize gaze during head rotations in roll
30. However, Dell’Osso et al recently found 
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sub-clinical SSN embedded in 46.67% of patients with apparent typical horizontal 
congenital nystagmus waveforms and hypothesized that in this case SSN is due to slight 
innervational (or force) imbalances of the vertical and oblique extraocular muscles
65. 
Therefore, it seems likely that even SSN may results from differing aetiologies.
1.3.4.2.1.8 Periodic Alternating Nystagmus
Acquired periodic alternating nystagmus (PAN) is a spontaneous horizontal 
nystagmus, present in primary gaze, that reverses direction approximately every 2 
minutes
30. It has been reported in association with a number of conditions, many of 
which involve the cerebellum
66;67. It may also occur in a congenital form
68. In some CIN 
patients, the nystagmus periodically reverses direction, but this reversal seldom occurs 
in the regular manner seen in PAN
40;69.
1.3.4.2.1.9 Nystagmus amplitude 
Amplitude measurements have little value in either diagnosis or classification of 
nystagmus
70 although one study suggests that in rod monochromacy, horizontal 
nystagmus in primary gaze often has pendular and jerk waveforms with much lower 
amplitude than patients with other SDN
71.
1.3.4.2.1.10 Null position
Another important diagnostic feature of CIN is the presence in the majority of 
patients of a null position of gaze
39. This describes a particular position of the eyes 
within the orbit in which the nystagmus slow-phase velocity is at a minimum. Many 
patients with EON but few with acquired nystagmus develop the presence of a null 
position
39;70 so its presence can direct diagnosis and classification. Null positions are also 
important for management, as treatment options for congenital nystagmus without null 
positions are currently limited
72.
1.3.4.2.1.11 Visual effort
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Congenital nystagmus is often said to intensify with visual effort or near viewing. 
Most patients can recall instances in which a visual task was necessary but not possible 
due to worsening of their nystagmus. However, most do not report this phenomenon 
during clinical examination and it is possible that a combination of psychological factors 
influence either the nystagmus intensity, or the patient’s perception of it
39. Interestingly, 
there has been little published research in this area although one study designed to 
quantify how increased visual demand affects the severity of CN concluded that there 
was no relationship between the two
73. This may suggest that either the reported 
decreased visual function in times of high demand in CN patients is purely a subjective 
phenomenon or perhaps more likely, the visual tasks asked of CN patients in clinic do 
not accurately model ‘real life tasks’
39. However, in a different study 44% of CN patients 
demonstrated a decrease in nystagmus intensity during near fixation (1/3 metre) 
compared with distance fixation (6 metres)
70. Results from such studies are therefore 
variable.
1.3.4.2.1.12 Oscillopsia
In healthy subjects, perceptual stability is maintained only as long as retinal 
image motion is less than approximately 4°/s
74;75. In CN, despite slow phases that may 
exceed 100°/s, oscillopsia is rarely perceived
76. Conversely, oscillopsia is a common 
complaint of subjects with acquired types of nystagmus despite the similarly moving 
retinal images
77.
On careful questioning, many CIN patients describe particular specific short 
episodes of oscillopsia. Some studies have found that greater than 40% of CIN cases 
have experienced episodes of oscillopsia and that many of these instances are 
associated with exacerbations of the nystagmus by fatigue, illness, stress or looking in 
their ‘non-preferred’ gaze direction
78.
The mechanism of oscillopsia suppression is not fully understood and 
explanations have included: reduced sensitivity to retinal image motion, adaptation to 
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retinal image motion, information sampled only when the eyes are moving relatively 
slowly during the foveation periods and the use of extraretinal information (efference 
copy) to cancel the effects of eye movements
79.
1.3.4.2.1.13 Manifest-Latent vs Congenital Nystagmus characteristics
Early onset nystagmus is often grouped into either congenital nystagmus (CN) 
type or manifest-latent nystagmus (MLN) type
39. This classification is based on a group 
of clinical features including slow phase velocity and nystagmus direction under certain 
viewing conditions. The CN type is classically found in CIN whereas the MLN type is 
thought to be more commonly seen in SDN. MLN is also closely associated with the 
presence of strabismus and dissociated vertical divergence
80. In either case the 
anomalous eye movements are typically conjugate, horizontal, and jerk. Differential 
diagnosis is made on the basis that the CN slow phases are typically of an increasing 
exponential velocity form, whereas in MLN the slow phase is decelerating or linear. 
Additionally, for monocular viewing,  the fast phase of MLN always beats toward the 
viewing eye which is not the case for CN
80;81. A third, but less common, type is pure 
latent nystagmus (LN)
81. In this type, during binocular viewing conditions, the eyes are 
steady, but during monocular viewing, bilateral conjugate jerk nystagmus becomes 
manifest. As for MLN, the LN slow phase is either a decreasing or linear velocity, with 
the fast phase directed toward the viewing eye
81. 
One large study of MLN concluded that MLN and LN should be grouped together 
as a continuum called Latent Manifest Latent Nystagmus (LMLN) and then subdivided 
into 4 types based on the ocular movements seen during binocular viewing: Type 1; 
ocular stability (formally LN), Type 2; square-wave jerks, Type 3; Torsional nystagmus 
and Type 4; typical MLN waveform. In this study 94.6% of subjects exhibited a single 
constant MLN subtype throughout all recording sessions 
82. 
However, the distinction between LMLN and CN is not always clear. For example 
CN in addition to MLN may show a directional change with occlusion. In CN, this has 
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been termed a ‘latent shift’ or a ‘latent component’
83. Furthermore, LMLN and CN may 
also coexist in a single patient
80.
1.3.4.3 Classification of nystagmus by clinical frequency
Practical clinical classifications are often based on clinical frequency in addition 
to other criteria such as nystagmus waveform and inheritance pattern. It has been 
suggested that classifying nystagmus by using a single criterion is unhelpful in the clinical 
setting as it puts the cart before the horse
84. 
1.3.4.4 Summary of Nystagmus classification and 
nomenclature 
As detailed above, common classification systems for nystagmus employ either 
one, or a combination of the following features:




· Clinical frequency 
Consequently, classification systems often serve a specific function. For example, 
a Paediatric Ophthalmologist may use a classification and protocol in the clinical setting 
whose primary purpose is to identify those paediatric patients who have features 
suspicious of serious underlying disease (see Figure 1)
37 . Conversely, a clinical geneticist 
will use a system predominantly in order to describe the underlying mode of inheritance 
within a congenital nystagmus pedigree. 
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In 2001 the National Eye Institute sponsored a workshop by the Committee for 
the Classification of Eye Movement Abnormalities and Strabismus (CEMAS). The remit 
was to produce a new classification system for eye movement anomalies including 
nystagmus which was based on up-to-date clinical and scientific information and 
designed to be used as a resource for scientists, clinicians and educators
85. However, as 
can be expected from an ‘all encompassing’ classification system its overview is neat but 
for specific uses it falls short for both clinical and research applications. For example the 
diagnosis of ‘Infantile Nystagmus Syndrome’ under the CEMAS classification would 
comprise a multitude of aetiologies and pathologies and if using this classification 
strictly, different members of the same nystagmus pedigree may have different 
‘diagnoses’. It seems likely that until the pathophysiological basis of eye movement 
disorders is fully understood, classification systems and nomenclature will necessarily 
vary between professionals with differing priorities. 
In Figure 3, I suggest a classification system for fixation instabilities which is an 
amalgam of other systems and geared towards the interests of a clinical 
Ophthalmologist / Geneticist. This classification system has been used for the work 
presented in this thesis and in publications arising from it.
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Figure 3 A suggested classification system for fixation instabilities
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1.3.5Pathophysiological mechanisms of nystagmus
The pathogenesis of CIN remains poorly understood, and whether it represents a 
primary defect in the visual sensory system, or the ocular motor system is unknown. 
Some insights have arisen from patients with specific neurological injury’s
86-92 and have 
allowed some interpretation as to structures and possible pathways involved in ocular 
motor stability. Several proposed mechanisms underlying CIN have been suggested but 
are currently out of favour, these include: the presence of a leaky neural integrator
93, 
misdirection of the retinogeniculate or subcortical visual pathway
94, and albino-like 
abnormal chiasmatic decussation of the optic axons
95. CIN is currently thought by many 
to represent a primary disorder of some part of the oculomotor pathways, in particular 
the gaze-holding pathway 
93. Another recent theory has suggested that CIN represents a 
developmental adaptive response by the gaze-holding pathway to an early sensory 
anomaly
96. There is also some support for microscopically anomalous, incompletely 
developed, or dysmorphic extra-ocular muscle (EOM) ultrastructure in CIN. Findings 
have described abnormal proprioceptors, muscle fibres, sensory nerve endings and even 
vascular endothelial cells
97-100. However, there is no strong evidence that these changes 
are primary rather than secondary to nystagmus. 
It is hoped that identification of the responsible genes and characterisation of 
their expression should provide insights into the pathophysiology of this disorder and 
the normal functioning of the ocular motor system
101.
1.3.6Congenital Idiopathic Nystagmus
CIN as described by Casteels et al
37 is defined as nystagmus occurring before the 
age of six months and with no identifiable underlying visual or neurological disorder. 
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1.3.6.1 Inheritance 
Prevalence rates for CIN of 1:1000 to 1:1500 have been reported 
102;103. It is 
genetically heterogeneous as autosomal dominant (MIM 164100), autosomal recessive 
(MIM 257400) and X-linked (MIM 31700) patterns of inheritance have been reported. It 
has been suggested that X-linked inheritance with incomplete penetrance is the most 
common form
104. It is important to note that the different inheritance patterns cannot 
be distinguished clinically by visual acuity or waveform characteristics. 
1.3.6.1.1.1 Autosomal Dominant CIN
One form of autosomal dominant CIN has been mapped to an 18 cM region on 
chromosome 6p12. The causative gene was mapped to an 18 cM region between 
D6S271 and D6S455 by haplotype analysis
105. However, other autosomal dominant CIN 
genes also exist, e.g. in a German family with autosomal dominant CIN, exclusion of the 
6p12 locus and suggestive linkage to 7p11 has been demonstrated
106. Interestingly, the 
7p11 locus (or possibly a locus on chromosome 15) was has also been implicated when 
CIN was found to co-segregate with a balanced (7;15t(7;15)(p11.2;q11.2)) translocation 
in another family with autosomal dominant CIN
107. Studies of patients with deletions of 
18q have shown that within this group, individuals with nystagmus shared deletions 
between markers D18S812 (68.4 Mb) at 18q22.3 and D18S1141 (75.0 Mb) at 18q23. This 
suggests that the expression of at least one gene occurring at this site is also important 
for oculomotor control and the prevention of nystagmus
108. In a paper by Oetting in 
2000, all three presumed autosomal dominant CIN pedigrees showed negative linkage 
to the 6p12 locus with Z=−3.82, θ = 0.0 
109. In 2004, Hoffman et al. excluded the 6p12, 
15q11 and 7p11 loci in a German pedigree
110. 
Together these papers suggest at least three distinct loci for autosomal 
dominant CIN.
1.3.6.1.1.2 Autosomal recessive CIN
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No loci have currently been identified for autosomal recessive CIN genes 
although pedigrees consistent with this mode of inheritance have been described
104.
1.3.6.1.1.3 X-linked CIN
In 1999, two X-linked CIN loci were reported, demonstrating that X-linked CIN  is 
also genetically heterogeneous with a locus for X-linked irregularly dominant CIN 
reported by Kerrison et al. at Xq26-q27
104 in three families and a family with X-linked 
dominant CIN by Cabot et al. at Xp11.4 –p11.3
104. These loci were shown to be distinct 
when the family reported by Cabot was subsequently excluded by linkage analysis from 
the Xq26-27 locus (MIM entry 310700). The critical gene interval for these two loci were 
18.6 cM on Xp11.4 –p11.3 and 7 cM on Xq26-q27. Subsequently, the Xq26-q27 critical 
gene interval was narrowed to 5.4 cM in an additional Iowa family
104, and then reduced 
further by Kerrison et al to 5 cM
101. In January 2005 an interval within this region was 
narrowed to 4.4 cM in 22 members of a Chinese family with X-linked CIN. Two genes 
within this region were screened for mutations (SLC9A6 and FGF13) but no mutations 
were detected
104. In 2000 Oetting et al described 5 pedigrees with CIN, two with 
apparent X-linked inheritance and three with male–male transmission suggesting 
autosomal dominant inheritance
104. One of the X-linked families demonstrated 
suggestive linkage to the Xp11.4 –p11.3 locus with Z=2.08, θ = 0.0. The other X-linked 
family showed no linkage to either of the previously described loci. In October 2005 Guo 
et al described the first genetic locus for X-linked recessive CIN by linkage analysis of 
two Chinese pedigrees. These families (a total of 25 subjects) inherit CIN as an apparent 
X-linked recessive trait with full penetrance. No other ocular disease was identified and 
no affected females were observed in either family. However, VEP recordings and 
detailed eye movement recordings were not performed. The disease mapped to Xq23–
q27, between markers DXS8055 and DXS1205 with a highest LOD score of 3.53 for the 
marker DXS1047. This interval includes the locus described by Kerrison et al for X-linked 
dominant CIN which raises the possibility that X-linked recessive CIN and X-linked 
dominant CIN may be caused by the same gene with different mutations as has been 
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112). However, linkage to the same region does not rule out the possibility that 
the disease may result from mutations in different genes at the same gross 
chromosomal location.
In X-linked CIN pedigrees, penetrance among female obligate carriers has been 
variable. Values have ranged from 30 to 100%
101;113-115.Reasons for this may include 
skewed X-inactivation, interactions with other genes, and other non-genetic 
developmental influences on oculomotor development. 
In summary, for X-linked CIN, two loci have been identified, at least one other 
locus is thought to exist and no genes have currently been identified. 
1.3.6.1.1.4 Limitations of previous X-linked CIN linkage work
Several X-linked disorders have been associated with nystagmus, including 
Nettleship-Falls ocular albinism (Mendelian inheritance Man (MIM) # 300500), complete 
congenital stationary night blindness (MIM # 310500) and blue cone monochromatism 
(MIM # 303700). Therefore, as for any ‘diagnosis of exclusion’ it is important to exclude 
these other disorders by clinical examination
37;83;84;101, electroretinography 
(ERG)
37;37;101;101;116-118 and preferably visual evoked potentials (VEP)
37;119;120 before making a 
diagnosis of X-linked CIN. However, as has been previously noted
101, much of the 
previous linkage work on X-linked CIN has not included VEP
101;104;121-125 or even ERG
124 to 
exclude masquerading conditions.  This is important because just one of the genetic 
intervals (Xq26-27) includes genes for; congenital stationary night blindness, retinitis 
pigmentosa, Norrie disease protein, cone dystrophy, exudative vitreoretinopathy, Aland 
island eye disease and X-linked optic atrophy. Therefore, nystagmus in pedigrees 
phenotyped without detailed electrophysiology may, in fact be allelic with one of these 
disorders 
101. Furthermore, even when exhaustive investigations have been completed it 
seems likely that the underlying causation may vary such that ‘CIN’ describes a group of 
patients with differing underlying pathophysiologys. Therefore, combining multiple 
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families with apparent CIN may include more than one genetic cause and disrupt linkage 
results.
Subtle eye movement abnormalities have been detected among relatives of CIN 
patients
126;127 and it is also known that nystagmus waveform and phenotype may vary 
significantly, not only within pedigrees but even between monozygotic twins with 
CIN
42;128. Therefore, in order to avoid significant assignment errors in linkage projects of 
CIN it has been suggested that detailed eye movement recordings are performed on 
family members in order to identify subtle nystagmus which might otherwise go 
unseen
101. However, much of the linkage work of CIN has not included anything more for 
phenotyping than a gross pen-torch examination
101;104;122;124;125. Furthermore, Zhang et al 
(2005) published linkage results based on the assumption that nystagmus in their 
subject pedigree was a truly X-linked dominant trait with 100% penetrance. The results 
relied on data from 2 apparently unaffected females for whom it was presumed the 
disease gene had not been inherited. However, this would represent a very unusual 
inheritance pattern for X-linked CIN and it was done without detailed eye movement 
recordings. The results were then combined with Kerrison’s (2001) linkage data
101 which 
clearly demonstrated at least 6 females who necessarily carried the gene but do not 
have nystagmus.
Linkage work in CIN has been varied in its use of statistical analysis. LOD scores
129 
(log base 10 of the likelihood ratio under the hypotheses of linkage and non-linkage) are 
used as a statistical measure of how likely it is that a disease causing sequence change 
resides within a particular genetic interval. However, a number of factors including; the 
threshold value for proof of linkage, the method of calculation, and statistical packages 
used to create LOD scores have varied significantly between X-linked CIN linkage 
work
130.
Interestingly, there is a discrepancy between the marker order used in the 
original Kerrison (1999) paper
131 and the latest marker mapping data (UCSE website) 
possibly due to a contig inversion in the earlier data. This means that the original paper 
and the subsequent refinement papers will have used incorrect marker locations for 
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haplotype reconstruction. Therefore, it is possible that the boundaries of the Xq26 
interval described by these papers exclude the true nystagmus causing mutation. 
In September 2005, following a meeting organised by the Nystagmus Network 
(http://www.nystagmusnet.org/) I was invited to write a review of CIN genetics by the 
Journal ‘Seminars in Ophthalmology’. This paper included all the current linkage work in 
CIN, the limitations of previous work and suggestions for the design of future studies. It 
was published in April 2006
132.
1.3.6.2 Congenital Idiopathic Nystagmus Treatments
An important feature of CIN is the presence in the majority of patients of a null 
position of gaze; a position in which the nystagmus is least intense and vision is greatest. 
Even very young children may adopt this to improve their vision. Many simple therapies 
are intended to shift this null position as close to the primary position as possible, not 
only to increase acuity but also because nulls in eccentric gaze may lead to the 
development of another feature of CIN; abnormal head posture. The elimination or 
amelioration of head postures is important not only for cosmetic reasons but also to 
eliminate the possibility of later orthopaedic problems arising from long-term abnormal 
contracture of the neck muscles
39. The presence of a null is also important because it 
may lead to disparities between visual acuity measurements
39. For this reason, gaze-
dependent visual acuity tests, both with and without time restriction have been 
suggested as the most useful measure of visual function in patients with CN
133.
Simple treatment strategies for both head position and head tilts/turns include; 
positioning of children in the classroom or  prism spectacles to accommodate for their 
null position
39. Additionally, vision therapy to improve binocular vision may also play a 
role for some patients with MLN type nystagmus, as restoration of binocularity has been 
shown to convert MLN to LN in some cases
134.
Null position surgery was first described in 1960
135, and since then more than 20 
surgical procedures have been advocated for nystagmus, most of which employ 
Mr Jay Self 2008  Page 38 of 220Chapter One - Literature review
repositioning of the null, large recessions of all four horizontal rectus muscles, tenotomy 
of these same muscles or combinations of several of these proceedures
39;136;137. 
However, it has been proposed that with so many suggested techniques, the likelihood 
of multiple operations and the variability of outcome, it seems sensible to reserve 
surgery for specific patients with particularly troubling symptoms such as oscillopsia 
(very rare in CIN)
138. Currently, the majority of patients with nystagmus do not have a 
surgical treatment except perhaps correction of secondary squints.
Although several types of acquired nystagmus have been found to respond to 
various medical treatments
139;139-142 reports of drug-related reductions in CIN are often 
variable and in some cases possibly reflect the effects of sedation rather than a specific 
improvement in the oscillation itself
39. While a large number of drugs have been used 
with mixed success for specific forms of nystagmus (usually acquired types), many 
patients fail to respond or develop intolerable side effects such as sedation or ataxia
141-
144. However, in recent years some success has been made with Gabapentin (synthetic 
GABA with unclear action) 
145, Memantine (NMDA glutamate receptor blocker)
145 and 
the potassium channel blocker 4-Aminopyridine
146. These drugs have been shown to 
reduce nystagmus waveforms and increase foveation times with some corresponding 
effects on acuity. However, effects are limited and are seen in only some patients. 
Currently, no drugs are in routine use for CIN. 
Contact lenses have been recommended over spectacles in congenital 
nystagmus for many years because they have been reported to reduce the nystagmus, 
in addition to providing refractive correction
147-152. A possible mechanism for this is 
provision of tactile feedback to the ocular motor system
39. A similar approach has been 
adopted with the use of auditory biofeedback
72;153;154 with limited experimental success. 
Other suggested treatment modalities have included acupuncture
155 and injection of 
botulinum toxin into the oculomotor muscles
156;157.
In January 2008, a case report was published in which a patient with CIN had 
detailed eye movement recordings at 2 separate appointments, one after taking 10mg 
of cannabis and one after having no cannabis for 3 weeks. This patients eye movement 
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recordings showed a significant reduction in nystagmus intensity and a corresponding 
increase in visual acuity after taking cannabis
158. This is in accord with anecdotal reports 
from 2 of my CIN patients. This effect has yet to be evaluated in a clinical trial setting.
Currently, most patients with nystagmus and especially those with CIN have no 
specific treatment of any sort. 
1.3.6.3 New CIN work published during the course of this 
project
Following publication of my linkage work on the Xq26-q27 interval (Chapter 3), in 
November 2006 Tarpey et al identified 22 nystagmus causing mutations in the FERM 
domain-containing 7 (FRMD7) gene which resides within this refined interval
159. 16 X-
linked families underwent linkage analysis and 15 of these pedigrees had causative 
FRMD7 mutations. 42 simplex cases were screened for mutations in this gene and 
yielded 3 mutations (7%). Therefore, the overall contribution of FRMD7 mutations to 
the cause of both X-linked and singleton cases remained relatively unexplored.
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2 CHAPTER TWO - Methods
2.1 Standard Laboratory techniques
This section details the standard laboratory techniques used throughout this 
work.
2.1.1DNA and RNA collection
DNA and RNA can be collected by a variety of techniques depending on a 
number of factors including; the source of DNA/RNA required, the age of the patient 
and the amount of DNA/RNA required. 4 methods were used for this project. These 
protocols require some pre-made reagents which are listed below:
Proteinase K
Received as powder (Sigma-Aldrich, Dorset, UK)




4.9 mls 0.5M EDTA, pH 8
Make up to 100 mls with sterile dH2O
TE Buffer
1 ml 1M Tris HCL pH 8
200 µl 0.5 M EDTA pH 8
Make up to 100 mls with sterile dH2O, then autoclave
10% SDS
10g SDS
Make up to 100 mls with sterile dH2O
6M NaCL 
35 g NaCL
Make up to 100 mls with sterile dH2O
0.5% TBE buffer
500 mls 10% TBE buffer
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215 µL Bromophenol Blue
215 µL Xylenecyanine
2.1.1.1 DNA collection using ORAGENE
TM Vial format Saliva 
collection kits  
2.1.1.1.1.1 Sample collection
ORAGENE Vial Format
TM (DNA Genotek Inc. Ontario, Canada, 
www.dnagenotek.com) saliva sampling kits were used for DNA collection. Samples were 
collected by patients according to the manufacturer’s protocol (see Figure 4). Samples 
were then either frozen immediately or sent by post before freezing.
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Instructions for using the ORAGENE DNA saliva kit
The plastic tub has a small pot in it with a lid. The idea is to:
1. Not eat or drink for 30 minutes 
2. Undo the white lid and produce saliva (not flem) into the pot. 
3. It can be filled over 30 minutes or so, you need to see 2cm’s worth of liquid spit. 
4. Close the white lid again firmly and you will feel the seal at the bottom break. 
5. Invert the pot a few times. 
6. Please label with your name, date of birth and the date you made the sample. 
You must read the information sheet and sign the consent form
Then post back to me in the envelope provided (with the consent form)!  The samples 
can last a year at room temperature so there is no rush to send them off.
Thanks again for your help
Dr. Jay Self                               Tel: (0)23 8079 4590                         Email: Jes3@soton.ac.uk
Figure 4 Instructions for using the ORAGENE DNA saliva kit
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2.1.1.1.1.2 DNA collection from sample
The samples were incubated at 50°C in a water incubator overnight. The sample 
was then transferred to a 15 mL centrifuge tube and the volume of sample noted. 
1/25th of the sample volume of Oragene Purifier was added and mixed for a few 
seconds. The sample was then incubated on ice for 10 minutes. It was centrifuged at 
room temperature for 10 minutes at 2800 rpm. The clear supernatant was transferred 
with a pipette to a fresh 15 mL centrifuge tube and the pellet discarded. An equal 
volume of room temperature 95% ethanol was added to the supernatant and mixed by 
inversion. The sample was left to stand at room temperature for 10 minutes. The 
sample was then centrifuged at room temperature for 10 minutes at 2800 rpm. The 
supernatant was then poured away, as much of the alcohol was removed as possible 
and the tube left on the bench with the lid off for 30 minutes. Once dry, the DNA pellet 
was dissolved in 500 µL TE buffer, vortexed and left overnight to dissolve. The sample 
was then vortexed again and frozen when the pellet had dissolved.
2.1.1.2 DNA collection using ORAGENE
TM Saliva Sponge 
format collection kits  
2.1.1.2.1.1 Sample collection
ORAGENE Saliva Sponge format kits
TM (DNA Genotek Inc. Ontario, Canada, 
www.dnagenotek.com) were used for DNA collection from children too young to 
produce sputum via the ORAGENE Vial method. Samples were collected by parents 
according to the manufacturer’s protocol (see Figure 5). Samples were then either 
frozen immediately or sent by post before freezing.
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Instructions for using the DNA sponge collection kit for children
You must read the information sheet and sign the consent form
Then post back to me in the envelope provided (with the consent form)!  The samples 
can last a year at room temperature so there is no rush to send them off.
Thanks again for your help
Dr. Jay Self                               Tel: (0)23 8079 4590                         Email: Jes3@soton.ac.uk
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Figure 5 Instructions for using the DNA sponge collection kit for children
2.1.1.2.1.2 DNA collection from sample
The sample pot was incubated at 50°C in a water incubator overnight. The free 
liquid was transferred to a 15 ml conical tube. The barrel of a 5 ml syringe (without 
plunger) was then put in the same 15 ml tube. The sponges were transferred to the 
barrel of the syringe using forceps. The 15 ml tube containing the syringe barrel with 
sponges was centrifuged for 10 minutes at 1000rpm at 20°C. The syringe barrel and dry 
sponges were then discarded. The final volume in the 15 ml tube was noted. 1/25th of 
the sample volume of ORAGENE Purifier was added and mixed for a few seconds. The 
sample was then incubated on ice for 10 minutes. It was then centrifuged at room 
temperature for 10 minutes at 2800 rpm. The clear supernatant was transferred with a 
pipette to a fresh 15 mL centrifuge tube and the pellet discarded. An equal volume of 
room temperature 95% ethanol was added to the supernatant and mixed by inversion. 
The sample was then left to stand at room temperature for 10 minutes and 
subsequently centrifuged at room temperature for 10 minutes at 2800 rpm. The 
supernatant was then discarded, as much of the alcohol removed as possible and the 
tube left on the bench with the lid off for 30 minutes. The DNA pellet was dissolved in 
500 µL TE buffer, vortexed and left overnight to dissolve. The sample was then vortexed 
again and frozen when the pellet has dissolved.
2.1.1.3 DNA collection using mouth brushes
2.1.1.3.1.1 Sample collection
Plain sterile mouth brushes were used for DNA collection from children too 
young to produce sputum via the ORAGENE Vial method or the ORAGENE
TM Saliva 
Sponge format. Samples were collected by parents according to a protocol in use in our 
department (see Figure 6). Samples were then either frozen immediately or sent by post 
before freezing.
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Instructions for Mouth-brush DNA collection
In this pack contains 3 small sterile mouth brushes. The idea is to:
7. Collect the sample when you child has not eaten or drunk for 30 minutes. 
8. Undo the black lid on one tube and gently rub the brush inside the left 
cheek for 10 seconds. 
9. Re-sheath the tube and close the black lid again firmly.
10.Do the same with the right cheek and then a further time on the left cheek 
again with the further 2 brushes. 
11.  Please label with your child’s name, date of birth and the date you made 
the sample. 
You must read the information sheet and sign the consent form
Then post back to me in the envelope provided (with the consent form)!  The 
samples can last a year at room temperature so there is no rush to send them 
off.
Thanks again for your help
Dr. Jay Self                               Tel: (0)23 8079 4590                         Email: Jes3@soton.ac.uk
Figure 6 Instructions for using the Mouth-brush DNA collection method
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2.1.1.3.1.2 DNA collection from sample
The first brush was snapped off at 1cm length and put into a 1.5 ml centrifuge 
tube. 500 µL of re-suspension buffer was added. This tube was vortexed vigorously for 
10 seconds. The second brush was then snapped off into another 1.5 ml centrifuge tube 
and the process repeated. The cell suspensions were then combined in one of the 1.5 ml 
tubes and both the brushes were placed in the second tube. This tube (with the 2 
brushes) was then vortexed again, then centrifuged for 10 seconds at 1000 rpm. Any 
more liberated cell suspension was combined with the bulk of the sample so that all the 
collection was now in one of the 1.5 ml centrifuge tubes. 3 µl of proteinase K and 10 µl 
of 10% SDS were added to the cell suspension. The sample was vortexed and incubated 
at 37°C overnight, or until clear. The sample was allowed to return to room temperature 
and 166 µl 6M NaCL was added and the sample vortexed. The sample was then 
centrifuged for 10 minutes at 9000 rpm. The supernatant was removed into a fresh 1.5 
ml tube and 2x the volume of 100% ethanol was added. The sample was incubated at 
-20°C overnight. Subsequently, it was centrifuged at 9000 rpm for 10 minutes and the 
supernatant is carefully discarded using a pipette. 150 µl 70% ethanol was added and 
the sample was centrifuged for 10 minutes at 9000 rpm. The supernatant was carefully 
removed and discarded and the tube left on the lab bench for 30 minutes to dry the 
pellet. 50 µl of TE buffer was added and the sample gently vortexed. The sample was 
then left at room temperature and gently inverted occasionally for 12 hours before 
storing at -20°C.
2.1.1.4 DNA collection from blood 
2.1.1.4.1.1 Sample collection
10 ml blood samples were collected from patients by standard techniques in 10 
ml (K3E 15%) tubes. These were frozen within 12 hours of sampling.
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2.1.1.4.1.2 DNA collection from sample
Blood samples were defrosted and mixed for at least 1 hr on a rotary mixer in a 
cold room. In a 50 ml conical tube: at least 30 ml of cold Erythrocyte Lysis Buffer (ELB) 
was added to 10 ml blood sample, mixed and placed on ice for 15 minutes, mixing gently 
on the shaker. It was then centrifuged at 1500rpm for 10 minutes at 4°C. The 
supernatant was then poured into Virkon. Another 30 ml of cold ELB was added, mixed 
and placed on ice for 15 minutes, mixing gently on a shaker. The sample was then 
centrifuged at 1500rpm for 10 minutes at 4°C. The supernatant was poured off and a 
final 30 ml of cold ELB was added, mixed and placed on ice for 15 minutes, mixing gently 
on the shaker. The tubes were then centrifuged at 1500rpm for 10 minutes at 4°C. The 
supernatant was poured off and then keeping the tube upright, the excess supernatant 
was removed by blotting the tube on tissue. 1 ml of Nuclear Lysis Buffer (NLB) was 
added to all tubes and then each pellet was poured into a fresh 15 ml conical tube. 250 
µl 10% SDS was added and 150 µl 40mg/ml Protease to each of the tubes. The tubes 
were mixed and incubated at 37°C overnight in a shaker incubator.
The following day, 1 ml of saturated NaCl solution was added; the tubes were 
then shaken vigorously for 15 seconds, and centrifuged at 4000rpm for 20minutes at 
room temperature. As much as possible (3-4 ml) of the supernatant was removed and 
placed into fresh 15 ml tubes. If the last ml of supernatant was not clear, it was 
transferred it to a 1.5 ml eppendorf tube, labelled and spun in the micro-centrifuge at 
14,000rpm for 5 minutes. This was poured into the corresponding 15 ml tube. Using a 5 
ml pipette, exactly twice the volume of cold Absolute Ethanol was added and the tube 
gently inverted until the DNA precipitated out and formed a fluffy pellet. 1 ml of 70% 
Ethanol was added to labelled 1.5 ml centrifuge tubes. The sticky pellet was removed 
using a pipette tip on a 200 µl pipette and placed into the corresponding centrifuge 
tube. The tubes were pulse spun in micro-centrifuge, the ethanol poured off, the end of 
the tube blotted and the tube left open for 15 minutes on the bench to allow the DNA to 
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nearly dry. 500 µl of TE Buffer was then added and the DNA was allowed to dissolve 
overnight at room temperature and then transferred to the freezer.
2.1.2DNA quantification and quality measurement
For most laboratory techniques requiring DNA, the quality and concentration of 
the sample is imperative to success of the experiment. DNA quantification during this 
work was initially acheived by the Picogreen method but in 2006 the method of choice 
became the Spectrophotometer method because of the additional benefit of assessing 
DNA purity.
2.1.2.1 Picogreen DNA quantification
DNA samples were defrosted if necessary and gently mixed. 50 µl of TE Buffer 
was added to each well of a flat bottom welled reaction plate with 2 µl of DNA sample 
or standards (we used 5 µl of undiluted Picogreen reagent for every 1 ml of water in the 
Picogreen mix). 50 µl of Picogreen mix was added to each well and incubated for 15 
minutes in a dark room. Then the plate was scanned on a fluorescence imager and 
results are standardised according to serial dilutions of a DNA sample with a known 
concentration. This method is no longer in use in our laboratory and all samples have 
been reanalysed by spectrophotometer.
2.1.2.2 Spectrophotometer DNA quantification and quality 
assessment
The NanoDrop® ND-1000 Spectrophotometer (Wilmington, USA) was used 
according to the manufacturer’s protocol and allowed an accurate and immediate 
measurement of DNA concentration and a simultaneous assessment of the DNA purity. 
Before starting the software module, the sample surfaces were cleaned with dH2O to 
remove any dried sample that might be present. The Nanodrop program was opened 
and the appropriate module chosen (e.g., Nucleic acids - DNA). 1.5 μL of dH2O was 
pipetted onto the sensor and the lever arm was brought down. The onscreen prompts 
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were then followed to complete calibration. The sensors were wiped and 1.5 μL of the 
corresponding blank (TE buffer or dH2O depending on what the DNA sample is dissolved 
in) was pipetted onto the sensor. The level arm was brought down and the onscreen 
prompts are followed to complete a blank measurement. The sensor was wiped and 
1.5μL of the DNA sample pipetted onto the sensor. The lever arm was brought down 
and the ‘Measure’ button selected. For DNA samples, the peak of the results curve 
should be at a wavelength of 260 nm, and as a quality measure, the 260/280 ratio 
should be between 1.8 and 2.0. If poor quality was seen (i.e. low 260/280 ratio) the 
sample was cleaned using the Qiagen purification Kit (Qiagen Ltd, UK) following the 
manufacturer’s protocol, and then reanalysed.
Figure 7 A high quality DNA sample measured on the NanoDrop® ND-1000 
Spectrophotometer
To test multiple samples, the sensor was wiped in-between measurements with 
a clean tissue. Results were then exported as a CSV file into the CAS-1200™ robot (see 
section 2.1.2.2) for semi automated standard dilutions.
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2.1.3 The Polymerase Chain Reaction
2.1.3.1 Introduction
The Polymerase chain reaction (PCR) is a technique which is used to amplify the 
number of copies of a defined target segment of DNA from a heterogeneous DNA 
source (genomic or cDNA population), in order to produce enough DNA to be 
adequately tested. Initially described in the 1980's
160 it has now become an 
indispensable technique in molecular genetics. The reaction requires the presence of a 
buffered solution containing DNA polymerase with the cofactor MgCl2, the four 
deoxynucleotide building blocks of DNA precursors (the deoxynucleoside triphosphates 
dATP, dCTP, dGTP and dTTP), selected oligonucleotide primers and the DNA source. The 
PCR mixture proceeds through replication cycles consisting of three temperature states:
1. 30 seconds at 94-96 degrees C, during which the DNA is denatured into  single 
strands.
2.  1 minute 50-65 degrees C, during which the primers hybridize or "anneal" 
(by way of hydrogen bonds) to their complementary sequences on either 
side of the target sequence.
3. One minute at 72 degrees C, during which the polymerase binds and extends 
a complementary DNA strand from each primer. 
As amplification proceeds, the DNA sequence between the primers doubles after 
each cycle. Following thirty such cycles, a theoretical amplification factor of one billion is 
attained. A typical 35 cycle experiment theoretically produces a 2
34 amplification of the 
original desired sequence (plus an insignificant 35 copies of products with variable 3' 
ends). In practice this means that one can start with nanogram amounts of DNA and 
following PCR have a sufficient quantity to visualise the desired product by a convenient 
means such as agarose gel electrophoresis. 
Two important innovations were responsible for automating PCR. First, a heat-
stable DNA polymerase was isolated from the bacterium Thermus Aquaticus, which 
inhabits hot springs. This enzyme, called the Taq polymerase, remains active despite 
repeated heating during many cycles of amplification. Secondly, DNA thermal cyclers 
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were invented that use a computer to control the repetitive temperature changes 
required for PCR. In this work the Tetrad® thermal cycler (GRI, Essex, UK) was used for 
PCR reactions.
Many variations of PCR techniques exist for specific applications. In this work the 
following PCR methods were used; a standard PCR technique, Long PCR, Nested primer 
PCR, High Resolution Melt application PCR and real-time quantitative PCR.  The first 3 
methods are described below and the latter 2 are detailed elsewhere.
2.1.3.2 Standard PCR protocol
A standard template of PCR amplification conditions (used for the majority of 
applications in this work for products <800 base pairs) are as follows:
10 µl PCR reaction mix:
Genomic DNA 1 µl of 10ng/ul
ddH2O 7.6 μl
F primer 0.2 µl of 20 µM
R primer 0.2 µl of 20 µM
MgCl2 0.4 µl 
nTPs 0.4 µl of 20 µM 
Taq polymerase 0.04 µl of 500 µ/ µL 
Thermo-cycling conditions:
Denaturation  94°C (3 min)
Denaturation         94°C (1 min)
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Annealing 52 – 62°C (depending on primers) (1 min) 
Extension 72°C (1 min)
Steps 2-4 are repeated 30-35 times before step 5
Final extension 72°C (10 min)
For most applications the primers are optimised for the MgCl2 concentration and 
annealing temperature. This is achieved by varying the MgCl2 concentration from 1, 1.5 
and 2 µM per reaction and running at a range of PCR annealing temperatures from -8°C 
to +8°C around the predicted Tm. 
2.1.3.3 Long PCR
Small fragments of DNA can usually be amplified easily by a standard PCR 
protocol, however it becomes increasingly difficult to obtain efficient amplification as 
the desired product length increases.  This target length limitation to PCR amplification 
of DNA has long been recognised
161 which has lead to the development of various ‘Long 
PCR’ protocols which  allow the effective amplification of long DNA targets up to 
approximately 20 kb in length
162. In this work PCR amplification of products >800 bp was 
achieved, when necessary, by a ‘Long PCR’ protocol previously described by our 
group
163. In short, the method involves the use of an additional DNA polymerase which 
is extracted from Pyrococcus woesii, called Pwo polymerase. This polymerase has a 
lower error rate than Taq polymerase (approximately 1 in 10,000 bases) and is therefore 
called a ‘high fidelity’ DNA polymerase. This is achieved due to its 3'->5' exonuclease 
activity allowing it to proof read and correct mistakes in newly-synthesized DNA. When 
an incorrect base pair is recognized, the DNA polymerase reverses its direction by one 
base pair of DNA. The 3'->5' exonuclease activity of the enzyme allows the incorrect 
base pair to be excised. Following base excision, the polymerase can re-insert the 
correct base and replication can continue. This allows the production of long DNA 
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strands of high fidelity which are necessary for sequencing large DNA fragments. Pwo 
polymerase has a lower copy rate than Taq polymerase but has greater thermal stability 
with a half life of 2 hours at 100°C compared with 5 minutes for Taq. Therefore, the 
combination of both DNA polymerases combines the benefits of both which creates 
higher yields of product and allows amplification of longer templates than it is possible 
with single DNA polymerase
164;165. 
For the long PCR protocol used in this work the 20 µl reaction comprised: 3 µl (6–
7 ng/µl) of genomic
 DNA, 2 µl of 10xlong
 PCR buffer (140 mM ammonium acetate and 
500 mM Tris-HCl, pH
 8.9), 0.25 mM dNTPs, 0.4 pmol primers, 2 mM MgCl2, 1.3 M 
betaine, 0.05 U/µl Gibco Taq
 DNA polymerase (Promega, Madison, WI, USA), 0.1 U/µl 
1/250
 Pwo (Roche Diagnostics, Lewes, UK), and water to 20 µl.
 Thermal cycling was on 
the Tetrad® thermal cycler (GRI, Essex, UK):
 94°C for 2 min; 94°C for 20 s, 65°C for 30 s, 
68°C
 for 3 min, repeated for 35 cycles; then 68°C for 20 min.
2.1.3.4 Nested Primer PCR
This method is a way of increasing the specificity of a PCR reaction especially 
when the region of interest includes highly repeated motifs. An initial PCR reaction 
(often Long PCR) provides a template for subsequent shorter PCR amplimers using 
different sets of primers designed to correspond to sequences which are located close, 
but internal to those used in the first reaction. PCR conditions are based on the standard 
Long PCR protocol for the initial reaction and the standard short PCR protocol for the 
second set of reactions.
2.1.4Large plate 2% Agarose gel preparation
Agarose gels are used to asses the products of PCR by allowing an assessment of 
the approximate size, purity and quantity of the PCR product relative to a control. 10 g 
of Agarose was mixed with 500 µl of 0.5% TBE buffer in a 750 ml conical flask. This was 
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heated in the microwave oven for 3x 45 seconds bursts and mixed between bursts until 
the Agarose had dissolved.  The gel was cooled to 65 °C in a water bath and 25 µl of 
ethidium bromide (10mg/ml, Sigma cat no. E1510) was added and mixed well. Combs 
are inserted into the slots on the gel tank along with the end plates and the gel is 
poured between the combs. The gel is allowed to set for 30 minutes before putting into 
the tank. The tank is filled with 1.5% TBE buffer and the combs removed. Samples are 
mixed with bromophenol blue (BPB) loading buffer at a ratio of 10:1 before loading 5.5 
µl into each gel well.  3.5 µl of 100kb DNA ladder is loaded into the end lane as a marker. 
The gel is run for approximately 20minutes at 200mW for 250bp sample separation. 
Sections of the gel can be removed for imaging by cutting with a sharp spatula. Gel 
images are viewed and saved as TIFF (tagged image file format) files via a UV trans-
illuminator attached to a PC.  Unused sections of the gel can be kept submerged in the 
tank for up to 1 week.
2.1.5Operation of CAS-1200™ precision liquid handling system 
robot
The CAS-1200™ precision liquid handling system robot (Corbett Life Science, 
Brisbane, Australia) was used for a variety of functions including simple dilutions and 
PCR plate setup but its main use was for setting up HRM runs on the ROTORGENE 6000 
machine. For these functions all pipette speeds were set to 45 µl per second and tips 
were set to be used up to 5 times where possible. Blocks for holding reagents were kept 
in the fridge when not in use and either the 72 or 100 well rotor preparation blocks 
were used for all runs.
2.2 Genetic variations and molecular mutation detection 
systems
This section summarises the specific classes of genetic variation (polymorphisms 
and mutations) and mutation/polymorphism detection techniques utilised throughout 
this work.
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2.2.1Mutations vs Polymorphisms
'Mutation' refers to a heritable change in the DNA as opposed to polymorphisms 
which are allelic sequence variations (Mutation < 1% and Polymorphism > 1% 
frequency)
11. However, many different definitions and distinctions between mutations 
and polymorphisms exist. The distinction has become complex and inconsistent such 
that the idea of mutations causing disease and polymorphisms being benign is 
seemingly over simplistic. Additionally, the idea that any change occurring in greater 
than 1% of the population must be a benign polymorphism is also over simplistic 
especially considering recent association studies which seeming link one, or a collection 
of common variants with a disease ‘risk’
166 and rare polymorphisms occurring in less 
than 1% of people but with no apparent deleterious effect. Therefore, it is necessary to 
clarify the intended meaning of these words in any given document. Throughout this 
work the word ‘mutation’ is only used where a variation has been shown to be 
pathogenic with a reasonable level of supporting evidence including statistical or 
molecular data.   
2.2.2Polymorphisms
In any two unrelated individuals, 99.9% of the DNA sequence is similar and only 
0.1% contains genetic variants that influence how people differ in their risk of disease. 
Many forms of genetic polymorphism exist in the human genome and we are only 
starting to unravel the complexities and mechanisms by which genetic information can 
vary between individuals. Traditionally, Single Nucleotide Polymorphisms (SNPs) which 
are sites in the genome where DNA sequences differ by a single base
11, have been 
thought to be responsible for the majority of differences between the DNA of 
individuals. However, recent full genome sequencing work has shown that non-SNP DNA 
variation accounts for 22% of all variation events in a single donor, however they involve 
74% of all variant bases
167. Therefore, significant variation besides the simple SNP exist 
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in the human genome. Below I describe the polymorphisms/variations which are 
important to this work.
2.2.2.1 Single Nucleotide Polymorphisms (SNPs)
Single Nucleotide Polymorphisms (SNPs) are responsible for approximately 78% 
of human DNA variation
167. They represent possibly the simplest polymorphism class 
with only a single base change. For example, some people may have a chromosome with 
an A at a particular site where others have a chromosome with a G. As we have two 
copies of all chromosomes except for the sex chromosomes, for the above SNP a person 
could have the genotype AA, AG, or GG. Each form is called an allele and the set of 
alleles that a person has is called a genotype. A “Haplotype” refers to a set of associated 
SNP alleles in a region of the chromosome. Most chromosome regions have only a few 
common haplotypes (each with a frequency of at least 5%), which account for most of 
the variation in a population.
2.2.2.2 Short Tandem Repeat Polymorphisms (STRP or 
microsatellites)
Short Tandem Repeat Polymorphisms (STRP) represent a small run (usually less 
than 0.1kb) of tandem repeats of a very simple DNA sequence, usually 1-4 bp, for 
example (CA)n. They are a subclass of a larger group of polymorphism called Variable 
Number of Tandem Repeat polymorphisms (VNTR’s). They are common and often highly 
polymorphic making them useful as genetic markers particularly for linkage analysis
11.
2.2.3Mutations
Mutations can take the form of a genome mutation such as a change in 
chromosome complement e.g. Down's syndrome (trisomy 21), a chromosomal mutation 
such as a translocation, or a gene mutation involving a number of bases. Gene 
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mutations include base pair substitutions, deletions or insertions. They may originate 
through the normal process of DNA replication or because of mutagens. If they occur in 
the germ line they could be passed on to offspring. A point mutation in a gene may not 
confirm it as the disease causing mutation. The mean heterozygosity of human genomic 
DNA has been estimated to be 0.0037. This means that 1:250 to 1:300 bases are 
different between allelic sequences
168. This sequence variation is lower in conserved 
gene sequences, but in an average gene several neutral (non-pathogenic) variants are 
still likely to be found; without functional testing it may be impossible to differentiate a 
neutral from pathological variant. Mutation detection usually accomplishes one of two 
goals. Firstly, to detect or exclude known mutations (specific mutation testing) or 
secondly, to scan known genes or exons for any mutation (mutation scanning). There 
are several methods available for detecting mutations in candidate genes and a number 
have been employed in this project. 
2.2.4Mutation detection methods
Automated fluorescence sequencers are relatively standard laboratory 
equipment and direct dideoxy sequencing in the most reliable method of analysing 
genetic sequence. Although constantly improving, its use as a primary method of 
mutation scanning is limited by cost, relatively low throughput and requirement for 
output analysis. The other methods of mutation scanning serve mainly to reduce the 
sequencing load by scanning large fragments of sequence (amplicons) and identifying 
which amplicons contain sequence changes and therefore should be sequenced directly. 
These methods fall into three groups. The first is based on detecting aberrant migration 
of mutant molecules during electrophoresis through gel media. This includes hetero-
duplex analysis, single-strand conformation polymorphism analysis (SSCP) and 
fluorescence-based short tandem repeat polymorphism (STRP) genotyping analysis 
using an Automated Capillary DNA Sequencer. The second is a relatively new technology 
called high resolution melt analysis (HRM) which is based on the relative differences 
between the melting characteristics of amplimers with small sequence differences. Both 
Mr Jay Self 2008  Page 59 of 220Chapter 2 - Methods
these methods while simple do not reveal the position of the mutation and do not have 
100% sensitivity
169. The third group of methods relies on cleavage of RNA or DNA 
molecules prior to analysis and includes chemical and enzymatic mismatch cleavage for 
example the restriction enzyme digest method. All these methods have varying merits. 
For example some are quick (HRM), some are cheap (SSCP) and some provide special 
information in specific circumstances (STRP genotyping and restriction enzyme 
digests)
11. The techniques used in this work are detailed in the following sections.
2.2.4.1 Single-Strand Confirmation Polymorphism Analysis 
(SSCP)
SSCP is probably the most widely used mutation screening method and is a 
technically simple method with moderate sensitivity. It is based on the principle that 
single stranded DNA folds up and develops a sequence dependent secondary structure 
(conformers) under non-denaturing conditions. The electrophoretic mobility of such 
DNA on non-denaturing gels therefore depends not only on its chain length but also on 
this secondary structure which is dictated by the DNA sequence. DNA differing by as 
little as a single base substitution can form different conformers and migrate differently 
on a non-denaturing polyacrylamide gel
170. The precise pattern seen on a gel is very 
dependent on conditions used and variation being sought. Conditions need to be 
optimised for each amplimer being assessed. Wild type controls also need to be run on 
each gel. SSCP is most sensitive for detecting base substitutions for DNA fragments of 
150 bp. SSCP in this work was optimised for maximum sensitivity by running for 3.5 
hours using 6% polyacrylamide gels with added glycerol using standard protocols
171;172. 
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2.2.4.2 High resolution melt analysis (HRM)
HRM is a relatively new technique for detection of sequence variations. It works 
by characterizing nucleic acid samples based on their disassociation (melting) behavior. 
Samples can be discriminated according to their sequence, length, GC content or strand 
complementarity in this way with high sensitivity for single base changes. HRM requires 
the use of a dsDNA intercalation dye such as SYTO® 9 which intercalates between the 
complimentary DNA strands and fluoresces only when bound. Therefore, by performing 
conventional PCR followed by a slow ramp in temperature (melt) while simultaneously 
collecting florescence readings it is possible to accurately follow the liberation of dye 
(becoming non-fluorescent) as complimentary DNA strands dissociate on melting. This 
requires the use of a specialized real-time thermocycling machine capable of high-
intensity optical data collection, high-speed data capture and precise temperature 
control. This was achieved in this work by the Rotor-Gene 
TM 6000 (Corbett Life Science, 
Brisbane, Australia).
A protocol for HRM was followed, as recommended by the manufacturer with 
the following reagents in a 10 μl reaction: 5 μl of sensimix dt (Catalogue Number:QT6T3-
02, Quantace, Finchley, UK QT6T3-02), 0.15 μl of forward and reverse primer,  2.7 μl of 
ddH2O and 1 μl of Syto 9 (Catalogue Number:S34854, Invitrogen, Paisley, UK). It was 
found that in most cases, experimental conditions were identical. For the annealing 
temperature a touchdown method was used, where for 20 cycles the temperature 
dropped from 63°C to 59°C, where it remained for the last 20 cycles.  The touchdown 
method involves starting at an annealing temperature 4°C above the predetermined 
temperature and followed by a 20 cycle touchdown phase in which the annealing 
temperature dropped by 0.5°C below the primer temperature. The PCR process also 
includes a normal cycle of denaturing (at 93°C for 20secs), then annealing (at 63°C for 
15secs), and finally synthesis (at 72°C for 20secs). Also included are hold steps which 
were found to increase the sensitivity of the subsequent melt curves. Standard 
conditions were a follows:
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Hold




Hold temperature: 72°C. Hold time: 7 minutes.
Hold 3
Hold temperature: 95°C. Hold time: 5 seconds.
Hold 4
Hold temperature: 50C. Hold time: 5 minutes.
Following DNA amplification the melt curve was performed either immediately, 
or after storage of the amplification product.  
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93°C for 20 
seconds.
63°C for 15 
seconds. 
72°C for 20 
seconds.
Touchdown: for first 20 cycles, 
temperature drops by 0.2°C each cycle.Chapter 2 - Methods
Figure 8 A typical High resolution (HRM) melt curve. 
For all runs in this work a melt profile was run in which the temperature was 
incrementally increased by 0.5°C from 70-90°C and fluorescence readings were taken at 
each increment. Optimisation of all parts of this methodology was completed as part of 
this work including identification of the optimal DNA concentrations, tube formats, 
reagent formats and volumes, overall reaction volume, temperature conditions, 
thermocycling program, touch-down PCR, DNA quality requirements and results 
analysis. 
2.2.4.3 Direct DNA sequencing
DNA sequencing is the determination of the precise sequence of nucleotides in a 
sample of DNA and is the ‘Gold Standard’ for point mutation detection. The most 
commonly used method for this is the "dideoxy method" which was developed by Fred 
Sanger winning him his second Nobel prize in 1980
11. Automated capillary fluorescence 
sequencing is the most commonly used version of this technique in which a single 
stranded DNA template is labelled by incorporating fluorophore labelled dNTPs which 
then passes through a fine capillary filled with electrophoresis gel. As the samples pass 
through the capillary a monitor detects and records the fluorescence signal from all 4 
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fluorophores simultaneously
173.  For this project, Big Dye® Terminator v1.1.1 Cycle 
Sequencing Kit and the ABI Prism® 3100 (and later the 3130) Genetic Analyser were 
used. Samples to be sequenced were selected and a 50μl PCR reaction carried out for 
each.  Samples were then run on a 2% Agarose Gel to ensure adequate product 
formation.  Products appeared as distinct bands which were then sized by comparison 
with a 100bp PCR ladder run in an adjacent lane.  
The products were then purified using the Qiagen purification Kit (Qiagen Ltd, 
UK) following the manufacturer’s protocol.  After purification, a 20μl sequencing 
reaction (using half strength Big Dye) was carried out on the Thermal Cycler according to 
protocol.  This reaction contains 4μl Big Dye kit, 2μl 5X Buffer (Abgene), 3.2μl of 1μM 
primer, 3 – 10ng of the purified PCR product and 10.8μl sterile water.  Both forward and 
reverse sequencing reactions were performed per sample fragment.  
A Qiagen DyeEx 2.0 Spin Kit (Qiagen Ltd, UK) was used to remove excess big dye 
and precipitate the DNA from the sequencing reaction.  The products from this were 
then re-suspended in HiDi Formamide and transferred to a 96-well optical plate 
approved for use in the ABI Prism® 3100/3130 Genetic Analyser. This was set to 
denature at 94°C for ten minutes and 4°C after that until it was ready to be loaded into 
the sequencer.  The sequencer was loaded according to the recommended settings and 
left to run as long as necessary (45 minutes for 16 samples). Results were exported and 
sequences analysed by visual inspection of the sequence printout from sequence 
analysing software (BioEdit Version 7.0) and by sequence comparison using the BLAST 
algorithm from NCBI. 
2.2.4.4 Restriction enzyme digests
Restriction enzymes are enzymes that digest DNA at specific DNA sequences. 
Many enzymes exist and libraries can be searched to identify an enzyme which will 
cut/not cut a given amplimer according to a known sequence variation. To digest DNA 
with a given restriction enzyme, DNA is combined with the enzyme in a buffer and is 
incubated at a specific temperature that is appropriate for optimal enzyme 
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performance. These conditions vary according to the DNA sample and the enzyme used. 
The ability of the enzyme to digest the DNA is assayed by gel electrophoresis. In this 
work, restriction enzymes were selected and purchased from Promega (Madison, WI, 
USA) and incubated with a PCR amplimer following standard PCR amplification. 
Incubation conditions and buffers varied according to the enzyme and manufacturer’s 
protocols were followed. After incubation, products were identified on a 2% Agarose 
electrophoresis gel. A typical restriction enzyme digest protocol was for a 20 µl PstI 
enzyme digest which comprised; 16.3 µl of water, 2 µl of 10X buffer, 0.2 µl Acetylated 
BSA (10 µg/ul) and 1 µl of PCR amplimer. This mixture was combined and mixed before 
adding 0.5 µl of Pst1 enzyme (10 µ/ul) and incubating in a thermocycler for 1.5 hours at 
37°C.  
2.2.4.5 Short Tandem Repeat Polymorphism (STRP or 
Microsatellite) Genotyping 
STRP genotyping was performed for subsequent linkage analysis. Primer pairs 
can be designed to amplify these markers and have a fluorescent tail allowing 
identification of product sizes on a capillary sequencer. By using a number of differing 
dyes and amplimers of significantly different sizes, four or more amplimers can be 
simultaneously run in one capillary to allow multiplexing and increased throughput. 
Optimised sets to cover particular chromosomal regions at particular density can be 
purchased for ease of use. In this work forty eight fluorescently labelled microsatellite 
markers from the ABI Prism Linkage Mapping Set v 2.5 – HD5 (Applied Biosystems, 
Foster City, USA, www.appliedbiosystems.com) were used for genotyping (panels 28, 83, 
84, 85 and 86) with the polymerase chain reaction (PCR) according to manufacturer’s 
instructions. These sets covered the X chromosome at a density of approximately one 
marker per 5cM and multiplexing was possible due to the 3 incorporated dyes VIC, 6-
FAM and NED. Additional sets and individual primer pairs were subsequently designed 
(with 5-prime FAM labels) and run using identical conditions (Operon Biotechnologies 
GmbH, BioCampus Cologne, Nattermannallee 1, 50829 Cologne, Germany). Amplified 
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products were then analysed on an ABI Prism 3100 and later the 3130 Genetic Analyser 
(Applied Biosystems), and the Genotyper v 3.7 NT and later the GeneMapper® Software 
v4.0 software were used to identify and call alleles.
2.2.5Designing primer oligonucleotides
Primers were custom made using "Primer 3" and “Exonprimer” software to 
balance the following considerations/principles:
1. If using genomic DNA, oligonucleotides should be greater than 20 bases (up to 24 
bases) in length to ensure sequence specificity. It is extremely unlikely with this 
base length that a second sequence would exist which would be a perfect match 
to the target region. The primer design programs also Blast search human 
genome repositories for sequence similarity and exclude any primers with more 
than one matched product. Primer length is also proportional to annealing 
efficiency: in general, the longer the primer, the more inefficient the annealing. 
With fewer templates primed at each step, this can result in a significant 
decrease in amplified product.
2. Primers should not contain runs of a single base or a tandem repeat (Poly G or 
Poly C stretches). This avoids matching to known repetitive DNA sequences 
(which could produce non-specific products). The base composition of primers 
should ideally be between 45% and 55% GC. Poly A and Poly T stretches are also 
to be avoided as these will open up stretches of the primer-template complex 
lowering the efficiency of amplification. The ideal primer will have a near random 
mix of nucleotides, a 50% GC content and be ~20 bases long. This will put the Tm 
in the range of 56°C – 62°C.
3. To reduce primer-dimer formation there should be no base homology internally 
or at the 3' end of primers. The inclusion of a G or C residue at the 3' end (GC 
Clamp) helps to ensure correct binding at the 3' end due to the stronger 
hydrogen bonding of G/C residues. 
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4. The %GC content plus length of the primers should allow for the melting 
temperature (Tm) of the two primers to be equal. If primers are mismatched in 
terms of Tm, amplification will be less efficient or may not work at all since the 
primer with the higher Tm will mis-prime at lower temperatures and the primer 
with the lower Tm may not work at higher temperatures. The Tm is the 
temperature corresponding to the midpoint in the observed transition of double 
stranded to single stranded DNA. The PCR annealing stage is usually most 
efficient if set at a temperature corresponding to the Tm -5 °C of the chosen 
primers. The Tm (°C) may be calculated approximately by the equation: Tm (°C) = 2 
´ no. of (A + T) bases + 4 ´ no. of (G + C) bases. 
Primers were ordered from either OPERON Biotechnologies (Cologne, Germany 
https://www.operon.com) or Applied Biosystems (Foster City, USA, 
www.appliedbiosystems.com). Most primer sets were ordered at the 10nmole scale and 
having undergone ‘Salt-Free’ purification.
2.3 Methods used for RNA work
This section details the techniques used for the extraction, storage, handling and 
quantification of RNA.
2.3.1Tissue storage prior to RNA extraction
All cultured cells underwent RNA extraction directly after being removed from 
their supporting media with no prior storage of cells. Tissues and embryonic organs 
were placed in RNAlater® (Catalog# AM7020; Ambion®, Applied Biosystems, 
Warrington, UK) according to the manufacturers guidelines. These samples were then 
stored at -20°C for 2 hours prior to indefinite storage at -80°C.
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2.3.2RNA extraction and cDNA synthesis
RNA extraction was performed by 2 methods. Initially the method used for cells 
was the SuperScript™ III CellsDirect cDNA Synthesis Kit (Invitrogen™ life technologies). 
This kit was used to directly synthesize the first-strand cDNA from our cells in one simple 
protocol combining RNA extraction and cDNA synthesis. However, due to the low 
abundance of the gene of interest, we sought to maximise the quality and yield of cDNA 
from each experiment. We found that the highest yields and greatest cDNA quality were 
produced by using an optimised method comprising RNA extraction by an adapted 
TRIZol method (Invitrogen, Paisley, UK), DNAse treatment by a method adapted from 
the DNA-free™ kit (AM1906, Ambion, UK) and a reverse transcription method adapted 
from the Primerdesign RT protocol (PrimerDesign Ltd, Southampton).
Control human kidney cDNA which had been extracted by commercial methods 
was purchased by PrimerDesign Ltd (Southampton). This was compared with cDNA 
extracted from the same quantity of SHSY5Y cells by either the CellsDirect cDNA 
Synthesis Kit (Invitrogen™ life technologies) method or the adapted method described 
above (see Figure 9). It can be seen that in both qPCR runs the control cDNA PCR 
amplifies after approximately 20 cycles. However, the ‘cells direct’ extracted cDNA 
amplifies after 27 cycles and the cDNA extracted by our adapted method, after only 16 
cycles. This shows that the cDNA quality and abundance of GAPDH in the cDNA 
extracted by our adapted method is significantly higher.
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Figure 9 A comparison of 2 methods of RNA extraction and cDNA synthesis. 
Quantitative real-time PCR results are shown for detection of the GADPH housekeeping gene in 
cDNA prepared from the human SHSY5Y cell line by the CellsDirect cDNA Synthesis Kit 
(Invitrogen™ life technologies), our adapted method and for control adult kidney cDNA 
purchased from PrimerDesign Ltd (Southampton). All further results presented in this project 
were obtained following RNA extraction and reverse transcription by our adapted method 
described below.
 
2.3.2.1 RNA extraction and reverse transcription by an 
optimised method
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2.3.2.1.1 Cell lysis and RNA extraction adapted from the TRIzol method 
(Invitrogen, Paisley, UK)
Cell cultures were prepared for RNA extraction according to the TRIzol
® 
(Invitrogen, Paisley, UK) standard protocol. Briefly, cell culture medium was removed 
and 1 ml of TRIzol reagent was added to the cells for each sample. This was mixed by 
pipetting and incubated at room temperature for 5 minutes. Samples were then 
incubated at -80°C until required.  
For RNA extraction from tissues, samples were either placed in RNAlater® 
(AM7020; Ambion®, Applied Biosystems, Warrington, UK) or directly homogenised 
(ribolysed) in TRIzol using Lysing Matrix D tubes (Qbiogene, UK) and 1 ml of TRIzol
® on a 
Hybaid RiboLyser
™ Cell Disrupter (Thermo Life Sciences, Hybaid UK). Such samples were 
homogenised in Lysing Matrix D impact-resistant 2.0 ml tubes containing 1.4 mm 
ceramic spheres (Qbiogene, UK) and 1 ml of TRIzol
® ((Invitrogen, Paisley, UK) at speed 
settings 6.0 and for 40 seconds. Tubes were cooled on ice for 2 minutes and ribolysed 
for 2 to 4 times with the same settings to completely homogenise the pieces of tissue 
and then cooled down on ice for 2 minutes and incubated at room temperature for 5 
minutes. 
After homogenisation, tissue or cells samples were either processed immediately 
for RNA extraction or stored at -80°C. Further stages of RNA extraction and processing 
were performed in a specifically designated desktop RNA hood in the Gift of Sight 
research laboratory. The RNA work bench was cleaned with ‘RNAseAWAY’ (10328-011, 
Invitrogen, Paisley, UK) to prevent RNA degradation and DNA contamination of the 
samples before the start of each experiment. To prevent contamination from pipettes, 
aerosol resistant barrier tips were used for all experiments.
200μl of chloroform, minimum 99% (C2432-500 ml, Sigma, UK) per ml of TRIzol 
were added to tubes containing the fresh or defrosted samples in TRIzol. Samples were 
shaken vigorously by hand for 15 seconds and incubated at room temperature for 10 
minutes. They were then centrifuged at 12,000rpm for 15 minutes at 4°C. After 
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centrifugation the mixture separated into a lower red, organic phenol-chloroform phase 
containing protein, an interphase containing DNA, and a colourless upper aqueous 
phase, containing RNA. The aqueous phase was carefully (to avoid carry over of genomic 
DNA from the interphase) transferred into fresh 1 ml centrifuge tubes. The organic 
phase and interphase were discarded. Prior to precipitation with isopropyl alcohol, 10ug 
of RNase-free glycogen (Cat. No 10814, Sigma-Aldrich, UK) was added to each sample as 
a carrier for the RNA. To precipitate RNA, 500μl of isopropyl alcohol (2-Propanol, for 
molecular biology, minimum 99%, I9516-500 ml, Sigma, UK) was added to each sample. 
The samples were then incubated overnight at -20°C to increase the precipitation of 
RNA. Samples were incubated at room temperature for 15 minutes and then vortexed 
for 10 seconds and centrifuged at 13,000rpm for 35 minutes at 4°C. The RNA precipitate, 
often invisible before centrifugation, formed a gel-like pellet on the side and bottom of 
the tube. The supernatant was removed by pouring off under visual control to prevent 
loss of the pellet. The RNA was washed in 75% ethanol by adding 1 ml of 75% ethanol to 
each sample and then centrifuging at 7,500rpm for 5 minutes at 4°C. The supernatant 
was poured off under visual control to prevent loss of the pellet and the samples were 
shortly pulse spun to collect all ethanol left on the walls of the tubes, after which it was 
carefully removed using a 200μl pipette tip. The pellet was air dried for 5 to 10 minutes 
(not completely to prevent decrease of its solubility) before it was dissolved in the 
DNase treatment mixture.
2.3.2.1.1.1 DNase treatment adapted from the DNA-free™ kit (AM1906, Ambion, 
UK)
To remove trace contamination by genomic DNA, samples were treated with 
DNA-free™ (AM1906, Ambion, UK) for DNase treatment and removal. The dry RNA 
pellet was dissolved in 20 μl of total DNase digestion reagents. This was made up by 
combining 17μl  nuclease-free water, 2μl 10x DNase I buffer (100mM Tris-HCl pH 7.5, 
25mM MgCl2, 5mM CaCl2) and 1μl of recombinant DNase I (2Units/μl). The samples 
were incubated in a water bath or warm air incubator at 37°C for 60 minutes after which 
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the DNase was inactivated by adding 5μl of the DNase Inactivation Reagent to the 
samples and incubating them for 2 minutes at room temperature and occasionally 
mixing them. The samples were spun at 12,000rpm for 2 minutes at 4°C and the RNA 
was kept on ice and used immediately for quantification and reverse transcription.
2.3.2.1.1.2 Quality check and quantitation of RNA
The method used to assess the quality and quantity of RNA was a 
spectrophotometric approach using a Nanodrop ND 1000 (Nanodrop Technologies, 
Wilmington, DE, USA) (see section 2.3.2.1.1.2). Briefly, 1.5μl of total undiluted RNA was 
placed into the machine on a pedestal that formed a sample column by surface tension 
(1mm path length) when the apparatus was closed. The absorbance at 260 and 280nm 
using a 10mm light path equivalent was measured and this was used to determine the 
RNA concentration and purity (pure RNA: A260/A280 ratio: 1.8 to 2.1).




Following quantitation of RNA,  a 10 μl reaction was prepared for each sample in 
a 200 μl thin-walled PCR tube with the following reagents from PrimerDesign Ltd. 
(Southampton): 100ng-1μg RNA (1 μg was preferred), 2μl Oligo dT primer/dNTP mix, 1μl 
hexamer primer, RNA/DNAase free water to make up to a final volume of 10μl. Each 
reaction was prepared on ice and then heated to 65°C for 5 minutes in a PCR 
thermocycler. Samples were then removed and placed immediately in an ice water 
bath. Each sample then had the following reagents added: 4 μl MMLV 5x buffer, 5.2 μl 
RNA/DNAase free water and 0.8 μl MMLV enzyme. Samples were then flicked to mix the 
contents and pulse centrifuged to collect the contents. They were incubated on a 
thermocycler to 37°C for 10 minutes and then 42°C for 50 minutes. Samples were then 
routinely diluted 1:10 with RNA/DNAase free water and stored at -20°C or 4°C prior to 
use.
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2.3.3Real-time quantitative polymerase chain reaction (RT 
qPCR) protocol
Real-time quantitative PCR has made quantifying mRNA transcripts a simpler 
automated process
174. It is also considered to be a very sensitive technique for mRNA 
detection and quantitation
175 (Heid et al., 1996). It is particularly useful when compared 
to other commonly used techniques, such as Northern blot analysis, as it enabled 
researchers to quantify mRNA from small samples of RNA. It can also be an extremely 
sensitive technique for low copy number mRNAs and is possibly even capable of 
allowing quantification of RNA from single cells
176. All methods of real-time quantitative 
PCR require measurement of the abundance of the PCR product during amplification. 
This can be achieved by a number of methodologies. Two different detection 
chemistries were employed in this project, namely the asymmetrical fluorescent cyanine 
dye SYBR green (PrimerDesign Ltd, Southampton) and a real time PCR probe called a 
PerfectProbe
TM (PrimerDesign Ltd, Southampton). For both methods, sample reactions 
were prepared either by hand, or using the CAS-1200™ precision liquid handling system 
robot (Corbett Life Science, Brisbane, Australia). All experiments were run using the 
Rotor-Gene 
TM 6000 real time thermo-analyser (Corbett Life Science, Brisbane, Australia). 
Specific protocols are detailed in the relevant subsequent chapters.
2.4 Cell culture methods and protocols
The cell culture methods and protocols used in this work are varied. This section 
describes only the standard techniques used in multiple experiments. Details of the 
specific conditions and protocols for each experiment can be found in the relevant 
subsequent chapters.   
2.4.1Standard growth media for SHSY5Y neuroblastoma derived 
cells
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This media comprised: 90 mls Minimum essential medium, Eagle (ATCC, Cat no. 
30.2003), 90 mls nutrient mixture F-12 ham (Sigma, cat no. N6658), 20 mls foetal bovine 
serum (ATCC, Cat no. 30-20-21) and 1 ml of antibiotic/antimycotic solution (100x) 
(Sigma, Cat no. A5955). Media was made and used within 2 weeks. It was stored at 4°C 
in Plug seal cap 75 ml cell culture flask (Corning, Cat no.430720).
2.4.2NB-B27 growth media for SHSY5Y neuroblastoma derived 
cells
This media comprised: 194 mls of Neurobasal-A medium (-L-Glutamine) (Gibco, 
Cat no.10888), 2 mls B-27 supplement (Gibco, 17504-044), 2 mls L-Glutamine (Sigma, 
Cat no.G7513) and 2 mls of antibiotic/antimycotic solution (100x) (Sigma, Cat no. 
A5955). Media was made and used within 2 weeks. It was stored at 4°C in Plug seal cap 
75 ml cell culture flask (Corning, Cat no.430720).
2.4.3Standard growth media for Y-79 Retinoblastoma derived 
cells
This media comprised: 90 mls RPMI with Glutamax (Invitrogen, Cat no. 72400-
021), 10 mls foetal bovine serum (ATCC, Cat no. 30-20-21) and 0.5 ml of 
antibiotic/antimycotic solution (100x) (Sigma, Cat no. A5955). Media was made and 
used within 2 weeks. It was stored at 4°C in Plug seal cap 75 ml cell culture flask 
(Corning, Cat no.430720).
2.4.4Haemocytometer method of cell counting
The Haemocytometer method was used for all cell counting in this work. Cell 
media was first discarded and 3 mls of 1x non-enzymatic cell dissociation solution 
(Sigma, Cat no. C5914) was added per 200 ml flask (1 ml was used for 75 mls flasks). 
Flasks were swirled and incubated at 37°C for 5 minutes. The flask was then swirled 
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again and tapped to remove any adherent cells. 5 mls of fresh media was added before 
centrifuging at 1000rpm for 5 minutes. Supernatant was then removed by pouring and 
12 mls of fresh media added. This suspension was mixed by pipetting and a small 
amount was add to a 200 μl eppendorf tube with an equal volume of trypan blue 
(Trypan blue solution (0.4%) 100 mls (Sigma, Cat no.T8154)). This suspension was then 
mixed by pipetting. A clean haemocytometer chamber slide (Neubauer, Germany) was 
then cleaned again with 70% ETOH and a clean coverslip (Neubauer, Germany) was 
applied over the chamber. Cell suspension was then pipetted into each end of the 
chamber and the slide viewed on an inverted DM IRB microscope (Leica Microsystems 
UK Ltd, Milton Keynes, UK). All living cells located within the 4 large squares of the 
chamber were counted and the concentration of cells in the cell suspension calculated 
using the following formula:
      Cells/ml = Total cell count per 4 large squares x 5000  
2.4.5Cell freezing
Cells were periodically frozen in aliquots at -80°C to maintain a stock of cells at 
low passage values. Cells were counted and 1 million cells were added to 1 ml of cell 
freezing buffer (Sigma Cat no.C6164) in a 2 ml centrifuge tube. Tubes were then frozen 




Cells were rapidly defrosted by swirling in a beaker of hand warm water. 10 mls 
of media was then added and this suspension and centrifuged at 1000rpm for 5 
minutes. The supernatant was poured off and cells re-suspended in 10 mls of fresh 
media. This was incubated overnight at 37°C in 5% CO2.  
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2.4.7Poly-L-Lysine coating culture wells
6 well cell culture plates (Nunclon, Cat no.140685) or 24 well cell culture plates 
(Corning, Cat no.3524) were coated with Poly-L-Lysine to aid attachment for some 
experiments. 300 µl of Poly-L-Lysine 0.001% solution (Sigma, Cat no. P4707) was added 
to each well of a 24 well plate (600 µl for the 6 well plates) and incubated at room 
temperature for 5 minutes. Wells were then washed twice with the intended culture 
medium. 1 ml of culture medium was then added to each well and incubated at 37°C in 
5% CO2 until it reached 37°C. Medium was then removed and plates used immediately 
or stored at room temperature for up to 3 days prior to use.
2.4.8Immunohistochemistry
Immunohistochemistry was performed on cell lines in this work using two 
primary antibodies (see Table 1). At the indicated times for each experiment, cells were 
rinsed free of medium with phosphate buffer solution (PBS) and immediately fixed in 4% 
paraformaldehyde (PFA) for a minimum of 30 minutes at 4°C. Fixed cells were then 
washed 3 times in PBS to remove the PFA. After rinsing, non-specific binding sites were 
blocked with 5% donkey blocking serum in 0.1%Triton-X in Tris-buffered saline (TBS) for 
30 minutes at room temperature. Primary antibodies were then applied at the given 
concentration (see Table 1) in 1 ml of water containing 10 µl TBS with 0.1% Triton-X. 
These were then incubated at 4°C overnight. Cells were then rinsed once with PBS and 
incubated in PBS with 0.1% Triton-X containing: Cy3-conjugated anti-mouse diluted 
1:250 and Cy2-conjugated anti-rabbit diluted 1:250 secondary antibodies for 2 hrs at 
room temperature. Cells were then washed once with PBS and counterstained with the 
nuclear stain 4',6-diamidino-2-phenylindole (DAPI;5 µg/mL) (Sigma) for 6 min. Finally, 
cells were washed twice in PBS to remove excess DAPI and were kept in 1 ml of water 
per well. For each experiment, negative controls (the addition of secondary in the 
absence of primary antibodies) were used to rule out any non-specific secondary 
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antibody binding. Imaging was performed using an inverted DM IRB microscope (Leica 
Microsystems UK Ltd, Milton Keynes, UK) with separate photographs taken at the 
specific wavelength required for each stain. The Volocity™ software package V4.2.1 
(Improvision, Coventry, UK) was used to capture and combine images. For Cy2 
absorbance is at 492nM and fluorescence is at 510nM, for Cy3 absorbance is at 550nM 
and fluorescence is at 590nM and for DAPI absorption is at 358 nM and emission when 
bound to DNA is at 461nM.
 Primary antibody Working 
dilution 
Company
Mouse anti-GFAP 1:500  Sigma
Rabbit anti-TUJ1 1:500  Covance
  Secondary antibodies  Working 
dilution
Company
Donkey Cy3 conjugated anti-mouse 1:250 Jackson  ImmunoResearch
Donkey Cy2-conjugated anti-rabbit 1:250 Jackson  ImmunoResearch
Table 1 Antibodies used in this research. 
This table shows the different antibodies used with the working dilution as worked out from the 
dilution experiments and the company from which each antibody was purchased. 
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3 CHAPTER THREE - Positional cloning of a 
nystagmus gene by linkage analysis 
3.1 Introduction
CIN is genetically heterogeneous and has been described as an autosomal 
dominant
177, autosomal recessive
104 and X-linked dominant 
104 or recessive trait
178. 
Although X-linked regions have been identified at Xp11.4 –p11.3 
178 and Xq26-q27 
104 no 
genes have been identified. These linkage studies have been criticised on a number of 
aspects including exclusion of alternative diagnoses, limited phenotyping, incorrect 
marker location information, combining families with different inheritance patterns and 
the variable measures of significant linkage (see 1.3.6.1.1.4 Limitations of previous X-
linked CIN linkage work). Consequently, all of these issues were addressed in the design 
of the following linkage mapping work. A large 3 generation pedigree with apparent X-
linked CIN was identified. This family underwent detailed phenotyping followed by X 
chromosome wide STRP genotyping and subsequent linkage analysis.
3.2 Methods
3.2.1Clinical methods
The study had the approval of the local and regional ethics committee and 
conformed to the tenets of the Declaration of Helsinki. Twenty nine individuals (7 
affected males, 2 affected females, 11 obligate female carriers and 9 unaffected 
members) in a single CIN pedigree (pedigree 1) underwent detailed clinical examination 
(see figure 10) including LogMAR visual acuity, refraction, colour vision testing with 
Ishihara plates, intra-ocular pressure (IOP) recording, anterior and posterior segment 
slitlamp examination including iris transillumination testing in a darkened room and 
orthoptic assessment.
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Figure 10 Pedigree 1; a large apparent X-linked Congenital Idiopathic Nystagmus pedigree
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Twenty four patients also had eye movement recordings using Skalar IRIS IR Light 
Eye Tracker equipment (Cambridge Research Systems Ltd. Rochester UK, 
www.crsltd.com) (see Figure 11).
Figure 11 Skalar IRIS IR Light Eye Tracker equipment used for eye movement recordings
Eye movement analysis comprised 24 recordings for each patient. Binocular and 
uniocular saccades were recorded to calibrate amplitude measurements at ±10° and 
±20° from fixation in the horizontal plain using a 1° red square target moving at 500ms 
intervals. Binocular and uniocular optokinetic nystagmus (OKN) measurements were 
carried out to rightward and leftward drifting gratings measuring 0.2 cycles per degree 
at a velocity of 25° per second. Waveforms were analysed whilst viewing in 5 positions 
(primary, 10° right, 10° left, 20°right and 20°left of fixation) both binocularly and 
uniocularly using a 1° red square target. 
Seven patients also had extensive clinical neurological examinations.
International Society for Clinical Electrophysiology of Vision (www.iscev.org) 
standardised electroretinograms (ERGs) and visual evoked potential (VEP) recordings 
were recorded in 2 affected males and 2 obligate female carriers. Monocular stimulation 
and a 3 channel trans-occipital electrode montage were employed for VEP recordings to 
optimise detection of neuronal misrouting suggestive of ocular albinism.
Informed consent was obtained from all subjects for genetic studies and genomic 
DNA was isolated from ORAGENE saliva sample kits (see section 2.1.1.2).
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3.2.2Laboratory methods
Forty eight fluorescently labelled microsatellite markers from the ABI Prism 
Linkage Mapping Set v 2.5 – HD5 (panels 28, 83, 84, 85 and 86)  (Applied Biosystems, 
Foster City, USA, www.appliedbiosystems.com) and four further fluorescently labelled 
microsatellite markers (Operon Biotechnologies GmbH, BioCampus Cologne, 
Nattermannallee 1, 50829 Cologne, Germany) were used for genotyping with the 
polymerase chain reaction (PCR) according to manufacturer’s instructions:
15 µl PCR reaction:
True Allele® PCR premix 9 μl
ddH2O 3.8 µl
supplied labelled primer pair 1 µl                
DNA template(50ng/ul)  1.2 µl 
PCR conditions:
95°C for 12 min       x1 
Melt at 94°C for 15 sec
Anneal at 55°C for 15 sec               x10 
Extend at 72°C for 30 sec
Melt at 89°C for 15 sec
Anneal at 55°C for 15 sec              x20 
Extend at 72°C for 30 sec
Extension at 72°C for 10 min       x1
Hold at 4°C Forever
Samples were then multiplexed, pooled and diluted with ddH2O to a 
concentration of 1/20 for 6-FAM and VIC labelled amplimers and 1/10 for NED labelled 
amplimers. 0.5 µl of these samples were then added to a 10 µl 18:1 mix of Hi-Di
TM 
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Formamide / Genescan
TM -500 LIZ size standard. Samples were finally denatured at 95°C 
for 5 minutes immediately prior to analysis on an ABI Prism 3100 and later the 3130 
Genetic Analyser (Applied Biosystems). The Genotyper® v 3.7 NT and later the 
GeneMapper® Software v4.0 were used to identify and call alleles. Manufacturer’s 
recommendations for allele calling and binning were followed.
3.2.3Bioinformatic methods
Bioinformatic methods for linkage analysis were completed with the assistance 
of the Southampton Bioinformatic group headed by Professor Andy Collins. Two-point 
and multipoint linkage analyses were performed using the VITESSE program 
179. The 
PEDCHECK program 
180 was used to examine the pedigree for genotyping errors and 
mendelian inconsistencies. Both marker locations and inter-marker centimorgan 
distances (cM) were taken from the Rutgers combined linkage-physical map of the 
human genome
181 based on the NCBI build 35 (National Center for Biotechnology 
Information, U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894 
USA). Therefore, the marker position data quoted by ABI (based on an earlier map) was 
updated and refined. The inheritance pattern was assumed to be X-linked recessive and 
the disease gene frequency was taken at 0.001 with penetrance of 0.1 in female 
heterozygotes and 1 in female homozygotes and male hemizygotes. Other penetrance 
values between 0 and 0.25 for female heterozygotes were also tested but the results 
were consistent throughout.
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3.3 Results
3.3.1Clinical Results
Flash and pattern ERG and occipital pattern VEP recordings in 2 affected males 
and 2 obligate female carriers were normal thus excluding the most common 
masquerading eye conditions. Computerised Tomography brain scans were performed 
on 2 affected individuals at diagnosis with no abnormal findings. Ophthalmic 
examinations were also normal except for nystagmus in affected patients. The 
prevalence of squint was 4 of 9 (44%) affected subjects and 3 of 19 (15.8%) unaffected 
subjects. Refractive errors ranged from uni-ocular LogMAR acuities of 0.1 to 0.5 in 
affected subjects. Eye movement recording results are presented for all patients with 
positive findings in Table 2 and examples of nystagmus waveforms seen in this pedigree 
are presented in Figure 12. 18 unaffected subjects including 6 obligate female carriers 
had no abnormalities on any of the 24 recordings and so are not included. Also included 
are results for a female carrier with nystagmus possibly secondary to a cochlear implant 
(III:16) and a male subject (III:8) who has nystagmus but was excluded due to a history 
of congenital cataract. The results also exclude an affected subject (IV:15) for whom eye 
movement recordings were not collected.
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Table 2 Infra red limbal nystagmology in affected members of a nystagmus pedigree 
(pedigree 1). 
Abbreviations: L, left; R, right; P, pendular; D, decelerating slow phase; Lin, linear slow phase; A, 
accelerating slow phase; PC, pseudocycloid waveform; MLN, manifest-latent nystagmus; NP, not 
present (disrupted).
* OKN observed with monocular naso-temporal asymmetry
† Low gain OKN but only in the direction of the nystagmus
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IV:15 IV:18 III:16 V:4 II:5 III:8 III:6 V:8 V:9 III:2 IV:2
Optokinetic 
nystagmus present? 
(OKN) x NP Present* NP NP NP NP NP Low gain Low gain† NP
Direction in primary x P R P R P P R R R R
Amplitude in primary  x 2.5° 0.25° 2.22° 1.7° 3.5° 2.5° 5.4° 0.31° 5.6° 4.2°
Frequency in primary 
(cycles per second) x 2.66 1.10 3.92 3.33 3.00 4.44 3.60 1.47 1.40 4.50
Waveform in 
primary x P D P A P P A Lin D A
Direction in L gaze x L R L L P L L R P L
Amplitude in L gaze x 2.6° 0.3° 2.8° 1.0° 3.2° 3.3° 2.2° 0.2° 2.8° 4.1°
Frequency in L gaze 
(cycles per second) x 4.20 0.92 5.50 5.00 2.94 5.50 2.80 2.10 8.50 3.80
Waveform in L gaze x A Lin Lin Lin P Lin D Lin P PC
Direction in r gaze x R R R R R P P R R R
Amplitude in r gaze x 2.9 ° 0.3° 2.1° 2.1° 3.1° 1.6° 0.5° 0.2° 0.8° 5.3°
Frequency in r gaze 
(cycles per second) x 4.16 1.20 3.00 2.25 3.06 5.00  3.33 1.12 3.56 3.42
Waveform in r gaze x PC D PC Lin PC P P Lin Lin PC
Waveforms seen any 
direction  x
Lin,P,A 








PS,P, A Lin  Lin, P, D,A
A,P,
PC
Rebound seen Y/N x No No No No No No No No No No
Changes in 
phenotype when 
viewing monocularly x MLN No  MLN No No No No No  MLN MLNChapter 3 – Positional cloning of a nystagmus gene by linkage analysis
Figure 12 Eye movement recordings from a pedigree with CIN (pedigree 1). 
Infrared eye movement recordings are shown. Each recording is binocular with the left eye trace on top 
of the right eye trace. The following examples are shown: normal recording from IV:17 with a normal 
finding of a square-wave jerk (a), accelerating slow phase nystagmus typical of CIN from IV:18 (b), 
decelerating slow phase nystagmus atypical for CIN from III:2 (c), subtle nystagmus waveforms missed 
by clinical examination from V:9 (d), normal OKN from IV:18 (e), disrupted (absent) OKN (on a pendular 
nystagmus background) typical of CIN from III:6 (f), low gain OKN unusual for CIN from V:9 (g), and 
pseudocycloid nystagmus  (a combination of pendular and accelerating slow phase) common in CIN 
from V:9 (h).    
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Individual V:9 from pedigree 1 had been previously diagnosed as unaffected by 
an experienced ophthalmologist but was found to have subtle nystagmus only after 
examination with infra-red nystagmology. For subject III:16, a female carrier also known 
to have a cochlear implant, OKN was preserved, the nystagmus amplitude was very low 
and no accelerating slow phases were seen. Subject III:8 who has nystagmus but was 
excluded from linkage analysis due to a history of congenital cataract, has nystagmus 
waveforms that are very similar to the affected subjects including disrupted OKN and 
accelerating slow phases. 
3.3.2Linkage Analysis Results
The highest two-point LOD score (Z) of 3.0 at θ =0 was found for marker 
DXS1047 (see ). Subsequently, 4 additional markers were added to increase resolution 
around the DXS1047 locus which resulted in a higher two-point LOD score (Z) of 4.24 at 
θ=0 for both markers DXS8044 and DXS994 (see Table 4). 
Marker                  LOD Score at θ =
 Order           0.0   0.1 0.2 0.3 0.4
DXS8055          -¥    1.64 1.57 1.17 0.59
DXS8064          -¥    0.00 0.00 0.00 0.00
DXS8067          -¥    1.08 1.02 0.79 0.45
DXS1001          -¥    2.08 1.76 1.25 0.61
DXS8009          1.19  1.01 0.81 0.58 0.31
DXS1047          3.00  2.54 2.03 1.45 0.79
DXS1062          -¥    0.66 0.85 0.73 0.44
DXS984           -¥    1.68 1.66 1.31 0.76
DXS1205          -¥   -0.61 -0.17 0.00 0.05
Table 3 Two point LOD score results for nystagmus phenotype in pedigree 1
                      LOD score at θ=
Marker    
 Order     0.0     0.1     0.2     0.3     0.4    0.5
Mr Jay Self 2008  Page 86 of 220Chapter 3 – Positional cloning of a nystagmus gene by linkage analysis
DXS8088    - ¥     1.38    1.37    1.03    0.54   0.00
DXS8055    -¥     1.64    1.57    1.17    0.59   0.00
DXS8064   -0.00   -0.00   -0.00   -0.00   -0.00  0.00
DXS8067    -¥     1.08    1.02    0.79    0.45   0.00
DXS1001    -¥     2.08    1.76    1.25    0.61   0.00
DXS1212    -¥     1.08    1.02    0.79    0.45   0.00
DXS8009    1.19   1.01    0.81    0.58    0.31   0.00
DXS8044    4.24   3.55    2.77    1.91    0.94   0.00
DXS1047    3.00   2.54    2.03    1.45    0.79   0.00
DXS994     4.24   3.55    2.78    1.91    0.94   0.00
DXS8041    3.03   2.53    1.96    1.32    0.63   0.00
DXS1062    -¥     0.66    0.85    0.73    0.44   0.00
DXS984     -¥     1.68    1.66    1.31    0.76   0.00
Table 4 Two point LOD score results for nystagmus phenotype in pedigree 1 
Multipoint analysis provided a maximum LOD score of 4.54 between markers 
DXS994 and a critical LOD-1 support interval of ≈8.0 cM between markers DXS1212 and 
DXS1062 (using the Rutgers combined linkage-physical map) (see Figure 13). The 
method of calculating critical interval in this work (LOD-1 method)
130 is a recognised 
method in which a threshold for the interval is drawn at a level of 1 LOD unit below the 
maximum multipoint calculated LOD score. This is a relatively conservative method. 
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Figure 13 Multipoint LOD score results.
Results are presented with a LOD-1 support interval showing that the X-Linked recessive 
nystagmus locus has been narrowed to an 8.4 cM (approximately 14Mb) region between 
markers DXS1212 and DXS1062.
These results were confirmed by haplotype analysis (see Figure 14).
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Figure 14 Haplotype analysis for nystagmus phenotype transmission in pedigree 1. 
Markers are listed top to bottom centromere-DXS8067- DXS1001- DXS1212-DXS8009-DXS8044-
DXS1047-DXS994-DXS8041-DXS2499-DXS1062-DXS984-telomere. The haplotype co-segregating 
with the nystagmus phenotype is boxed. A question mark indicates that the genotype is not 
determined and for clarity, identifiers from  are used. Marker DXS2499 was uninformative in this 
pedigree.
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It can be seen that centromeric and telomeric boundaries for the shared 
haplotype in this pedigree are defined by; a recombination between markers DXS1001 
and DXS1212 for individual IV:21 and a recombination between markers DXS1062 and 
DXS2499 for individual III:6.
3.4 Discussion
3.4.1Clinical Phenotyping
These results have shown that CIN patients in a single family have extremely 
variable nystagmus phenotypes. Classically the hallmarks of the CIN phenotype are 
accelerating slow phases, loss of OKN and no changes in phenotype on monocular 
viewing
37. However, in pedigree 1, 7 out of 9 patients with CIN had 3 or more waveforms 
seen including prolonged periods of decelerating or linear slow phases which are more 
commonly seen in patients with nystagmus of neurological origin. Similarly, OKN was 
preserved to some degree in 2 patients which is considered to be rare in CIN. 
Interestingly, in subject III:16 (female carrier but also known to have a cochlear implant), 
OKN was preserved (rare in CIN), the nystagmus amplitude was very low and no 
accelerating slow phases were seen (also rare in CIN). These findings might suggest that 
her nystagmus is secondary to the cochlear implant and not CIN. Subject III:8 who has 
nystagmus but was excluded due to a history of congenital cataract, has nystagmus 
waveforms that are very similar to the affected subjects including disrupted OKN and 
accelerating slow phases. These findings would be more suggestive of CIN than Sensory 
Deficit Nystagmus (SDN)
37 due to congenital cataract. (This subject is subsequently 
found to be hemizygous for the causative mutation in this family). 
The clinical phenotyping demonstrated that in some cases waveform 
characteristics were indicative of underlying aetiology in this family but conversely, 
many of the waveform characteristics seen in individuals of this pedigree would suggest 
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wholly different aetiologies. These results support the opinion that waveforms alone 
should be interpreted with caution when employed as a diagnostic tool in CIN. However, 
detailed eye movement recordings may be necessary to assign affection status in CIN 
pedigrees and the families of CIN singleton cases. An example is individual V:9 from 
pedigree 1 who had been previously diagnosed as unaffected by an experienced 
ophthalmologist but was found to have subtle nystagmus only after examination with 
infra-red oculography (and was subsequently found to be hemizygous for the causative 
mutation in this family). This has significant implications for diagnosis and genetic 
counselling for this individual and other currently undiagnosed individuals from CIN 
pedigrees.
3.4.2Linkage Studies
The genetic intervals identified in previous linkage studies of X-linked CIN at the 
q27 locus are illustrated along side the results from this work in Figure 15.
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Figure 15 Diagram of the X chromosome showing the q24-q26 locus for X-linked CIN. 
A, B and C represent the critical regions for X-linked dominant CIN reported by: (a) Kerrison et al. 
1999, (b) Kerrison et al 2001 and (c) Zhang et al. 2005. D and E represent the critical regions for 
X-linked recessive CIN reported by: (d) Guo et al 2006 and (e) our work.
It can be seen from Figure 15 that the results from our linkage work significantly 
narrowed the only previous X-linked recessive CIN interval identified by Guo et al (≈37.9 
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cM to ≈8.0 cM). It was also completed using a single CIN pedigree which therefore 
reduced the risk of error due to locus heterogeneity. The identified interval still included 
a region of overlap (≈3.4cM interval between DXS8033 and DXS1062) with the interval 
for X-linked dominant CIN refined by Zhang to a 4.4 cM region between markers 
DXS8033 and DXS1211
125. Therefore, these results did not rebuke the hypothesis that X-
linked recessive CIN and X-linked dominant CIN may be caused by mutations in the same 
gene. However, comparison of overlapping linkage intervals from multiple studies 
should be interpreted with caution especially when studies employ different diagnostic 
criteria, different methods of phenotypic assignment, different methods of critical 
interval calculation and different families in a disease known to be heterogeneous. It is 
also important to note that previous linkage studies have employed various genetic 
maps to assign marker positions and cM distances. Many of these locations and even 
marker orders have changed over time due to updated mapping information. 
In this work, the potential errors identified in previous linkage work by us and 
other groups were minimised. Exhaustive and high resolution methods of phenotyping 
to avoid errors of phenotypic assignation were employed and patients with any other 
possible cause for nystagmus were excluded. A single family was used for linkage 
analysis which reduced the risk of errors due to locus heterogeneity. Only the most up-
to-date mapping information and statistical packages were used along with a 
conservative method of critical interval calculation. Previously published linkage data 
was not combined with our data as most of these studies had been criticised for the 
above reasons. 
Therefore, this work represented the first study of an X-linked CIN pedigree to 
employ high resolution phenotyping and a single large pedigree for linkage analysis. We 
demonstrated that X-linked CIN families could have a small number of manifesting 
females and suggested that this may be due to X-linked recessive inheritance with X-
inactivation. The interval for X-linked CIN was narrowed and the great variability in 
phenotype and necessity for accurate examination of all family members was 
confirmed. This work was published in October 2006
38. 
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4 CHAPTER FOUR – Screening pedigree 1 for 
mutations in the Cerebellar Degeneration-Related 
Protein 1 (CDR1) gene 
4.1 Introduction
In May 2005 at the Association for Research in Vision and Ophthalmology (ARVO) 
conference in Fort Lauderdale USA, Schorderet et al presented the discovery of a 
sequence variation found in the Cerebellar Degeneration-Related Protein 1 (CDR1) gene 
in a family with CIN
182. This gene is located on the X chromosome at position q27.1 and 
the sequence change reportedly segregated with the disease but no further information 
was provided at this time. The linkage work reported in chapter 3 was incomplete at this 
stage and so there was a possibility that a mutation in this gene was responsible for 
nystagmus in pedigree 1. Consequently, the CDR1 gene was screened for mutations in 
this family while the linkage work was underway.
4.2 Methods
Two affected members of pedigree 1 (IV:15 and IV:18) were screened for 
sequence variations by direct sequencing on the ABI 3130 automated capillary 
sequencer as detailed in section 2.2.4.3. Primers were designed (as described in section 
2.2.5) to include all coding sequence of the 1 exon CDR1 gene and 30 bp of the 5-prime 
and 3-prime intronic sequence using reference mRNA sequence NM_004065.2. The 
Nested PCR technique (section 2.1.3.4) was used such that Long PCR (section 2.1.3.3) 
was initially performed to produce a 1.6 kb product which was then used as a template 
for 10 shorter amplimers which were amplified by conventional PCR methods (section 
2.1.3.2). Problems were initially encountered with the shorter primer sequences due to 
multiple short sequence repeats in the CDR1 gene (see Figure 16):
Mr Jay Self 2008  Page 94 of 220Chapter Four – Screening pedigree 1 for mutations in the Cerebellar Degeneration-Related Protein 1 (CDR1) gene
Figure 16 The Cerebellar Degeneration-Related Protein 1 (CDR1) gene sequence. 
The sequence of reference mRNA NM_004065 is shown with an example of a highly repeated 
motif shown in red.
 Following these problems, new primers were designed which excluded any 
apparent repeat from the primer sequences. Primer sequences are detailed in Table 5. 
Sequencing results were analysed as detailed in section 2.2.4.3.
Long PCR primers
  Forward primer Reverse primer
Set 1 ggaagacctggagatataggaagac caaatacagatcttccagctaatcc
Set 2 gttggaagacgtagcttagttgga caagaagctccaagtcttccagta
Set 3 ggagatataggaagacatggatttgt atttcaaggtcttccatcaaatacaga
Set 4 acctggagatataggaagacatgg caaatacagatcttccagctaatcc
Short PCR Primers
  Forward primer Reverse primer
Set 1 ccaggtcttccagtcaatca ggaagacatggctttgttgg
Set 2 acatcttccaatggcctcca ggaagacgtggattttctgg
Set 3 tccacgtcttccaacaaagc  tgattgactggaagacctgga
Set 4 ctggaagacattaatttgatggaag caatatatgtcttcctgaagatccac
Set 5 gattttcaggaagacccaaattatc gtcttccctcaaatccatagcttc
Table 5 Sequencing primers for the Cerebellar Degeneration-Related Protein 1 (CDR1) 
gene.
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4.3 Results
No sequence variations were identified for either affected member of pedigree 
1.
4.4 Discussion
Mutations in the CDR1 gene were excluded as the cause of nystagmus in 
pedigree 1. Interestingly, following completion of the linkage analysis for pedigree 1 (see 
section 3), it was noted that according to the latest Rutgers combined linkage-physical 
map (March 2006 build), the CDR1 gene was located at position 139,693,500 which is 
just telomeric to the identified interval for pedigree 1 between markers DXS1212 
(position 122,214,416) and DXS1062 (position 137,150,000). This suggested that even if 
additional, as yet un-identified, exons existed for CDR1, mutations in these exons were 
unlikely to be the cause of nystagmus in pedigree 1 as they would likely lie outside the 
linkage interval. Additionally, Kerrison et al in their 1999 linkage paper of this region 
screened the CDR1 gene in one CIN pedigree that had linked to this region. No 
mutations were found, however the reference sequence used was not presented. In 
2004 the NM_004065.1 reference sequence was updated to NM_004065.2 so it is likely 
that the sequence used by Kerrison et al in this paper was the NM_004065.1 version. By 
using the ‘Blast 2 Sequences’ algorithm of the online BLAST program via the National 
Centre for Biotechnology Information (NCBI) website (http://www.ncbi.nlm.nih.gov) it is 
possible to compare the two versions (NM_004065.1 and the updated NM_004065.2) of 
the CDR1 reference mRNA. It can be seen that from bases 9-1165 of the older sequence 
(NM_004065.1) there are 3 small sequence changes between the two versions (see 
Figure 17). However, most significantly the latest sequence (NM_004065.2) includes an 
additional 141 base pairs at the 5-prime end. Furthermore, the primer sequences 
quoted in this paper for Long amplification of the initial 1.3-kb fragment were; forward 
5’-GGAAGACCTGGAGATGTTGGAAGACGAGCAGA-3’ and reverse 5’-
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AATGTTTCAATGTCAGGAGTTCCGATGGCACC-3’. However, by using the ‘Blast 2 
Sequences’ algorithm and the Vertebrate Genome Annotation (VEGA) database (http://
vega.sanger.ac.uk) (a central repository for high quality, frequently updated, genomic 
sequence) it can been seen that neither of these sequences exist in any orientation 
within the genomic sequence or 2000 bp flanking sequence of the CDR1 gene. 
Therefore, it is possible that the reference genomic sequence also varies from the latest 
builds.
These inconsistencies illustrate the constantly updating nature of genetic 
sequence databases. Therefore, it is important to qualify all experiments using reference 
DNA sequences (most modern genetic techniques) with the possibility that the 
sequences used may be inaccurate or subsequently updated. Similarly, it is important to 
recognise these inconsistencies when comparing different studies using different 
resources and techniques. For the above reasons it is possible that a mutation in parts of 
the CDR1 gene may have been missed by Kerrison’s group in 1999. However, it is 
possible that a mutation could be missed in our family for the same reasons. 
Score = 2192 bits (1140),  Expect = 0.0
 Identities = 1156/1159 (99%), Gaps = 2/1159 (0%)
 Strand=Plus/Plus
NM_004065.2  141   AGCTTAGTTGGAAGACATATATTTTCTGGAAGACGTGGATTTTCTGGAAGACATGGCTTG  200
NM_004065.1  9     .........................T..................................  68
NM_004065.2  201   GTTGGAAGACGTGGATTTTCTGGAAGACGTACCTTTGTTGGAAGACATACCTTTGTTGGA  260
NM_004065.1  69    ............................................................  128
NM_004065.2  261   AGACGTACCTTTGTTGGAAGACGTACCTTTGTTGGAAGACACAAGTAGGCTGGAAGACAT  320
NM_004065.1  129   ............................................................  188
NM_004065.2  321   TAATTTGATGGAAGACATGGCTTTGTTGGAAGACGTGGATTTGCTGGAAGACACGGATTT  380
NM_004065.1  189   ............................................................  248
NM_004065.2  381   CCTGGAAGACCTGGATTTTTCGGAAGCTATGGATTTGAGGGAAGACAAGGATTTTCTGGA  440
NM_004065.1  249   ............................................................  308
NM_004065.2  441   AGACATGGATAGTCTGGAAGACATGGCTTTGTTGGAAGACGTGGACTTGCTGGAAGACAC  500
NM_004065.1  309   ............................................................  368
NM_004065.2  501   GGATTTCCTGGAAGACCCGGATTTTTTGGAAGCTATAGATTTAAGGGAAGACAAGGATTT  560
NM_004065.1  369   ............................................................  428
NM_004065.2  561   TCTGGAAGACATGGATAGTCTGGAAGACCTGGAGGCCATTGGAAGATGTGGATTTTCTGG  620
NM_004065.1  429   ...............................-............................  487
NM_004065.2  621   AAGACATGGCTTTTTTGGAAGACGTAGATTTTCAGGAAGACCCAAATTATCCGGAAGACT  680
NM_004065.1  488   ............................................................  547
NM_004065.2  681   TGGATTGTTGGGAAGACGTGGATTTTCTGGAAGACTGGGAGGTTACTGGAAGACATGGAT  740
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NM_004065.1  548   ......................................-.....................  606
NM_004065.2  741   TTTCTGGAAGACATGGATTTTCTGGAAGACGTGGATCTTCAGGAAGACATATATTGGCTG  800
NM_004065.1  607   ............................................................  666
NM_004065.2  801   GAAGACCTGGATTTTTTCCGGAAGATGTGGATTGACTGGAAGACCTGGATTTGGTGGAAG  860
NM_004065.1  667   ............................................................  726
NM_004065.2  861   ACGTAGATTTTTCTGGAAGACACTGACTGACTGGAAGACCTGGATTTCTTTCTGGAAGAC  920
NM_004065.1  727   ............................................................  786
NM_004065.2  921   ACTGATTGACTGGAAGACCTGGATTTCTTTCTGGAAGACACTGATTGACTGGAAGATCTA  980
NM_004065.1  787   ............................................................  846
NM_004065.2  981   GATTTTTCTGGAAGAACTAGATTTACTGGAAGACTTGGATTTGGTGGAAGACACAGATTT  1040
NM_004065.1  847   ............................................................  906
NM_004065.2  1041  TTCTGGAAGACATGGATTAGCTGGAAGATCTGTATTTGATGGAAGACCTTGAAATTATTG  1100
NM_004065.1  907   ............................................................  966
NM_004065.2  1101  GAAGACATGGATTTCCTGGAAGACGTGGATTTTCCTGGAAGATCTGGATTTGGTGGAAGA  1160
NM_004065.1  967   ............................................................  1026
NM_004065.2  1161  CCAGTAATTGCTGGAAGACTGGATTTGCTGGAAGACTTGATTTACTGGAAGACTTGGAGC  1220
NM_004065.1  1027  ............................................................  1086
NM_004065.2  1221  TTCTTGGAAGACATGGATTGTCCGGAAGACATGGATTGTCTGGAAGATGTGGATTTTCTG  1280
NM_004065.1  1087  ............................................................  1146
NM_004065.2  1281  GAAGCTCAGGATTATCTGG  1299
NM_004065.1  1147  ...................  1165
Figure 17 A comparison of reference mRNA sequences for the CDR1 gene.
This figure shows the alignment of the NM_004065.1 and NM_004065.2 reference sequences 
for the CDR1 gene. Differences are highlighted in red.
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5 CHAPTER FIVE – Mutation screening genes from 
within the identified nystagmus linkage interval for 
pedigree 1
5.1 Introduction
Following exclusion of the CDR1 gene and the identification of a linkage interval 
for nystagmus in pedigree 1, it was necessary to identify and prioritise candidate genes 
from within the linked region. The coding sequence of these genes was subsequently 
screened for mutations by direct sequencing. During the course of this experiment 
another group (Tarpey et al) found mutations in the FRMD7 gene (located within the 
identified interval for pedigree 1) in some families and sporadic cases of CIN. At this 
stage the FRMD7 gene was immediately prioritised and screened in pedigree 1.
5.2 Methods
 The UCSC Genome Browser (http://genome.ucsc.edu/index.html?org=Human), 
created by the Genome Bioinformatics Group of UC Santa Cruz and based on the March 
2006 human reference sequence (NCBI Build 36.1) was used to identify all known 
protein coding genes and predicted genes from the region between the 2 markers 
DXS1212 and DXS1062. This region contained 70 known protein coding genes and 23 
provisional RefSeq (NCBI) predicted genes (see Figure 18).
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Figure 18 Prioritised genes identified from within a nystagmus locus.
Known protein coding and predicted genes from within the linkage interval identified for 
nystagmus phenotype in pedigree 1. (USCS genome browser)
The identified genes and predicted genes were then prioritised for mutation 
screening. 
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Initially, only protein coding genes were prioritised because of the likelihood that 
the causative mutation would lie in one of these genes. This has been the case for most 
recent gene discoveries and was described by Strachan and Read in 2003 as follows; ‘as 
our knowledge of the human genome improves, it becomes increasingly likely that the 
cause of a disease under investigation will be mutation in a known gene’
11. Following 
this, the process of prioritisation was achieved using a set of criteria including; 
expression pattern (UniGene, GEO Profiles and GEO Datasets, NCBI website), known or 
predicted function (GeneRIF and GeneOntology functions of the gene-centred 
information database, NCBI website), homology to relevant paralogous human genes 
(PSI- and PHIblast functions, NCBI website) and homology to relevant orthologous genes 
(PSI-, PHI- and RPS-blast functions, NCBI website). The online databases described 
offered an initial starting point for an extensive literature search for all genes which 
were subsequently priority ordered. Primers for PCR were designed to include all of the 
coding exons of each gene and 30 bp of intronic and UTR boundaries (as described by 
the NCBI and ENSEMBLE online annotation software systems). All amplimers were 
subsequently sequenced directly (see section 2.2.4.3) for one affected and one 
unaffected male from pedigree 1 (individuals V:4 and V:3 respectively). To assess 
segregation of a sequence variation in the pedigree, a restriction enzyme digest was 
designed using the PstI enzyme and the protocol was the same as that described in 
section 2.2.4.4. A digest was performed for all informative family members.
5.3 Results
5.3.1Sequencing results
The results of candidate gene prioritisation are presented in Table 6. The top 9 






     
1 MBNL3 18 35 RBMX2 -
2 ZIC3 20 36 FAM45B -
3 FHL1 5 37 COVA1 -
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4 OCRL 32 38 RP13-102H20.1 -
5 FGF13 7 39 IGSF1 -
6 SMARCA1 24 40 OR13H1 -
7 RP1-203C2.1 6 41 RP11-453F18__B.1 -
8 BCORL1 64 42 RP6-213H19.1 -
9 GPR119 5 43 RAP2C -
10 GRIA3 - 44 HS6ST2 -
11 ODZ1 - 45 USP26 -
12 RP6-213H19.2 29 46 TFDP3 -
13 BRS3 - 47 PHF6 -
14 GPC4 - 48 HPRT1 -
15 GPC3 - 49 PLAC1 -
16 THOC2 - 50 RP11-308B5.5  -
17 PDCD8 - 51 RP3-473B4.1 -
18 GLUD2 - 52 MOSPD1 -
19 RP1-57A13.2 - 53 CXX1 -
20 BIRC4 - 54 RP13-565O16.1 -
21 STAG2 - 55 ZNF75 -
22 SH2D1A - 56 ZNF449 -
23 RP11-13E5.1 - 57 DDX26B -
24 WDR40B - 58 XX-FW88277B6.1  -
25 RP13-218H24.1 - 59 RP13-36C9.1 -
24 WDR40B - 60 SAGE1 -
25 RP13-218H24.1 - 61 TMEM32 -
26 APLN - 62 SLC9A6 -
27 XPNPEP2 - 63 GPR112 -
28 CXorf9 - 64 HTATSF1 -
29 ZDHHC9 - 65 VGLL1 -
30 UTP14A - 66 CD40LG -
31 ELF4 - 67 ARHGEF6 -
32 RAB33A - 68 RBMX -
33 SUHW3 - 69 GPR101 -
34 SLC25A14 - 70 F9 -
Table 6 Candidate nystagmus genes screened for mutations.
Sequencing was completed for genes marked red and the number of amplicons per gene is 
shown.
In October 2006, Tarpey et al published a series of families and sporadic CIN cases with a 
number of different causative mutations in the FRMD7 gene. This gene was previously known 
as LOC90167 or RP6-213H19.2. At this stage screening had revealed no mutations in the top 9 
prioritised genes and so the FRMD7 gene (prioritised number 12 in Table 6) was screened in 
both subjects V:4 and V:3 using the primers listed in . 
1f AGGCCAGAACCAATCACTTC 1R CAGTTTGTTTATCTAATATTTCCTGCC
2f ACCTGGATTTTCCATCACAC 2R AGAGCCAGACATAAACCAGATG
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3f TTCTGGCAGGAAATATTAGATAAAC 3R GGAGGTGGTGGCATAGATCC
4f TCATCTGGTTTATGTCTGGCTC 4R GGGCCCAGTAGAAATGGTC
5f TCTATGCCACCACCTCCTTC 5R AGCGTCTAATGGCATTTAGTG
6f ACTGGGCCCCACACAAATAG 6R GCAAGGTGGGTATTTGTCATC
7f TGAAGAGCCTGACCTTCACTC 7R TTTTCTTGGTTACTACATATTCATTGG
8f AGGCAACAGCTGGATCTTTC 8R CAACACACCAACTGCTGAAG
9f CGGTAACATGGAACTGGCTC 9R CCAGCAGTTCTAATGGATCAAAG
10f GCCATGGGTGACCTTATTTC 10R AAAAGGTCCCAGAGCCAATC
11f TGACTGAGAGCAGGACAAGG 11R AAGAGCTTTCAGCAAGACCTG
12f TTTGGGTCTTCCTCTTCTAGACC 12R TTGGTATTATGCCTCCCCAG
13f GGACTTGTCCTTTCCTCTGC 13R AGCTCCTTCCAAACAAGCTG
14f CACTTTGCTTGTGAGGCCAG 14R CAACTGAGCTGGAGCATTCC
15f AAAGAGGAACTGCTTTGGGAC 15R CCTCCCCCAGCCCTAAC
16f GCAGAATCAATTCATGGAAGC 16R TTGGAGATTTCTATGTATCCTGG
17f TGAAATGACCTTCATGTGAATACC 17R TGATTTCAACAATAAACGAGGC
18f GATTGAAATGGATTCTTTGTTGC 18R TGCAAGGATACCTTGGAGTTC
19f TTTGATTTGGGCTCTTCCG 19R TTGGGATTTGAAGGTCTTTG
20f AAACGATTTGCAGAAACAACC 20R TGCACTGTCTTACAAGCCAAC
21f TTGAGCCAAGATAACCACCC 21R TGGAAATGTCATTCTTGAGGC
22f AAGAGTCTGTCCCCAATTTTAGTG 22R CCATTGCTAAGTTCCTCAAAGG
23f TGTGCTTGGTTCTCTACCTGG 23R TCATCTTGGATCTGGGAGAAG
24f GAGCCAAATCCTTCTTTATTTG 24R GGTCTGGTTTGGGGCTG
25f CCAAACAGGAGACTGCCC 25R GCTGCAAGCAGGCTCAG
26f CTGACAGTGGGAATGCCTG 26R TCTAATGGGCTGTTCACAAATG
27f TACCCTTTATTCCGTGCTGC 27R ACATACCTAGCTGCAAACTGC
28f TGCTCAATGCCATGCTCTAC 28R TTGTTGAAACCTTTCTCAAGCTC
29f TGTGTGTGTGTACCTATAACTGTTGTG 29R AGAATGGCCAGAAGCACTTG
Table 7 PCR primers used for sequencing the FRMD7 gene.
Sequencing of the FRMD7 gene revealed a single base insertion (A) after base 
880 (reference cDNA sequence NM_194277) in affected subject V:4 but not unaffected 
subject V:3. The sequence change was designated ‘880insA, 293fs’ using the reference 
cDNA sequence NM_194277 and the A of the first coding ATG at position 179 as a basis 
for numbering.  This sequence change was evaluated using the SeqBuilder application of 
the LASERGENE 6 v6.1.3 build 143 sequence analysis software suite (DNASTAR, Inc. 
Madison, USA). The frameshift variation was predicted to cause a premature stop codon 
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at amino acid position 301 (reference protein sequence NP_919253) thereby truncating 
the FRMD7 protein or leading to nonsense mediated decay of the mRNA.
5.3.2PstI Restriction Enzyme Digest Results
The PstI enzyme was chosen to cut wildtype (5’..CTGCA^G..3’) but not variant 
(5’..CTGCAAG..3’) sequence in the PCR amplimer of exon 9. Therefore, the wildtype 
allele (cut) produced 2 fragments of 133-bp and 134-bp length and the variant allele 
(uncut) produced a single 267-bp fragment. Results are illustrated in Figure 19 along 
with a condensed pedigree to aid subject identification. The variant sequence co-
segregated with all affected and carrier females but not unaffected patients. Notably, 
affected individual III:8 who was excluded from initial work because of a history of 
congenital cataract was also hemizygous for the 880insA, 293fs variation.
Figure 19 A Restriction Enzyme Digest analysis of an FRMD7 variation
An abbreviated pedigree diagram and gel photograph of a restriction enzyme digest analysis are 
presented.  The PstI enzyme was used to cut wildtype (5’..CTGCA^G..3’) but not mutant 
(5’..CTGCAAG..3’) sequence from the 880insA, 293fs variation in FRMD7 in pedigree 1.The 
mutant (uncut) allele generates a 267-bp fragment, while the wild type allele (cut) produces 
fragments of 133-bp and 134-bp. Control lanes are included: (a) unaffected male III:17 with no 
PstI enzyme and (b) unaffected male III:17 with PstI enzyme.   
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5.4 Discussion
The 880insA, 293fs variation identified in pedigree 1 segregated with the disease 
and was predicted to cause a premature stop codon, thereby truncating the FRMD7 
protein or leading to nonsense mediated decay of the mRNA. The genetic cause of CIN 
in pedigree 1 had therefore been identified as this new mutation which had not been 
described in the Tarpey et al paper
159. 
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6 CHAPTER SIX – Assessing the genetic 
contribution of the FRMD7 gene to Congenital 
Idiopathic Nystagmus
6.1 Introduction
The FRMD7 gene had been identified as a ‘nystagmus gene’ however, its full 
contribution to the pathogenesis of CIN was not known. A large cohort of X-linked and 
sporadic CIN cases were screened for FRMD7 mutations in order to identify how 
commonly mutations in this gene caused CIN and to identify new mutations which may 
provide insights into the significance of various domains within the FRMD7 gene.
6.2 Methods
Following full Local and Regional Ethics Committee (LREC) approval, 28 simplex 
CIN cases and 9 additional apparent X-linked CIN pedigrees (see Figure 20) were 
identified. Patients were either recruited in the Southampton Eye Department or 
contacted us directly through a call for patients on the Nystagmus Net website 
(http://www.nystagmusnet.org). All patients had a diagnosis of CIN from an experienced 
Ophthalmologist and most had undergone full electro-diagnostic investigation with 
ERG/VEP studies. Where this had not occurred patients were questioned about family 
history, medical and ophthalmic history and degree of visual impairment before 
inclusion or exclusion. Patients were excluded if there was any history of other 
ophthalmic or medical conditions which may suggest an alternative diagnosis to CIN. 
Informed consent was obtained from all subjects for genetic studies and genomic DNA 
was isolated from either blood or ORAGENE saliva sample kits (see section 2.1.1).
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Figure 20 X-linked congenital nystagmus pedigrees. 
9 additional pedigrees screened for FRMD7 mutations.
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SSCP was performed (see section 2.2.4.1) following standard PCR amplification 
using the FRMD7 primers in .   Specifically, 6% polyacrylamide gels with glycerol were 
run for 3.5 hours at 25W per gel and at room temperature. 96 female controls (182 
control X chromosomes) were screened along with the 37 probands. Direct sequencing 
(see section 2.2.4.3) was performed for samples with either ‘shifts’ or failed PCR seen on 
SSCP gels. 
6.3 Results
13 shifts on SSCP gels were found in 9 amplimers in controls and affected 
probands in equal numbers and these were checked by sequencing and corresponded to 
known SNPs. In an affected male from X-linked pedigree 2 and an unrelated singleton 
female, a shift was seen in an amplimer containing exon 4 (see Figure 21). 
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Figure 21 A Single Stranded Conformation Polymorphism (SSCP) gel. 
This gel illustrates the two shifts found in single stranded DNA (S) from exon 4 of the FRMD7 
gene when screened in 37 affected nystagmus probands. 5 water controls (controls) and one 
failed PCR (F6) are also seen. The shifts and failed PCR were all subsequently screened for 
sequence changes by direct sequencing.
Sequencing subsequently identified a point mutation in the first intronic base 
after exon 4 in both subjects designated ‘IVS4+1G→A’. This sequence change had been 
previously found in 2 subjects in the Tarpey et al paper. When assessed with the 
LASERGENE 6 v6.1.3 build 143 program this variation was predicted to cause a splice 
recognition site mutation leading to continued translation into intron 4-5 resulting in a 
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premature stop codon after 9 amino acids, thereby truncating the FRMD7 protein or 
leading to nonsense mediated decay of the mRNA. The mutation was not seen in 182 
control X chromosomes in this study or 300 male control individuals by Tarpey et al.
6.4 Discussion
The combined results of mutation screening the FRMD7 gene in pedigree 1 and 
37 probands are illustrated in .
Sample Pedigree Class Mutation Origin
XN3P X-linked 
(pedigree 1)
Truncating 880insA, 293fs English 
Caucasian




Truncating IVS4+1G→A English 
Caucasian
Table 8 Mutations identified in the FRMD7 gene. 
The reference cDNA sequence NM_194277 is used as a basis for numbering the nucleotide of 
the mutation. All mutations are located relative to the A of the first coding ATG at position 179. 
The reference protein sequence NP_919253 is used as the basis for numbering the amino acid 
variation starting from the first methionine at position 1.
These results confirmed that FRMD7 mutations are a cause of X-linked CIN and 
described a novel protein truncating mutation (880insA, 293fs). By screening all exons 
and splice sites of the FRMD7 gene we identified mutations in 2/10 (20%) of apparent X-
linked pedigrees. This percentage is significantly smaller than that found by Tarpey et al 
(2006) who identified mutations in 8 of 14 (57%) apparent X-linked pedigrees and 15 of 
16 (94%) of proven X-linked pedigrees. This may be because SSCP was our initial method 
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of mutation screening as apposed to direct sequencing. In our experience, SSCP has a 
sensitivity of  89%: (95% confidence interval: 79%–96%) compared with direct DNA 
sequencing 
183. Therefore, our detection rate is likely to be lower than that found by 
Tarpey et al who used direct DNA sequencing.  However, in addition, the cohort used by 
Tarpey et al had been previously used for linkage analysis to identify the causative gene 
inevitably leading to an ascertainment bias. We also identified FRMD7 mutations in 1/28 
(3.6%) singleton cases which is similar to 3/42 (7%) singleton cases found by Tarpey et 
al. Therefore, according to our results the majority (80% in this study) of unselected X-
linked families and 96.4% singleton CIN cases do not have FRMD7 mutations as a cause 
for nystagmus. This suggests the existence of other prevalent nystagmus genes on the X 
chromosome and possibly elsewhere. Alternatively, mutations in as yet uncharacterised 
parts of FRMD7 such as additional exons, promoters, silencers or enhancers may also 
exist but would not be detected by the above work. 
The FRMD7 mutations found by Tarpey et al are clustered around the B41 and 
FERM-C domains
159 (see ). The FARP2 gene on chromosome 13 shares significant 
homology with a large portion of FRMD7 including these domains. It is also known that 
FARP2 alters neurite length and degree of sprouting in rat embryonic cortical 
neurones
184;185. This has lead to the hypothesis that mutations in FRMD7 may cause 
nystagmus by altering the neurite length and degree of branching of neurons as they 
develop in the midbrain, cerebellum and retina
159. The mutation identified in our study 
is also located within these domains and thus our results support the hypothesis that 
mutations in this region of FRMD7 are particularly important for nystagmus. FARP2, 
FARP1 and other homologues may also be potential candidates for nystagmus genes. 
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Figure 22 An illustration of the mutations identified in the FRMD7 gene. 
The novel mutation found in pedigree 1 is identified in RED print. (adapted from Tarpey et al 
2006
159)
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7 CHAPTER SEVEN - Assessment of the role of X-
inactivation in pedigree 1
7.1 Introduction
In publications describing X-linked CIN pedigrees, penetrance among obligate 
female carriers has been variable ranging from 30 to 100%
38;104;125;178. Possible 
mechanisms for this variability include skewed X-inactivation, genetic modifiers such as 
polymorphisms within interacting proteins and other non-genetic influences (such as 
environmental) on oculomotor development. These factors may also explain why X-
linked dominant and recessive pedigrees, with nystagmus (or other ocular diseases), can 
show linkage to the same region 
38;121;186. In this study we investigate the hypothesis that 
skewing of X-inactivation is a major contributor to the variable penetrance seen in X-
linked nystagmus pedigrees. 
The laboratory work for this study was completed at the Wessex Regional 
Genetics Laboratory, Salisbury District Hospital, Salisbury, UK by Dr Simon N Thomas.
7.2 Methods
For X-inactivation analysis all informative female carriers and affected females 
were genotyped along with their informative relatives (usually their father) using 2 
previously described methods involving the Human Androgen Receptor gene (HUMAR) 
24 and the zinc finger, MYM-type 3 (ZNF261)
187 gene. Both assays comprised 
amplification of a short fragment of X chromosome (Xq13 in both assays) which was 
used to determine the activation status of each X chromosome (i.e. the maternal or 
paternal X chromosome). Each amplimer contains a polymorphic marker adjacent to the 
promoter of the gene (HUMAR or ZNF261) which is unmethylated on the active X 
chromosome and methylated on the inactive chromosome. Prior to amplification, both 
assays employed a methylation sensitive restriction enzyme which cuts at the promoter 
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site on the active (unmethylated) but not on the inactive (methylated) X chromosome. 
Therefore, by examining the size and peak heights of the amplification products and by 
tracking the inheritance of alleles from parents to offspring, we ascertained the 
percentage of cells in which the maternal or paternal X chromosome had been 
inactivated. To calculate the X-inactivation ratio, each sample was set up in duplicate: 
one digest and one mock digest without enzyme. Both were then PCR amplified and 
analysed on the ABI 3130 Genetic Analyser and the GeneMapper® Software v4.0 (see 
section 3.2.2). Manufacturer’s recommendations were followed for allele calling and for 
heterozygotes, the ratio of the two peaks was compared between the undigested and 
digested samples. Male samples were used for haplotype reconstruction.
7.3 Results
The results of the X-inactivation assays are summarised in Table 9:




















activity) Size (% 
activity) Size (% 
activity) Size (% 
activity)
II : 3 Saliva F Carrier 233 (44) 
(failed) 241 (56) 
(failed) 264 (52) 
(53) 272 (48) 
(47) Random
II : 5 Blood F Affected 233 (05) 
(04) 241 (95) 
(96) 264 (98) 




III : 2 Saliva M Affected 233 - - - 264 - - - -
III : 6 Saliva M Affected 233 - - - 272 - - - -
III : 16 Saliva F Carrier 233 (n/i) 
(n/i) - - 256 (14) 
(15) 272 (86) 
(85) Skewed
III : 17 Blood M Normal 233 - - - 268 - - - -
III : 18 Blood F Normal 233 (n/i) 
(n/i) - - 256 (98) 




III : 19 Blood F Carrier 233 (n/i) 
(n/i) - - 256 (88) 
(87) 272 (12) 
(13) Skewed
IV : 1 Saliva F Carrier 241 (n/i) 
(n/i) - - 264 (73) 
(69) 270 (27) 
(31) Skewed
IV : 2 Saliva F Affected 236 (27) 
(29) 241 (73) 
(71) 264 (n/i) 
(n/i) - - Skewed
IV : 6 Saliva  F Carrier 227 (39) 
(40) 233 (61) 
(60) 270 (42) 
(42) 272 (58) 
(58) Random
IV : 7 Saliva F Carrier 230 (31) 
(27) 233 (69) 
(73) 262 (23) 
(27) 272 (77) 
(73) Skewed
IV : 14 Blood F Normal 233 (73)  256 (27)  264 (18)  266 (82)  Skewed
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(71) (29) (18) (82)
IV : 15 Blood M Affected 233 - - - 272 - - - -
IV : 17 Saliva F Carrier 233 (n/i) 
(n/i) - - 268 (51) 
(52) 272 (49) 
(48) Random
IV : 17 Blood F Carrier 233 (n/i) 
(n/i) - - 268 (54) 
(57) 272 (46) 
(43) Random
IV : 18 Blood M Affected 233 - - - 272 - - - -
IV : 19 Blood F Normal 221 (20) 
(30) 233 (80) 
(70) 262 (44) 
(43) 270 (56) 
(57) Skewed
IV : 21 Blood F Carrier 215 (94) 
(91) 233 (06) 
(09) 256 (04) 




V : 2 Blood F Carrier 233 (63) 
(63) 256 (37) 
(37) 264 (21) 
(20) 272 (79) 
(80) Skewed
V : 6 Saliva F Carrier 221 (53) 
(67) 233 (47) 
(33) 270 (55) 
(fail) 272 (45) 
(fail) Random
V : 7 Saliva F Normal 221 (56) 
(56) 233 (44) 
(44) 256 (41) 
(33) 264 (59) 
(67) Random
Table 9 Humar and ZNF261 X-inactivation assays for pedigree 1. 
Random = average result of skewing between 50% and 70%; Skewed = average result of skewing 
between 70% and 90%; Very Skewed = average result of skewing greater than 90%.
Ten of the 16 females tested demonstrated at least moderate skewing, including 
both affected females, and three cases showed skewing  of >95%. However, as 
illustrated it is not always possible to tell which X chromosome is inactivated.  Mutation 
status of each X chromosome was known for one affected female and the X carrying the 
FRMD7 mutation was active in 73% of cells. For informative unaffected carriers, the X 
chromosome carrying the FRMD7 mutation was active in between 6 and 80 % of cells. 
Therefore, there was no clear-cut difference in the pattern of X-inactivation between 
affected and unaffected carriers of the mutations. Interestingly, for individual IV:17 
assays were performed for both blood and saliva extracted DNA with identical results. 
7.4 Discussion
We had previously proposed that the most likely explanation for the variable 
phenotype in carrier females in pedigree 1 was variability in the pattern of X-
inactivation
38;132. Skewed X-inactivation, (significant deviation away from the expected 
50:50 contribution of each X chromosome)  has been described in other ocular 
diseases
186;188 and may explain why other X-linked nystagmus pedigrees linked to the 
locus containing FRMD7 have shown either dominant or recessive inheritance 
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patterns
38;104;159;178. The vast majority of genes on the long arm of the X chromosome are 
subject to X-inactivation, including those immediately flanking FRMD7: MST4, MBNL3 
and RAP2C 
27. Since genes which are subject to, or escape from, X-inactivation tend to be 
clustered into domains, it is very likely that FRMD7 is inactivated. Only a very small 
proportion of normal females show significant levels of skewed inactivation
189. However, 
our results suggest an excess of skewing in pedigree 1 (10 of 16 females including 3 with 
>95% skewing). Interestingly, of the 10 females with skewing, 7 are under the age of 40 
and for 3 of these patients the assays were performed on saliva samples. This suggests 
that the observed skewing in pedigree 1 is not due to age-related secondary skewing
24 
or specific to blood. 
In October 2007, Kaplan et al published the results of an X-inactivation study in a 
large Turkish pedigree with CIN caused by a novel non-truncating missense mutation in 
FRMD7 (c.686C>G)
190. Using the HUMAR assay they found that skewed X-inactivation 
was significantly
 increased in the CIN affected females when compared with the 
unaffected
 females in the pedigree (odds ratio was 26:1; 95% CI = 1.83 to
 367.7). They 
also found that one female who was homozygous for the mutation, was not 
phenotypically different to the heterozygous manifesting females. These results added 
weight to our findings of skewed X-inactivation in an FRMD7 mutant CIN pedigree. 
Furthermore, if a homozygous mutant female has a similar phenotype to a manifesting 
heterozygous female, this might also suggest that X-inactivation is occurring for the 
FRMD7 gene.
By combining these data it seems likely that there are four possible explanations 
for the X-inactivation results in FRMD7 mutant CIN pedigrees:
 Firstly, the effect of X-inactivation on penetrance may be subtle, rather than all-
or-nothing, as neither unaffected nor affected carrier females have complete skewing. It 
is possible that the proportion of cells in which the mutation-carrying X is active may be 
higher in the crucial tissues in the affected cases than in carrier females.  Many X-linked 
disorders do not fit classical dominant or recessive modes of inheritance and female 
carriers display variable penetrance
191. For example, mutations in the dystonia-deafness 
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peptide gene (DPP) cause incomplete penetrance in females with variable X-inactivation 
in blood from 50:50 to >95:5
192. Thus mutations in X-linked genes can cause partial cell 
selection and incompletely skewed X-inactivation. This could explain variable clinical 
expression within the same family.
Secondly, the results obtained from lymphocytes and saliva samples may not 
necessarily reflect the patterns of X-inactivation in the tissue whose pathophysiology 
causes nystagmus (as yet unknown). In normal females X-inactivation ratios are 
normally similar between tissues
24. However, for certain X-linked conditions complete 
skewing may be restricted to specific cell lineages and different patterns of X-
inactivation are seen in all other tissues
25. Selection against cells which have inactivated 
the normal X may be more pronounced in tissues where most FRMD7 expression occurs, 
possibly parts of the developing brain and retina
159.
Thirdly, variable penetrance may be at least in part due to other genetic factors. 
The results of the X-inactivation studies give a clear overlap in the patterns of X-
inactivation between unaffected and affected carrier females, and IV:18 who is negative 
for the FRMD7 mutation is one of the females with severe skewing. It is possible that 
the higher frequency of skewed X-inactivation seen in this family may be unrelated to 
nystagmus as we know that skewed X-inactivation per se may run in families
23. 
Finally, a major caveat of these results is that both assays used markers at the 
Xq13 locus. This is a considerable distance from the location of FRMD7 at Xq26-27. This 
could be important as approximately 15% of X-linked genes escape X-inactivation to 
some degree, and this proportion of genes differs dramatically between different 
regions of the X chromosome
26;27. Additionally, 10% of X-linked genes show variable 
patterns of inactivation and are expressed to different extents from some inactive X 
chromosomes
27. Therefore, it is possible that the assays do not accurately represent X-
inactivation occurring in the FRMD7 gene. If it were possible to design an assay 
incorporating a polymorphic marker and methylation sensitive promoter at the FRMD7 
site, this would address these caveats.
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Importantly, by showing that there is no definitive pattern of X-inactivation in 
carrier or manifesting females, this work has shown that determining the X-inactivation 
pattern in blood or saliva cannot be used to identify carrier status for nystagmus caused 
by FRMD7 mutations using such assays. This is important from a diagnostic viewpoint as 
X-inactivation is used as a surrogate test for carrier status in other X-linked 
conditions
193;194. 
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8 CHAPTER EIGHT – Clinical and genetic 
investigation of a family with an atypical congenital 
nystagmus syndrome
8.1 Introduction
Nystagmus before six months of age can be defined as early onset nystagmus
37. 
As detailed previously (see Chapter 1), it may be divided into three categories: sensory 
defect nystagmus (SDN) in which there is a proven sensory impairment, congenital 
idiopathic nystagmus (CIN) also known as “motor nystagmus” in which no visual or 
neurological impairment can be found and neurological nystagmus (NN) which is 
associated with neurological disease
37. CIN is a diagnosis commonly made after full 
ophthalmic examination and ideally also after a normal ERG and VEP. Typically, CIN has 
a horizontal, uniplanar nystagmus waveform with accelerating slow phases
37 although 
other waveforms have been described in patients with CIN
37.




The study had the approval of the local and regional ethics committee and 
conformed to the tenets of the Declaration of Helsinki. 8 individuals from a single 
pedigree (VNCM family, see Figure 23) underwent a full clinical history interview, 
detailed clinical examination including LogMAR visual acuity, intra-ocular pressure (IOP) 
recording, anterior and posterior segment slitlamp examination including iris trans-
illumination testing in a darkened room and full orthoptic assessment. Clinical 
neurological examination was performed by a clinical geneticist and comprised cranial 
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nerve examination, cerebellar examination and both upper and lower limb examination 
for power, tone, sensation, vibration sense and coordination.
Figure 23 A pedigree diagram of a family with atypical hereditary nystagmus. 
Subject ID codes and age at the time of examination are presented for all phenotyped family 
members of the VNCM pedigree. Black circles/squares are affected subjects; clear 
circles/squares are unaffected subjects.
All patients had detailed clinical eye movement examination by an orthoptist 
including: assessment in primary position and 9 positions of gaze, horizontal saccades, 
vertical saccades, smooth pursuit eye movements, cover/uncover test and 
accommodation testing. Subjects in whom nystagmus was found, also had eye 
movement recordings using a Skalar IRIS IR Light Eye Tracker equipment (Cambridge 
Research Systems Ltd. Rochester UK, www.crsltd.com) (see Figure 11) except for VNCM-
5 who was a 3 month old baby and had clinical examination only. Measurements in all 
other subjects using a 1° red square target comprised; fixation waveform, fixation 
amplitude, fixation frequency, waveform in left gaze (20 degrees), waveform in right 
gaze (20 degrees), horizontal binocular OKN to rightward and leftward drifting gratings 
measuring 0.2 cycles per degree at a velocity of 25° per second, horizontal smooth 
pursuit, horizontal saccades using a 1° red square target moving at 500ms intervals, 
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waveform in vertical positions of gaze, vertical binocular OKN, vertical saccades using a 
1° red square target moving at 500ms intervals and vertical smooth pursuit recordings.
Three patients also had extensive electrophysiological examinations. 
International Society for Clinical Electrophysiology of Vision (www.iscev.org) 
standardised electroretinograms (ERGs) and visual evoked potential (VEP) recordings 
were recorded in 3 females (VNCM-1, VNCM-3 and VNCM-5). Monocular stimulation 
and a 3 channel trans-occipital electrode montage were employed for VEP recordings to 
optimise detection of neuronal misrouting suggestive of ocular albinism.
Magnetic resonance brain scans had been performed and sagittal t1 and axial 
dual echo images were obtained in individuals VNCM-3 and VNCM-5.
Informed consent was obtained from all subjects for genetic studies and genomic 
DNA was isolated from ORAGENE saliva sample kits (see section 2.1.1.2).
8.2.2Molecular genetic methods
Initially 2 samples from this pedigree (VNCM-1 and VNCM-2) were included in 
FRMD7 gene screening by SSCP analysis as detailed in chapter 6. 
Subsequently, exons 2-12 of the FARP1 gene (VEGA transcript ID 
OTTHUMT00000045541) were also screened for mutations in the same 2 subjects by 
HRM analysis using optimised amplimers <200bp in length . These exons were targeted 
as they contain the domains which are homologous to the FRMD7 gene as detailed 
previously (Chapter 6).
The CACNA1A gene (NM_000068.3) was subsequently screened in subject 
VNCM-1 by direct sequencing at the Leiden University Medical Centre (LUMC) postnatal 
DNA analysis service. This sequencing work was outsourced due to the significant 
financial saving when screening only one sample for a very large gene (48 exons). This 
gene was targeted following identification of certain similarities between the clinical 
features in this family and that of other patients with Episodic Ataxia 2 (EA2, MIM 
108500)
195;196 and Spinocerebellar ataxia type 6 (SCA6, MIM 183086)
197;198, both of which 
are associated with genetic variations in this gene.
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To assess co-segregation of an identified sequence variation in the pedigree, 
direct sequencing of this variation was performed in all 8 VNCM family members by 
standard methods.
This sequence variation was subsequently sought in 150 normal control subjects. 
An HRM assay was optimized to detect this variation within a 120bp fragment by 
standard methods using; AGCCCCTCATGCTCTCTGT sense primer and 
CGGCGAAGATGAACATGAATA antisense primer. This assay was run by standard methods 
(see section 2.2) using an annealing temperature of 60°C and a 10 μl reaction volume 
comprising: 1 μl genomic DNA, 5 μl of sensimix dt (Catalogue Number:QT6T3-02, 
Quantace, Finchley, UK QT6T3-02), 0.15 μl of each primer,  2.7 μl of water and 1 μl of 
Syto 9 (Catalogue Number:S34854, Invitrogen, Paisley, UK) on the Rotor-Gene 
TM 6000 
(Corbett Life Science Ltd, Brisbane, Australia). The efficacy of the assay to discriminate 
the variation from wildtype was tested using the VNCM samples as controls. The 
positive control (VNCM-4), a negative control (VNCM-8) and two water controls were 
run in the same experiment. The 150 normal control DNA samples came from patients 
who had been evaluated and phenotyped for another study into Age Related Macular 
degeneration (ARMD) and did not have nystagmus or any other eye disease.
8.3 Results
8.3.1Clinical phenotyping results
8.3.1.1 History and examination
VNCM-3 is a female who was 54 years old at the time of examination. On 
detailed questioning it was revealed that this subject had been found to have a subtle 
ataxia of unknown cause and had been discharged from care 10 years earlier. An MR 
brain in 1995 had shown a small cerebellar vermis, possibly an early sign of vermis 
atrophy. Onset of symptoms was at approximately 35 years and her symptoms had not 
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deteriorated greatly since then. A slightly fluctuating course with slurred speech and 
unsteady gait on bad days but without dramatic disabling episodes was described. She 
had occasional migrainous headaches but without any accompanying symptoms. 
Examination showed a broad based gate, no dysarthria, moderate finger-nose ataxia 
and mild shin-heal ataxia, no weakness, normal tendon reflexes, flexor plantar 
responses and no sensory loss. Interestingly, VNCM-3 had no response to oral 
acetazolamide treatment for 3 weeks and this was subsequently discontinued. This is 
notable as oral acetazolamide treatment can prevent or abort the episodic symptoms of 
EA2 and FHM
199;200. 
MR brain scanning in subject VNCM-5 found no abnormalities and VEP and ERG 
recordings were normal for all the subjects recorded (VNCM-1,VNCM-3 and VNCM-5).
All the other family members had no clinical symptoms or signs of neurological 
disease. Other family members included; a 22 year old female VNCM-1, a 57 year old 
female VNCM-2, a 30 year old female VNCM-4, a 3 month old female VNCM-5, a 1 year 
old male VNCM-6, a 6 year old female VNCM-7 and an 7 year old female VNCM-8.
Interestingly, subsequent to our examination of this family, subject VNCM-4 
(now age 31) has developed a mildly unsteady gait and minimal finger-nose ataxia with 
no other symptoms or signs. She still describes no episodic nature or migrainous 
symptoms.
8.3.1.2 Nystagmology
VNCM-2, 6 and 8 had no eye movement anomalies on clinical examination and 
therefore subsequent eye movement recordings were not performed. Subjects VNCM-1, 
3, 4, 5 and 7 all had nystagmus. VNCM-5 had clinical nystagmology but not limbal 
infrared nystagmology because of her young age at the time of examination (3 months). 
She had conspicuous downbeat nystagmus in the primary position and in either lateral 
gaze or down gaze. She also had gaze-evoked nystagmus in either lateral gaze and 
horizontal eye movements on spinning were preserved with no evidence of a saccade 
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palsy. Eye movement findings for VNCM-5 and all other subjects with nystagmus are 
summarised in Table 10. All waveforms exhibited linear or decelerating slow phases, no 
accelerating slow phases were seen in any waveform. 
Patient ID VNCM-1 VNCM-3 VNCM-4 VNCM-5* VNCM-7
Clinical status Nystagmus Nystagmus Nystagmus Nystagmus Nystagmus












0.8 deg (2 
beats/sec)
2.5 deg (3.5 
beats/sec)
1 deg (2 
beats/sec) not recorded na
Waveform in left gaze left beating left beating left beating left beating left beating 
Nystagmus amplitude/
frequency in left gaze
0.2 deg (2 
beats/sec)
2 deg (4 
beats/sec) 





1 deg (2 
beats/sec)
Waveform in right 
gaze  right beating right beating right beating right beating right beating
Nystagmus amplitude/
frequency in left gaze
5 deg (2.5 
beats/sec)
3 deg (4 
beats/sec) 





2 deg (2 
beats/sec)
Horizontal OKN
low gain in 
both 
directions
low gain in 
both 
directions
low gain in 
both 
directions not recorded



















Waveform in upgaze steady steady upbeating upbeating upbeating
Nystagmus amplitude/
frequency in upgaze na na





2 deg (6 
beats/sec)
Waveform in 




2.5 deg (2.5 
beats/sec)
2.5 deg (4 
beats/sec)





2.5 deg (2.5 
beats/sec)
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Vertical OKN
low gain in 
both 
directions




low gain in 
both 
directions not recorded not recorded













Rebound nystagmus present not seen  not seen not recorded not seen
Gaze paretic 
nystagmus present present present present present
na = not applicable
* = subject examined clinically only. 
Table 10 Summary of nystagmus waveforms identified in the VNCM pedigree.  
All subjects (except for VNCM-5) had detailed nystagmology using the Skalar IRIS IR Light Eye 
Tracker equipment (Cambridge Research Systems Ltd. Rochester UK, www.crsltd.com)
8.3.2Molecular genetic results
Screening of all known exons and splice sites of the FRMD7 gene by SSCP analysis 
and of exons 2-12 of the FARP1 gene by HRM analysis identified no mutations in either 
subject VNCM-1 or VNCM-2. 
Direct sequencing of the CACNA1A gene for subject VNCM-1 identified a 
sequence variation; Chr19(NCBI 36):g.13233416T>G which corresponds to c.4110T>G 
p.Phe1370Leu in the NM_000068.3 transcript (see Figure 24). No other variations were 
identified in this gene. 
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Figure 24 Electropherogram results of direct sequencing for the CACNA1A gene. 
Direct sequencing of the CACNA1A gene in individual VNCM-1 reveals the Chr19(NCBI 
36):g.13233416T>G mutation.
Direct sequencing of the c.4110T>G p.Phe1370Leu (NM_000068.3) variation in 
subjects VNCM-1:8 showed that the variation co-segregated with the disease 
phenotype. All affected subjects had the c.4110T>G p.Phe1370Leu (NM_000068.3) 
variation and all unaffected subjects the wildtype allele (see Figure 25).
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Figure 25 Co-segregation of a variation in a nystagmus pedigree. 
Co-segregation of the c.4110T>G p.Phe1370Leu (NM_000068.3) variation in a pedigree with 
atypical hereditary nystagmus (VNCM family) is presented. Mutant sequence shows a 
heterozygote peak at position 3 of the electropherogram cut-outs and wildtype sequence shows 
a single red peak corresponding to a thymine base.
Co-segregation confirms that this sequence variation could be the causative 
mutation in this pedigree. Assuming that co-segregation of the disease phenotype with 
the variation would be expected to occur by chance in 50% of cases, a simple calculation 
could be applied to asses the likelihood of this apparent familial co-segregation 
occurring by chance. By multiplying the 1:2 probabilities for each of the 6 informative 
meioses (therefore excluding VNCM-2), it can be seen that the likelihood of this co-
segregation occurring by chance is 1:64. 
Another, similar way to asses the significance of this co-segregation is by using 
the LOD score
129. For the purpose of this test we again excluded individual VNCM-2 
whose contribution to the genetic information is negligible. Given all seven remaining 
meioses showed no evidence of recombination and our hypothesis that the c.4110T>G 
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p.Phe1370Leu variant may be causal, we assumed no recombination (θ = 0). Using 
standard methods
201 the LOD score for these data is calculated as 2.11. As the CACNA1A 
gene has already been identified for similar phenotypes by a number of groups, it is 
reasonable to impose a higher prior probability of linkage  as has been described 
before
201. Under such circumstances it has been asserted that the critical LOD score 
should be set to 2 rather than 3. Therefore, using these measures and corrections, a 
LOD score of 2.11 would be formally assessed as significant. 
Prior to screening 150 control DNA samples for the variation, the efficacy of the 
HRM assay to discriminate the variation from wildtype was tested using the VNCM 
samples. VNCM-6 and VNCM 8 (wildtype) were compared with VNCM-4 and VNCM-7 
(variation) and all were run in duplicate. Results showed that the variation could be 
readily discriminated (see Figure 26).
Figure 26 Validating a High resolution melt (HRM) assay. 
A validation curve for the HRM assay is presented to highlight the melting differences between a 
wildtype amplimer and that with the CACNA1A C.4110T>G p.Phe1370Leu (NM_000068.3) 
variation. A screen shot from the Rotorgene 6000 real-time thermocycler demonstrates the 
discrimination between the melt profiles for the sequence variation (VNCM-4 and VNCM-7, RED) 
vs wildtype (VNCM-6 and VNCM-8, BLUE). 
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Subsequent screening for the C.4110T>G p.Phe1370Leu (NM_000068.3) 
variation using this assay in 150 unrelated control subjects (300 chromosomes) did not 
identify any heterozygous or homozygous individuals.
 
Figure 27 A High resolution melt (HRM) assay of a CACNA1A gene variation.
An HRM assay to identify the C.4110T>G p.Phe1370Leu (NM_000068.3) variation in 150 control 
chromasomes. The Rotorgene 6000 real-time thermocycler demonstrates that the melt profile 
for normal control subjects (GREEN) is identical to that of wildtype controls (VNCM-6 and 
VNCM-8, BLUE) and not sequence variation controls (VNCM-4 and VNCM-7, RED). 
8.4 Discussion
The CACNA1A gene codes for the Cav2.1 subunit of P/Q type voltage gated Ca2+ 
channels expressed in the brain and particularly in cerebellar Purkinje and granule cells, 
as well as in neuromuscular junctions
202;203. The protein is predicted to have four 
domains or repeats, each formed by six transmembrane hydrophobic segments. 
Segments S5 and S6 of each domain line the pore region. The S5–S6 linkers are highly 
conserved sequences folded to leave their extremes in the extracellular space, and place 
























Temperature (°C)Chapter Eight – Clinical and genetics investigation of a family with an atypical congenital nystagmus syndrome
within the pore a P sequence which exerts a critical role for ion selectivity and 
permeation of the Ca2+ channel
204. 
Three allelic disorders are caused by mutations in this gene; spinocerebellar 
ataxia type 6 (SCA6, MIM 183086), familial hemiplegic migraine (FHM, MIM 141500) and 
episodic ataxia type 2 (EA2, MIM 108500). SCA6 is characterized by adult-onset, slowly 
progressive cerebellar ataxia, dysarthria, nystagmus, and impaired sensations of 
vibration and proprioception
205. Symptoms of SCA6 can occur for the first time as late as 
65 years of age, indeed patients with a genetically confirmed diagnosis may remain 
asymptomatic until old age
206;207. FHM is characterised by migraine attacks preceded by 
symptoms such as unilateral limb paresis or paralysis, paraesthesias, dysphasia and 
interictal cerebellar signs which are reported in about 50% of patients
208. EA2 is 
characterised by a complex and highly variable phenotype, widely overlapping that of 
SCA6
209;210.  Its main features are episodes of vertigo or ataxia of variable frequency and 
duration, a permanent cerebellar deficit of variable severity, sometimes progressive, 
and a cerebellar atrophy typically starting from the anterior portion of the vermis
205. 
About 50% of individuals with EA2 have migraine headaches (suggesting overlap with 
FHM) and onset is typically in childhood or early adolescence although the age range is 
variable. Interestingly, it is commonly associated with interictal nystagmus and patients 
with EA2 mutations have been reported in whom the only interictal sign or symptom is 
nystagmus
195. Other features occurring with EA2 include: dyskynesia, muscular 
weakness and epilepsy
205. An interesting feature of EA2 and FHM is that oral 
acetazolamide treatment can prevent or abort the episodic symptoms
199;200. Indeed, 
response to Acetazolamide is sometimes used diagnostically when EA2 is called by one 
of its alternative names; Acetazolamide-responsive hereditary paroxysmal cerebellar 
ataxia (APCA). Acetazolamide is also known to be effective in suppressing episodic or 
fluctuating symptoms of SCA6, although chronic progressive ataxia does not respond
211. 
Typically, the nystagmus phenotype in these disorders may include vertical jerk 
nystagmus (downbeat, upbeat), gaze evoked nystagmus, acquired pendular nystagmus, 
periodic alternating nystagmus and rebound nystagmus
212;213.   However, many different 
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nystagmus phenotypes have been described including periodic alternating nystagmus
214 
and vertical or horizontal nystagmus
215-217. Smooth pursuit and fast OKN are mediated 
via the cerebellar flocculus/paraflocculus and vermis and so pursuit is typically saccadic 
and OKN is absent or of low gain.  The vermis is involved in controlling the accuracy and 
timing of saccades and so they may be dysmetric in these disorders
212;213. 
Point mutations in the CACNA1A gene are responsible for EA2 and FHM (see 
Figure 28), whereas small expansions of a CAG repeat characterise SCA6. However, an 
EA2 phenotype was also found in association with an expanded CAG allele of the 
CACNA1A gene
195 and with a point mutation of the auxiliary b4 subunit of the same P/Q 
Ca2+ channel, coded by gene CACNB4
218. FHM patients carry exclusively missense 
mutations
219;220. In the case of EA2 however, many truncating
205;215;221-224 and non 
truncating 
205;225-232 mutations have been identified. Some point mutations in CACNA1A 
have been evaluated electrophysiologically and of 3 mutations causing EA2, all were 
found to decrease the current through these Ca channels
228;233. Alternatively, some 
CACNA1A mutations, such as those seen in FHM, result in increased Ca
2+ entry and, 
thereby, aberrant transmitter release and possibly excitotoxictly
196;219. 
In a review of the previously published EA2 mutations by Mantuano et al in 2004 
it was suggested that non-truncating mutations which have been associated with EA2 
were preferentially located in the S5–S6 linkers (9/12), and particularly those of domain 
I and III (8/12), where they tended to cluster at the extremities and their borders
205. 
Other groups have subsequently found mutations in many different parts and domains 
of this gene in subjects with EA2 and have suggested that the type of mutation, 
missense versus nonsense, or the location of altered or truncated amino acid residues 
does not predict the clinical phenotype
234. 
Using a computer-annotated protein sequence and structure database 
(http://beta.uniprot.org/uniprot/O00555) the c.4110T>G p.Phe1370Leu (NM_000068.3) 
variation identified in this work is predicted to be located within a small 19bp 
topological domain of the Cav2.1 subunit of P/Q type voltage gated Ca2+ channel. This 
domain is located within the cytoplasm between segment 4 and segment 5 of the repeat 
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domain 3 (see Figure 28). It is interesting to note that the Phe-to-Leu result of the 
c.4110T>G p.Phe1370Leu (NM_000068.3) variation is a conservative change as 
phenylalanine and leucine are similarly non-polar amino acids with only a small 
physiochemical differences. This is unusual for mutations causing EA2 which tend to 
cause non-conservative amino acid changes
205.
Figure 28 An illustration of the locations of pathogenic mutations in the CACNA1A gene.
 Mutations are illustrated  within the protein product of this gene (the Cav2.1 subunit of P/Q 
type voltage gated Ca2+ channel). Non-truncating mutations in subjects with EA2 are illustrated 
with red dots, truncating mutations in EA2 are illustrated with orange dots, those with FHM are 
illustrated with green dots. The blue dot shows a mutation in a family with severe progressive 
ataxia from age 44 years (diagnosed as SCA6 clinically). The red circle with yellow centre 
illustrates the c.4110T>G p.Phe1370Leu (NM_000068.3) mutation found in the VNCM family. 
It can be seen that mutations and CAG repeat expansions in the CACNA1A gene 
are associated with a high degree of clinical heterogeneity. Furthermore, the clinical 
features of SCA6, EA2 and FHM are also associated with significant locus and allelic 
heterogeneity. In one study, up to 33% of individuals with 21 or more CAG repeats in 
CACNA1A had episodic features prominent enough to warrant the diagnosis of EA2
235. In 
one family with a CAG repeat expansion, some members were reported to have had 
episodic ataxia and others had progressive ataxia
195. In one family with a CACNA1A 
missense mutation, phenotypes of both SCA6 and FHM were observed
236. In another 
family with a CACNA1A mutation, both SCA6 and EA2 phenotypes were reported
195. 
Therefore, many different clinical phenotypes are known to exist due to various 
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mutations in the CACNA1A gene. However, the VNCM family presented with a number 
of features which are unusual for the spectrum of diagnoses spanning EA2, SCA6 and 
FHM. They presented to the clinic because of isolated nystagmus in a 3 month year old 
baby (VNCM-5) which has not been previously reported. Only when  the rest of the 
family were examined in clinic was it found that many others also had undiagnosed (and 
asymptomatic) nystagmus. In EA2, interictal nystagmus tends to occur only after a series 
of attacks of episodic ataxia and other cerebellar symptoms. Interictal nystagmus in this 
disorder is also usually only evident after the development of cerebellar vermis atrophy 
which the index child in the VNCM family did not have. Only one (VNCM-3) of the 8 
subjects in this pedigree describe migrainous headaches and none describe episodes of 
hemiplegia. Indeed, all but the 3 month year old proband with nystagmus and VNCM-3 
with onset of subtle ataxia age 56, were completely asymptomatic and had no other 
signs of cerebellar dysfunction except for subtle nystagmus at the time of examination. 
Again, this has not been previously reported. 
The nystagmus phenotype in this pedigree was largely typical of cerebellar 
disease with disturbed OKN and dysmetric saccades. It is interesting to note that of the 
3 subjects in whom nystagmus had never been previously noted, one had no nystagmus 
in the primary position (VNCM-7) and the other 2 had fine nystagmus of low intensity 
(VNCM-1 and VNCM-4). Furthermore, rebound nystagmus was only noted in one 
subject. Also, subsequent to our examination of this family subject VNCM-4 (now age 
31) has developed a mildly unsteady gait and minimal finger-nose ataxia with no other 
symptoms or signs. She still describes no episodic nature or migrainous symptoms. 
Therefore, this family represents an unusual clinical manifestation of a CACNA1A 
mutation which may be due to the mutations location in a novel part of the Cav2.1 
subunit of P/Q type voltage gated Ca2+ channel.
Proving pathogenic causality of a given sequence variation for a given disease 
can be complex
11.There is however, some strong evidence that the c.4110T>G 
p.Phe1370Leu (NM_000068.3) variation identified in this pedigree is the pathogenic 
cause of the nystagmus phenotype. Firstly, this variation was not seen in 300 control 
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chromosomes suggesting that it is not a simple polymorphism. Secondly, as has been 
detailed above, the gene has a relevant and appropriate function and it is known that 
other mutations in this gene cause similar phenotypes. Thirdly, the variation was seen to 
segregate with the disease in this pedigree which has shown that the chance of the 
variation and the disease phenotype being unlinked is extremely low. Finally, this 
variation occurs in a highly conserved domain and the phenylalanine to leucine amino 
acid change occurs at a position which is also highly conserved throughout evolution 
(see Figure 29).
Figure 29 Evolutionary conservation of the CACNA1A gene. 
An illustration of the conservation of a phenylalanine base which is altered to a leucine base by 
the c.4110T>G p.Phe1370Leu (NM_000068.3) variation identified in the VNCM family. The 
phenylalanine amino acid (F, surrounded by red box) is conserved throughout evolution, and 
resides within a highly conserved domain. Sequences are from the UNIPROT database 
(http://beta.uniprot.org/); Human CACNA1A, O00555; Rabbit CACNA1A, P27884; Mouse 
CACNA1A, P97445; Danio Rerio (zebrafish), novel protein similar to vertebrate voltage-
dependent calcium channel, P/Q type, alpha 1A subunit, Q5RHB1; Drosophila Melanogaster 
(Fruit fly), Voltage-dependent calcium channel type A subunit alpha-, P91645.
This family was initially found after subject VNCM-5 presented to the ophthalmic 
unit aged 3 months with apparent isolated atypical CIN. After full ophthalmic, 
neurological and general physical examination and following a VEP, ERG and MR brain 
scan this child’s diagnosis was one of isolated atypical CIN. Only after examination of the 
relatives was it found that many of them also had nystagmus and the clinical details of 
subtle cerebellar symptoms/signs was elicited in an older relative (VNCM 5). This 
emphasises the necessity for ophthalmic examination of relatives in cases of apparent 
sporadic CIN, particularly if the waveform is atypical. It also lends weight to the 
suggestion that idiopathic nystagmus, as is the case for any diagnosis of exclusion, is 
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likely to represent a range of underlying pathologies with similar functional results. 
Furthermore, it has suggested that perhaps CACNA1A mutations can cause subclinical 
nystagmus before the onset of other cerebellar symptoms and signs. In this pedigree the 
subtle cerebellar signs seem to occur at age 30-35. However, the nystagmus is likely to 
have been present in the affected members since very young age as in all patients there 
is an absence of oscillopsia which is usually a feature of early onset congenital 
nystagmus 
76;77. 
The distinction between CIN and NN has been blurred by the description of a 
number of families with predominant nystagmus and more subtle neurological 
symptoms or signs such as the VNCM family
237. Perhaps, in searching for genes for 
idiopathic nystagmus we should prioritise the genes which are known to cause some of 
these other complex diseases.
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9 CHAPTER NINE – Spatial and temporal FRMD7 
expression profiling during murine development
9.1 Introduction
The expression profile of the FRMD7 gene is poorly understood. There is some 
evidence that the mRNA is present in most tissues at low levels and is possibly greatest 
in kidney and testis (http//symatlas.gnf.org/symatlas/). Using RT-PCR,  Tarpey et al 
detected mRNA expression in human adult kidney, liver, pancreas and, at lower levels, 
in heart and brain
159. In human foetal tissue they found the transcript only in kidney. 
Using in situ hybridisation this group found that in human embryonic brain at day 56 
post ovulation, there was expression in the ventricular layer of the forebrain, midbrain, 
cerebellar primordium, spinal cord and developing neural retina. In day 37 post 
ovulation embryos, expression was restricted to the mid- and hindbrain, regions known 
to be involved in motor control of eye movement
159. No further expression work has 
been published in any species. 
It has been postulated that the FRMD7 gene is likely to be involved in neuronal 
development
159;238;239. It is also known that gaining an understanding of the spatial and 
temporal expression of genes can provide insights into complex self-organizing 
processes such as mammalian
 central nervous system development
240. It is also thought 
that comparing gene expression patterns of neurodevelopment in the embryonic brain 
in relation to the adult can provide valuable information. Often clues to adult gene 
expression and gene function can be determined by examining embryonic 
development
241.
This chapter describes a detailed temporal expression study of FRMD7 in the 
developing brain, lung and heart in mice.
Mr Jay Self 2008  Page 136 of 220Chapter Nine – Spatial and temporal FRMD7 expression profiling during murine development
9.2 Methods
9.2.1Preparation of cDNA samples
Murine cDNA samples were kindly donated as a gift following their preparation 
by Dr Hans Michael Haitchi, Clinical Research Fellow, Roger Brooke Laboratory, 
University of Southampton. Specific pathogen free 6 weeks old out bred MF-1 mice 
(obtained from Harlan UK Limited, Bicester, UK), had been kept in the animal facility, 
and were time mated by detection of a vaginal plug. This day was taken as embryonic 
day (ED) 0. Pregnant mice between ED 10-20, newborn and juvenile mice had been 
killed using a Schedule 1 method (cervical dislocation). Gravid uteri had been removed 
under sterile conditions and embryos killed according to schedule 1 method (neural 
tube dissection, cervical dislocation). Maternal adult, embryonic and postpartum lungs, 
hearts and brains had been dissected in a laminar flow hood. Embryos had been 
dissected under a dissecting microscope (LEICA WILD M3Z, Wetzlar, Germany). The 
dissected lungs, hearts, and brains had then been placed in RNAlater® (Catalog# 
AM7020; Ambion®, Applied Biosystems, Warrington, UK) or directly homogenised in 
TRIzol
® (Invitrogen, Paisley, UK) and stored for later RNA extraction. Approximately, 10-
18 embryos had been obtained from each pregnant mouse. Each time point was 
represented by 2 animals from 2 separate mothers. Therefore, 2 independent samples 
were obtained for heart, brain and lung for ED11-19, adult female mice and day 1 and 
day 8 post delivery pups. The RNA extraction and reverse transcription methods were 
performed by Dr Haitchi in the Roger Broke laboratory by near identical methods to 
those described in section 2.3.
9.2.2Quantitative real time PCR protocol
Quantitative real-time PCR was performed to assess the relative abundance of 
murine FRMD7 compared with 2 housekeeping genes; Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and Actin, beta (ACTB). Two housekeeping genes were used 
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due to the well known increase in accuracy of relative qPCR when using greater than 
one normalising control gene
242. The choice of these 2 housekeeping genes was based 
on their previous use in heart, lung and brain tissues
243 and demonstration that their 
abundance is high and relatively similar in these tissues
242. Furthermore, these 2 genes 
have been utilized previously for murine brain studies by RT-PCR and GAPDH has been 
shown to have an almost constant expression value from ED10-P0
244.
The quantitative real-time-PCR was carried out using a one-step PCR kit (Custom 
real-time PCR assay for use with SYBRgreen chemistry) (PrimerDesign Ltd, Southampton) 
in a real-time thermocycler (Rotor-Gene 6000, Corbett Robotics. Ltd). PCR reactions 
were performed according to the kit instructions for 45 cycles. Using this chemistry, the 
SYBRgreen dye intercalates between complimentary DNA strands. This DNA-dye-
complex absorbs blue light (λmax = 488 nm) and emits green light (λmax = 522 nm). 
Therefore, fluorescence increases with the amount of PCR product.
Primers were designed by PrimerDesign Ltd (Southampton) for the FRMD7 gene 
and 2 housekeeping genes (GAPDH and ACTB). The FRMD7 gene had a sense primer: 
ATGCAAGGCTTTCTGGAAGAC and an antisense primer: CGGAAACTGGAACCTTTGCTA 
with an amplimer size of 111. The control gene sequences are the intellectual property 
of PrimerDesign Ltd and are not available.
PCR reactions were performed in 100 well Gene-Discs (6001-012, Corbett Life 
Science, Brisbane, Australia) on the Rotor-Gene 
TM 6000 real time thermo-analyser 
(Corbett Life Science, Brisbane, Australia).  Each 20 µl comprised: 5 µl of cDNA (at 
approximately 50ng/ul), 1 µl of the reconstituted primer mix, 10 µl of PrimerDesign 2X 
Precision
TM MasterMix with SYBRgreen and 4 µl PCR-Grade water. PrimerDesign 2X 
Precision
TM MasterMix is a pre-prepared/optimized mastermix containing 2X reaction 
buffer, 0.025 U/ µl  of a chemical Hotstart Taq, 5 mM MgCl2 and DNTP mix (200 µM each 
dNTP). 
The Rotor Gene run settings were according to the standard protocol suggested 
for custom qPCR assays by PrimerDesign. Briefly, the two-step amplification conditions 
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were: enzyme activation for 10min at 95°C, followed by 45 cycles of: 15 seconds 
denaturation at 95°C, 60 seconds annealing and extension at 60°C and fluorescence data 
collection at the end of the denaturation step. A high resolution melt was also 
performed for each run to assess product purity with ramping from 60-95°C with 
fluorescence data collection at 0.5°C increments. Each developmental time point was 
represented by 2 samples and all samples were run in duplicate with duplicate water 
controls (cDNA replaced by water) for each gene in each run.
9.2.3Data analysis methods
By monitoring the fluorescence values of each sample it was possible to 
determine the quantity of PCR product on a cycle-by-cycle basis. To account for 
differences in background fluorescence, the Rotorgene software automatically 
normalised the data. Once normalization was complete, a threshold was set at which 
fluorescence data was analysed. This threshold was set at a level where the rate of 
amplification was greatest during the exponential phase. In this experiment the same 
threshold fluorescence value was used in all runs and was set at a normalised 
fluorescence value of 0.12. The number of cycles taken for each sample to reach the 
threshold level was defined as the Ct-value (threshold cycle) and was taken as a 
measure of the abundance of cDNA target present. 
Results were analysed using the ‘Comparative Ct method’  which is also known 
as the ‘delta delta CT’ method
245. This method involves comparing the values of the 
sample with those of a calibrator or control. For the purpose of these experiments, 
heart, brain and lung samples were analysed separately and calibrated to the earliest 
time point sample. Each tissue was represented by 2 samples per time point and each 
sample was run in duplicate for all genes. Therefore, for each time point the average Ct 
value (avr-Ct) for each gene was calculated from 4 recordings. Then the ΔCt-value was 
calculated according to the following equation:
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  ΔCt-value = avr-Ct(gene of interest) – avr-Ct(2 housekeeping genes)
Having calculated the ΔCt-values, the delta-delta Ct value (ΔΔCt) was calculated 
as follows:
ΔΔCt = ΔCt (ED11 control) – ΔCt (sample of interest)
In the last step of quantification the ΔΔCt values were transformed into absolute 
values of the level of comparative expression according to the formula below: 
Comparative Expression Level = 2 ^ΔΔCt.
For this method of analysis to be successful, a validation experiment is required. 
This validation experiment is considered successful when the dynamic change of both 
the target and reference gene are similar
246. Therefore, by serially diluting a sample and 
detecting corresponding serially lower CT values for housekeeping and target genes, the 
efficiency of the PCR is validated over a range of concentrations. However, for low copy 
number genes this method is not always applicable as serial dilution of a cDNA sample 
over a wide range of concentrations is not possible. As this is the case for the FRMD7 
gene, we performed a number of validation experiments which are detailed in the 
results section. However, validation of the delta-delta CT methodology is also provided 
by other evidence in this case, as each gene assay was designed and manufactured by 
the Primerdesign Ltd. company. Each of these assays has been tested for PCR efficiency 
during production using a linear regression analysis method at the point of exponential 
fluorescence change such that all assays are guaranteed to have a PCR efficiency close 
to 100%. This means that for analysis of relative mRNA expression, 1 CT value is 
equivalent to a one fold difference in copy number and the delta-delta CT method of 
analysis is appropriate and valid
246.
In summary, for each tissue, 12 developmental time points were taken and for 
each time point 2 animals were sacrificed to allow relative cDNA expression 
measurements. FRMD7 expression was compared with expression of the GAPDH and 
ACTB control genes in each sample and samples were all compared to the ED11 samples 
for that given tissue.
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9.3 Results
9.3.1Assessment of assay validity
Initially, some preliminary qPCR runs were performed to confirm that the 
planned comparative experiments would be valid. 
Three murine heart cDNA samples from 2 time points (ED14b, ED13a and ED13b) 
were run with all three test genes, appropriate water controls and in duplicate using the 
protocol and analysis method designed for the relative expression experiments (see 
Figure 30 and Table 11).
Figure 30 An amplification plot from a real-time quantitative PCR run. 
This plot shows the amplification of 3 murine heart cDNA samples (ED14b, ED13a and ED13b), 
and water controls for 3 gene assays (GAPDH, ACTB and FRMD7), run in duplicate.
Sample CT Average replicate Ct
FRMD7 MIX,H14A 27.12 27.15
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FRMD7 MIX,H14A 27.19
FRMD7 MIX,H13B 27.85 27.86
FRMD7 MIX,H13B 27.88
FRMD7 MIX,H13A 28.09 27.79
FRMD7 MIX,H13A 27.49
GAPDH MIX,H14A 14.96 15
GAPDH MIX,H14A 15.05
GAPDH MIX,H13B 15.81 15.87
GAPDH MIX,H13B 15.93
GAPDH MIX,H13A 15.24 15.21
GAPDH MIX,H13A 15.17
ACTB MIX,H14A 15.36 15.37
ACTB MIX,H14A 15.39
ACTB MIX,H13B 16.73 16.65
ACTB MIX,H13B 16.57
ACTB MIX,H13A 16.02 16.01
ACTB MIX,H13A 15.99
FRMD7 MIX. 5 μl Water 28.76 29.12
FRMD7 MIX. 5 μl Water 29.48
GAPDH MIX. 5 μl Water 30.78 30.78
GAPDH MIX. 5 μl Water 30.78  
ACTB MIX. 5 μl Water 31.8 31.41
ACTB MIX. 5 μl Water 31.02
Table 11 Results of a real-time quantitative PCR run.
 Threshold cycle (CT value) results are shown for 3 murine heart samples (ED14b, ED13a and 
ED13b), and water controls for 3 gene assays (GAPDH, ACTB and FRMD7), run in duplicate. CT 
values were calculated according to a normalised threshold CT value of 0.12 fluorescence units.
It can be seen that for each gene, the two separate samples from a single time 
point, and the 2 replicates of each sample had similar CT values. Similarly, by displaying 
the 2 replicates for a single sample (ED14a), it can be seen that the amplification plot is 
near identical for replicates (see Figure 31).
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Figure 31 A calibrating amplification plot from a real-time quantitative PCR run. 
This plot shows the amplification of a single murine cDNA sample (ED14b) run in duplicate for 3 
gene assays (GAPDH, ACTB and FRMD7).
These results gave a preliminary indication that CT value variance was low 
between cDNA samples from the same tissue and time point, and duplicated runs using 
the same cDNA sample. For both GAPDH and ACTB control genes, the water control (no 
cDNA template) amplified significantly later than all cDNA samples (approximately 6 
cycles later). This is an indication of the specificity of the PCR assays and excludes the 
possibility of sample contamination contributing significantly to PCR amplification. 
However, for the FRMD7 gene assay, amplification in the water control is only 1.5 to 2 
CT values behind the cDNA samples. Therefore, it is necessary to study the melt curve 
characteristics of these samples to check for the specificity of the PCR assay. By plotting 
the negative derivative of fluorescence (−dF/dT) with respect to temperature, the 
Rotorgene software can display a melting peak for each sample. Different PCR products 
have melting peaks at specific temperatures. Therefore, if a sample has a clear, narrow 
based, single peak, this indicates that the amplimer is a single product. Similarly, a 
broad, diffuse, low peak indicates mis-priming and multiple products. Furthermore, 
when different samples are compared using the same assay, a melting peak centred 
around the same temperature is expected. When primer-dimers are formed, these can 
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be seen as peaks occurring typically at a lower temperature that that of the desired 
amplimer. In this preliminary experiment it can be seen that the control gene assays 
have tall, thin specific melting peaks and that the melting peaks for the corresponding 
water controls were typical of nonspecific priming (see Figure 32):
Figure 32 A melt curve analysis showing specific PCR product amplification.
This plot shows the negative derivative of fluorescence (−dF/dT) with respect to temperature 
during melting. GAPDH and ACTB gene assays are shown for each of 3 murine heart samples 
(ED14b, ED13a and ED13b) and water controls.  
 For the FRMD7 gene assay, the cDNA samples also had tall thin melting peaks 
indicative of a specific product but that the corresponding water controls had a peak 
centring on a lower temperature (see Figure 33):
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Figure 33 A melt curve analysis from a real-time quantitative PCR run. 
This plot shows the negative derivative of fluorescence (−dF/dT) with respect to temperature 
during melting. The FRMD7 gene assay is shown for each of 3 murine heart samples (ED14b, 
ED13a and ED13b) and water controls.   
This result is typical of primer-dimer formation (or possibly a single misprimed 
product from contaminating DNA) for the water controls and shows that the cDNA 
samples had a valid amplification curve as they have a true product which is not due to 
DNA contamination or primer-dimer formation. It also showed that this assay would 
have a tendency to primer-dimer formation when the target cDNA was low or absent. It 
was therefore necessary to perform melt-curves analyses on all subsequent runs and 
exclude samples for which amplification was the result of primer-dimer formation. 
The FRMD7 PCR products for 2 samples subsequently underwent direct 
sequencing to confirm the identity of the single product. This confirmed that the 
amplimer was the intended murine FRMD7 sequence. Similarly, the presumed primer-
dimer products of the FRMD7 water controls were also size banded on an agarose gel 
and directly sequenced showing absence of any PCR amplification product besides 
primer-dimer complexes. 
In order to confirm the claimed ‘near 100% PCR efficiency’ guaranteed by the 
Primerdesign company, a serial dilution experiment was performed for all 3 gene assays. 
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For each assay a series of 6 serial 1/10 dilutions was performed in duplicate and run as a 
standard curve experiment with the original neat sample on the Rotorgene 6000 
machine. For each standard curve, the Rotorgene 6000 software was used to perform a 
series of statistical calculations as follows:
M = the slope of a standard curve, i.e. the number of CT values corresponding to each 
1:10 dilution in template cDNA. For a 100% efficient curve this value is -3.322.
R^2 (correlation coefficient) = the percentage of the data which is consistent with the 
hypothesis that the standards form a standard curve. If the R2 value is low, then the 
given standards cannot be easily fit onto a line of best fit. An excellent R2-value is 
around 0.99.
R-value (square root of correlation coefficient) = the square root of the R^2 value. This 
value is rarely used for standard curve analysis.
B = the CT value of the neat cDNA sample or that sample given as a concentration of 1. It 
is rarely used in standard curve analysis.
Efficiency = the calculated reaction efficiency for all standards represented by the 
formula efficiency = [10
(-1/M)] – 1. The optimal value for a 100% efficient amplification is 
1.
It can be seen in Figure 34 that for both the GAPDH and ACTB assays, the PCR 
efficiency is close to 1 and that the R^2 is greater than 0.99. This confirms that the 
assays are very close to 100% efficient over a broad range in target gene copy number.
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Figure 34 Standard curves for the qPCR assays for 2 housekeeping genes.  
Standard curves are presented for GAPDH and ACTB by plotting CT values against template 
concentration on a log scale. The correlation coefficient (R^2), slope of the curve (M) and PCR 
-efficiency (efficiency) are also presented.
   
When the identical experiment was performed for the FRMD7 assay, serial 
dilution beyond a 1:10 dilution resulted in significant shift towards primer-dimer 
formation and minimal FRMD7 product amplification. It can be seen in Figure 35 that at 
high cDNA concentration (dark green lines) FRMD7 product was present with no primer-
dimer formation. However, as the cDNA concentration is reduced (progressively lighter 
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green lines) the FRMD7 product reduces and the primer-dimer peak increases such that 
at a dilution of 1:100000 (lightest green line) only primer-dimer complexes are present. 
Therefore, as expected, a standard curve could not be completed over a wide range of 
copy number for this assay.
Figure 35 A melt curve analysis for the FRMD7 qPCR assay.
This plot shows the negative derivative of fluorescence (−dF/dT) with respect to temperature 
during melting. Two peaks are labelled which correspond to the qPCR target and a primer-dimer 
peak. A single cDNA sample (darkest green) was serially diluted (lighter green hues) 6 times in a 
1:10 dilution.
Due to the low copy number of the FRMD7 gene target sequence, it was now 
clear that the planned experiments would be performing close to the threshold 
resolution for qPCR by this technique. Therefore, to test the limits of accuracy for these 
assays, an experiment was performed in which one sample (brain PD8) was serially 
diluted again but with only a 1 fold dilution per step. All 3 assays were performed for 
these samples which were run in duplicate. Both GAPDH (R^2 = 0.974, efficiency = 0.99) 
and ACTB (R^2 = 0.996, efficiency = 1.07) standard curves were again indicative of near 
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100% PCR efficiency. For the FRMD7 assay, dilution beyond 1/8 of cDNA template 
resulted in significant primer-dimer formation (see Figure 36). 
   
Figure 36 A melt curve analysis for the FRMD7 calibration curve qPCR assay. 
This plot shows the negative derivative of fluorescence (−dF/dT) with respect to temperature 
during melting. Two peaks are labelled which correspond to the qPCR target and a primer-dimer 
peak. A single cDNA sample was serially diluted (green lines) 6 times in a 1:2 dilution. Beyond a 
1:8 dilution (light green lines) primer dimmer formation was significant. The black line is a no-
template water control sample run in duplicate.
By performing a standard curve analysis on the 6 samples above this threshold, a 
standard curve with R^2 = 0.99628 and Efficiency = 0.92 was achieved (see Figure 37). 
This suggested that when samples with significant primer-dimer were excluded, PCR 
efficiency over this relatively narrow range in copy number, was similar to that of the 
control genes. Subsequently, any sample with a greater proportion of primer-dimer 
peak than that used in the above calculation (dark green curves in Figure 36) was 
excluded. 
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Figure 37 A standard curve for a qPCR assay for the FRMD7 gene.
The standard curve is presented by plotting CT values against template concentration on a log 
scale. The correlation coefficient (R^2), slope of the curve (M) and PCR efficiency (efficiency) are 
also presented.
The final optimisation experiment was performed to confirm that the relative 
expression methodology and data analysis was reproducible. For this purpose, two time 
points were selected from murine brain (ED17 and ED18). These time points were 
selected as more cDNA was available for these samples (the original use of these cDNA 
samples was for lung research). Each time point had 2 separate samples and each 
sample was run in duplicate for the GAPDH, ACTB and FRMD7 gene assays. This 
experiment (24 samples and 6 water controls) was run twice by the same protocol on 
two separate days and one after a freeze/thaw cycle for all reagents and samples. 
Results were analysed and are presented as the relative expression of FRMD7 on ED18 
compared with ED17 (see Table 12). 













FRMD7Chapter Nine – Spatial and temporal FRMD7 expression profiling during murine development







FRMD7 Brain 18b 24.11 25.0575 8.8575 1.9375 3.83
FRMD7 Brain 18b 24.45
FRMD7 Brain 18a 25.97
FRMD7 Brain 18a 25.7
FRMD7 Brain 17b 26.53 27.08 10.795
FRMD7 Brain 17b 26.68
FRMD7 Brain 17a 27.67
FRMD7 Brain 17a 27.44
GAPDH Brain 18b 18.3 18.275
GAPDH Brain 18b 18.72
GAPDH Brain 18a 18.25
GAPDH Brain 18a 17.83
GAPDH Brain 17b 18.69 17.8625
GAPDH Brain 17b 18.05
GAPDH Brain 17a 17.55
GAPDH Brain 17a 17.16
ACTB Brain 18b 13.81 14.125
ACTB Brain 18b 13.7
ACTB Brain 18a 14.52
ACTB Brain 18a 14.47
ACTB Brain 17b 14.85 14.7075
ACTB Brain 17b 15.01
ACTB Brain 17a 14.57







FRMD7 Brain 18b 24.16 24.755 9.48625 1.5875 3.01
FRMD7 Brain 18b 23.74
FRMD7 Brain 18a 25.72
FRMD7 Brain 18a 25.4
FRMD7 Brain 17b 26.33 26.7575 11.07375
FRMD7 Brain 17b 26.26
FRMD7 Brain 17a 27.34
FRMD7 Brain 17a 27.1
GAPDH Brain 18b 16.28 16.4875
GAPDH Brain 18b 16.36
GAPDH Brain 18a 16.78
GAPDH Brain 18a 16.53
GAPDH Brain 17b 17.04 16.7975
GAPDH Brain 17b 16.95
GAPDH Brain 17a 16.57
GAPDH Brain 17a 16.63
ACTB Brain 18b 13.71 14.05
ACTB Brain 18b 13.67
ACTB Brain 18a 14.36
ACTB Brain 18a 14.46
ACTB Brain 17b 14.78 14.57
ACTB Brain 17b 14.83
ACTB Brain 17a 14.35




Table 12 Results of a real-time quantitative PCR analysis. 
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An experiment was run on two separate occasions using the same samples, experimental 
protocol and analysis methods. Reagents in Experiment 2 had also undergone an additional 
freeze-thaw cycle.
The results showed that the relative expression of FRMD7 on ED18, compared 
with ED17, was calculated as 3.8 and 3.0. Therefore, the expression of FRMD7 was 
increased by approximately one third from the expression on ED17 and crucially, the 
values for the 2 experiments were similar.
Together, the results of these preliminary experiments showed that the 
methods, reagents and protocols to be used in the subsequent relative gene expression 
experiments were valid, appropriate and reproducible.
9.3.2Changes in FRMD7 gene expression during murine 
development
All samples were run in duplicate according to the protocols above with the 
GAPDH, ACTB and FRMD7 gene assays and water controls. Due to the number of 
samples and the necessity to include controls in each run, a total of 486 samples were 
analysed in 9 qPCR runs. In all runs, GAPDH and ACTB water controls showed no 
amplification until later than 8 CT values behind cDNA samples and had low broad melts 
indicative of mis-priming at very late CT values. Similarly, in all runs, the FRMD7 water 
controls amplified later than 2 CT values after the cDNA samples and had melting peaks 
indicative of primer-dimer formation after many cycles. 
Some samples were excluded due to a supra-threshold proportion of primer-
dimer formation as discussed previously. This tended to occur in sequential time points 
when the copy number was low, indicating that this phenomenon was due to such low 
abundance of the target gene. In some cases this occurred for only one sample per time 
point (7 samples). In these cases this sample was excluded and analysis made based on 
the other sample only. These samples have no error bar in Figure 38. In samples where 
both samples from a given time point were excluded for this reason (Lung ED11 and 
ED12), these time points were excluded from analysis and relative abundance was 
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recorded as 0. The comparative expression levels in the lung samples were therefore 
normalised to the next earliest time point, ED13. 
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Figure 38 Relative expression profiles for the FRMD7 gene.
cDNA samples were taken from 3 murine tissues during development and relative expression 
measurements for the FRMD7 gene relative to GAPDH and ACTB housekeeping genes are 
presented. * = All samples were normalised to this sample. Error bars represent the Standard 
Error of the Mean (SEM).
9.4 Discussion
The results presented above show that in murine heart and lung, FRMD7 
expression varied very little between ED11 and PD8. Interestingly, for both tissues, 
expression increased significantly in the adult samples following a similar pattern. In 
these tissues, overall expression of FRMD7 was very low and in most samples expression 
was at the limit of resolution for this technique. However, it is apparent that no 
significant increases in expression level occur during this critical period in murine 
development and that overall expression in these tissues during development is very 
low and consistent with the previously reported ‘low levels of expression in most 
tissues’
159.
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Overall expression levels in the murine brain samples were higher as seen by the 
low levels of primer dimer formation and earlier FRMD7 amplification in these samples. 
However, as detailed previously, quantitative comparison between tissues can be 
difficult due to differences in control gene expression and so are not presented here.
Interestingly, the overall pattern of expression in the brain tissue is noticeably 
different to that seen in the lung and heart tissues. Expression is seen to increase slowly 
between ED11 and ED18. It seems that expression levels remain higher after ED18 
although no more can be said about these subsequent samples as they have significantly 
greater error ranges representing greater differences between the 2 samples, per time 
point. However, it can be said with some certainty that FRMD7 expression is greatly 
increased at ED18 compared with earlier time points during murine brain development. 
It has been shown that genes expressed during murine develop exhibit 
functional clustering in terms of temporal and spatial expression profiles during 
development
244;247. In 2005 Matsuki et al used an oligonucleotide-based microarray 
system to study the expression of 12,422 genes in the mouse brain between on ED11, 
ED15, ED18 and P0
244. They found significant differential expression in 1413 of these 
genes when normalised to the ACTB gene. These genes were then grouped into 15 
clusters based on cellular events involved in brain development and known/predicted 
gene function. Interestingly, only 4 of these clusters showed an overall temporal 
expression pattern similar to our FRMD7 findings with characterised by low levels of 
expression until a significant increase at ED18. These 4 clusters were; ‘carbohydrate, 
lipid and amino acid metabolism (CLAM)’, ‘cell adhesion and recognition’, ‘Neurotrophin 
hormone, growth factor and cytokine (NHGC)’ and ‘neurotransmitter and ion channel 
genes (NT)’. This is an interesting finding as the CLAM genes supply molecular 
components required for active neurogenesis and hisogenesis, NT genes supply 
molecular components for the formation of neurnal connectivity and circuits and NHGC 
genes have a role in signalling for neural differentiation and survival
244. All these 
processes are known to be occurring at this developmental stage, showing the efficacy 
of this clustering methodology and a possible role for FRMD7 in these processes in 
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murine brain. This group subsequently selected 397 of these differentially expressed 
genes for which strong functional data was available. These genes were characterised 
into eight new clusters based on their developmental function. Interestingly, the 
expression pattern of up regulation at ED18/P0 was most strongly seen in 2 clusters. 
These clusters pertained to genes involved in: synapse formation and function (e.g. 
genes coding GABA receptors and intracellular calcium channels) and axon growth and 
guidance-related genes (e.g. Sema4f and Cdh8). Again, these results suggest a role for 
FRMD7 in these processes in murine brain development. However, samples were taken 
from whole brain and so there is no indication of which brain regions are expressing the 
gene at this time. Furthermore, earlier brain tissues used in this work (ED11 to 
approximately ED14) will have included the developing optic vesicle (developing eye) 
and all samples the developing primary visual cortex and connections. Therefore, no 
inference can be made from this work about which brain/eye structures are responsible 
for the peak in FRMD7 expression at ED18 or the pathophysiology of CIN. 
It is important to note that in this work, detection of FRMD7 expression was 
occurring at the limit of resolution for quantitative real-time PCR. In many samples the 
CT difference between housekeeping genes and the FRMD7 gene amplification curves 
was approximately 15 cycles. This corresponds to a difference in expression of 1:65536. 
At this very low level of expression primer-dimer formation occurred for poor samples 
which were then necessarily excluded. Possibilities for improving RT PCR results for such 
a low copy number gene include; increasing the number of animals/samples per time 
point to increase the power of identified expression differences, different FRMD7 
primers with a lower tendency for primer-dimer formation, gene specific RT PCR and the 
use of fluorescent labelled probes for specific detection of the target transcript. 
The final caveat to this work is that expression analysis was performed on 
murine samples with the possibility of differences to expression profiles in human 
tissues. For example, mice do not have fovea and their eyes do not open until 
approximately P10/11. Therefore, the visual systems of humans and mice are 
structurally different and development occurs over differing timescales. However, the 
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role of FRMD7 in mice is likely to direct further study of this gene in humans especially 
when a human FRMD7 antibody is available.
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10 CHAPTER TEN – A survey of FRMD7 expression 
10.1 Introduction
As detailed previously, the FARP2 gene on chromosome 13 shares significant 
homology with a large portion of FRMD7. It is also known that FARP2 alters neurite 
length and degree of sprouting in rat embryonic cortical neurones
184;185. These 
observations have lead to the hypothesis that mutations in FRMD7 may cause 
nystagmus by altering the neurite length and degree of branching of neurons as they 
develop in the midbrain, cerebellum or retina
159. Furthermore, the results in chapter 9 
have suggested that in mouse brain, the FRMD7 expression profile is consistent with a 
gene which has a role in these processes. However, detailed functional work will require 
a greater understanding of the cells which express FRMD7. A monoclonal primary 
antibody to human FRMD7 mRNA has been designed and purchased for this purpose 
and is currently in production with an expected availability date in December 2008 
(EZBiolab, Westfield, USA). Furthermore, in early 2007 I nominated the murine FRMD7, 
FARP1 and FARP2 genes for knockout via the NIH backed Knockout Mouse Project 
(KOMP) which aims to ‘generate a public resource of mouse embryonic stem (ES) cells 
containing a null mutation in every gene in the mouse genome’ 
(http://www.nih.gov/science/models/mouse/knockout/). Subsequently, the FRMD7 and 
FARP2 genes were both been selected out of 17,350 genes for priority targeting and the 
development of knockout ES cells is currently underway. The ES cells will be available to 
the authors on completion which is anticipated to be in 2008/2009. Until these two 
resources are available, any information about which cell types express the FRMD7 
gene, and under what circumstances, will be valuable for directing future work.
This chapter describes an expression study of the FRMD7 mRNA in cells from 
various human sources in order to identify differences in FRMD7 expression between 
tissues, cell types, and stages of differentiation. 
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10.2 Tissues used in this experiment
The tissues and cells used in this experiment are listed below:
· Human neuroblastoma derived cell line SHSY5Y (LGC Promochem-ATCC 
Middlesex, UK)
· Human retinoblastoma derived cell line Y-79 (LGC Promochem-ATCC 
Middlesex, UK)
· Human adult kidney tissue 
SH-SY5Y cells are a good model system for studying neuronal properties in 
culture, as many of their receptor systems have been well characterized and they 
display developmental phenotype plasticity
248;249. These cells are widely used as a model 
system for investigations into neuritegenesis
250-253 which can be stimulated via a variety 
of pathways. Nerve growth factor (NGF) has been reported to induce neuritegenesis
252 
and cell flattening in SH-SY5Y cells, predominantly via TrkA receptor activation
254. 
Treatment with retinoic acid (RA) has been reported to induce differentiation of SH-SY5Y 
cells with resultant neuritegenesis
248, without altering TrkA expression
255. Cyclic AMP 
(CAMP) has been shown to cause SHSY-5Y cells to form neurite-like extensions
256 via a 
pathway involving cAMP-dependent protein kinase (PKA) activation
256. These methods 
were chosen as models of neuritegenesis in which FRMD7 expression could be 
evaluated.
Y-79 cells are derived from retinoblastoma and thus originate from retinal cells. 
They can be differentiated into cells with a neuronal phenotype
257-259. They were 
selected as an additional neuritegenesis model because of the hypothesis that FRMD7 
may have a role in neuronal development in the retina
159.
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It has been reported that kidney is one of the adult human tissues with the 
greatest FRMD7 expression
159. Therefore, comparison of expression between different 
parts of this organ and between adult and embryonic kidney may yield insights into 
which tissues/cells express this gene. 
10.3 Methods
10.3.1 Differentiation and RNA extraction from SHSY5Y cells 
SHSY5Y cells were purchased from LGC Promochem-ATCC (Middlesex, UK) and 
cultured as described in section 2.4. Differentiation was attempted by 3 different 
methodologies having placed cells in a 6 well cell culture plate (Nunclon, Cat no.140685) 
at densities ranging from 10 to 100 thousand per well. Cells at passage 24-28 were 
grown in 2 mls of either standard SHSY5Y culture media or NB-B27 media (see section 
2.4) which was changed 3 times per week. For all differentiation protocols, cells were 
viewed by direct microscopy on an inverted stage microscope at 24hours, 3 days, 7 days 
and 10 days. 
Initially, recombinant nerve growth factor β-NGF (R and D systems, Cat no. 256-
GF) was used in standard growth media at a concentration of 100ng/ml according to 
previously published protocols
252;253. Subsequently, the concentration of NGF was varied 
from 10-200ng/ml both with, and without the addition of 10nM FK506 monohydrate 
(Sigma, Cta no. F4679) which may potentiate the neurite outgrowth effects of NGF
252. 
A second protocol was followed in which cells were transferred to NB-B27 media 
(see section 2.4) containing di-butyryl-cyclic AMP (cAMP, Sigma, Cat no.D0260) at 1mM 
concentration as previously decribed
256. Subsequently, the cAMP concentration was 
varied between 100uM and 10mM concentrations. 
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The third protocol used for differentiation of the SHSY5Y cell line was according 
to a previously published protocol
248 using 75uM all-trans retinoic acid (RA, Sigma, Cat 
no.R2625) in standard SHSY5Y media.
Following optimisation of all differentiation protocols, each method was 
employed using 2 wells of a 6 well culture plate. 2 wells from each protocol were used 
for mRNA extraction after 1 week of differentiation protocol. For the all-trans retinoic 
acid protocol, mRNA was extracted at 24hours, 48 hours, 3 days, 7 days and 10 days.  
10.3.2 Differentiation and RNA extraction from Y-79 cells 
Y-79 cells were purchased from LGC Promochem-ATCC (Middlesex, UK) and 
cultured in standard Y-79 media as described in section 2.4. Differentiation was 
attempted by a number of different methodologies having placed cells at passage P6  in 
a 6 well cell culture plate 6 well cell culture plates (Nunclon, Cat no.140685) at densities 
ranging from 10 to 100 thousand per well. For all differentiation protocols, cells were 
viewed by direct microscopy on an inverted stage microscope at 24hours, 3 days, 7 days 
and 10 days. 
Initially, a differentiation protocol was followed as previously described
257;259;260. 
Cells were grown in full Y-79 media and moved into identical media but without FBS and 
grown on for 1 week. Cells were then plated at a density of 1-10,000 cells per well in a 6 
well cell culture plate which had been pre-coated with poly-l-lysine (poly-D-lysine in the 
original protocol description). These cells were grown on in Y-79 media without FBS but 
with 20ug/ml of Laminin (Invitrogen, Cat no.23017-015) in the media. Both Laminin and 
media were replaced 3 times/week. This protocol was varied by culturing Y-79 cells for 1 
week prior to plating in y-79 media without FBS (as per protocol) or one of 2 brands of 
minimal essential medium (ATCC MEM eagle, Cat no. 30-2003 or Gibco MEM, Cat no. 
320-11). Additionally, a gradual reduction in FBS content of the media (by 25% per day) 
was tested over 1 week prior to removal of FBS from the media.     
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Due to lack of viable cells after following these protocols, RNA extraction and 
cDNA synthesis were completed (see section 2.3.2), for Y-79 cells cultured in full 
medium only.
10.3.3 RNA extraction from human adult kidney tissues
Human kidney tissues used in this experiment were anonymised generous gifts 
from Dr Jane Collins (Senior Lecturer, IIR Division, Southampton University). Human 
adult kidney tissues included samples that had been retrieved at nephrectomy in 2 
patients with transitional cell carcinoma (TCC). Small biopsies of healthy renal medulla 
and cortex had been taken immediately by the investigating pathologist and stored in 
RNAlater® (Catalog# AM7020; Ambion®, Applied Biosystems, Warrington, UK). RNA 
extraction and cDNA synthesis were completed as detailed in section 2.3.2.
10.3.4 Imaging of cell lines during differentiation protocols
Imaging was performed on an inverted DM IRB microscope (Leica Microsystems 
UK Ltd, Milton Keynes, UK). The morphology of SHSY5Y and Y-79 cells is changed 
significantly by differentiation and so cells were viewed and photographed by direct 
microscopy at 10X and 20X magnification. Cell counting and measurement of cell death 
was performed using the haemocytometer method as described in section 2.4.4. 
Immunohistochemistry was performed as detailed in section 2.4.8. Monoclonal 
anti-neuronal Class III ß-Tubulin (TUJ1) had been created commercially by raising against 
microtubules derived from rat brain. It is well characterized and highly reactive to 
neuron specific Class III ß-tubulin (ßIII) but does not identify ß-tubulin found in glial cells. 
Conversely, monoclonal anti-Glial Fibrillary Acidic Protein (GFAP) had been commercially 
derived from the hybridoma produced by the fusion of mouse myeloma cells and 
splenocytes from an immunized mouse. Purified GFAP from pig spinal cord was used as 
the immunogen. Anti-GFAP is a specific marker of glial cells. 4',6-diamidino-2-
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phenylindole (DAPI) is a fluorescent stain which binds to DNA in live and fixed cells. It 
can be used to identify the nucleus of any cell type. 
Therefore, DAPI was used to identify all cells, staining with anti-TUJ1 was used to 
indicate cells which have undergone some degree of neuronal differentiation and 
staining with anti-GFAP would suggest that cells have retained some glial cell 
characteristics. 
10.3.5 Quantitative real time PCR protocol
Quantitative real-time PCR was performed to assess the relative abundance of 
human FRMD7 compared with 2 housekeeping genes; Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and Actin, beta (ACTB). The choice of these 2 housekeeping 
genes was based on their previous use in human tissues
243 and demonstration that their 
abundance is high and relatively similar in these tissues
242. The quantitative real-time-
PCR was carried out using one custom designed (FRMD7) and 2 off-the-shelf 
(housekeeping genes) PerfectProbe
TM assays (PrimerDesign Ltd, Southampton). These 
assays include predesigned primer pairs with a probe comprising a fluorogenic dye and 
quencher. The design of these probes is such that background noise is reduced but a 
strong target signal is received for the desired amplification product.
The control gene sequences are the intellectual property of PrimerDesign Ltd 
and are not available. The FRMD7 gene assay had a sense primer: agggttccagtttccgctat 
and an antisense primer: agatgggtaatgtttcctttcaaat with an amplimer size of 96bp. PCR 
reactions were performed in 100 well Gene-Discs (6001-012, Corbett Life Science, 
Brisbane, Australia) on the Rotor-Gene 
TM 6000 real time thermo-analyser (Corbett Life 
Science, Brisbane, Australia).  Each 20 µl reaction comprised: 5 µl of cDNA (at 
approximately 50ng/ul), 1 µl of Perfectprobe/primer mix, 10 µl of PrimerDesign 2X 
Precision
TM MasterMix and 4 µl PCR-Grade water. PrimerDesign 2X Precision
TM 
MasterMix is a pre-prepared/optimized mastermix containing 2X reaction buffer, 0.025 
U/ µl  of a chemical Hotstart Taq, 5 mM MgCl2 and DNTP mix (200 µM each dNTP). 
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The Rotor Gene run settings were according to the standard protocol suggested 
for Perfectprobe qPCR assays by PrimerDesign. Briefly, the two-step amplification 
conditions were: enzyme activation for 10min at 95°C, followed by 45 cycles of: 15 
seconds denaturation at 95°C, 30 seconds annealing at 50°C and extension at 72°C for 
15 seconds with fluorescence data collection at the end of the annealing step. Each 
different tissue/time-point was represented by 2 separate samples and all samples were 
run in duplicate with duplicate water controls (cDNA replaced by water).
10.3.6 Data analysis methods
Results were analysed using the delta-delta CT method
245 as described in Chapter 
10. The Validation of the delta-delta CT methodology for use with the Perfectprobe 
assays is provided during their manufacture by Primerdesign Ltd. Each of these assays 
has been tested for PCR efficiency during production and validation using a linear 
regression analysis method at the point of exponential fluorescence change and all 
assays are guaranteed to have PCR efficiency close to 100%. However, to test this claim, 
a standard curve analysis was performed for all 3 probe assays as described in Chapter 
910. 
10.4 Results
10.4.1 Differentiation of SHSY5Y cells
Neither the β-NGF or the cAMP protocols resulted in differentiation of SHSY5Y 
cells into a morphologically distinct phenotype. Despite altering all parameters including 
exposure time, exposure concentration and addition of FK506, no change in cell 
morphology was observed when viewed on an inverted stage microscope at 24 hours, 3 
days, 7 days and 10 days. Conversely, differentiation with all-trans retinoic acid was 
readily achieved and significant morphological changes were seen after just 24 hours of 
exposure.
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Figure 39 Differentiation of SHSY5Y cells. 
Cells imaged with an inverted stage microscope (20x magnification) at 24 hours, 3 days, 7 days 
an 10 days. A scale bar is presented in each image.
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It can be seen that SHSY5Y cells 24 hours after plating have a rounded 
appearance with short neurite extensions.  With no treatment, the NGF protocol, or 
indeed with any of the differentiation protocols besides all-trans retinoic acid, cells 
tended to extend neuritis over the 10 day period at a constant rate. After 10 days these 
cells have adopted a flatter, longer morphology with numerous neurite extensions. With 
all-trans retinoic acid, cells adopt this appearance as early as 24 hours after initial 
exposure and by day 10 have significantly flatter, longer morphology than controls with 
longer and more numerous neurite extensions. In addition they tended to form fewer 
cell clusters than untreated cells. For comparison, Figure 40 shows the typical 
morphology of SHSY5Y cells following either no treatment or the all-trans retinoic acid 
protocol after 24 hours and  Figure 41 shows these cells after 10 days. To highlight the 
neurite extensions, in Figure 41 the images were captured whilst focussing the camera 
at a lower level in each well. Cell bodies and extensions appear darker for this reason.
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Figure 40 Morphology of SHSY5Y cells after 24 hours of differentiation
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Figure 41 Morphology of SHSY5Y cells after 10 days of differentiation
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10.4.2 Immunohistochemistry results
As details previously, anti-TUJ1 (Green fluorescence) was used to indicate cells 
which have undergone some degree of neuronal differentiation and staining with anti-
GFAP (Red fluorescence) would suggest that cells have retained some glial cell 
characteristics. DAPI (Blue fluorescence) was employed to identify all cell nuclei. 
Immunohistochensitry was performed after 10 days of all-trans retinoic acid 
differentiation. Controls included cells cultured without all-trans retinoic acid and 
immunofluorescence control wells which had undergone the standard 
immunohistochemical protocol but without a primary antibody (to exclude non-specific 
secondary antibody binding). 
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Figure 42 Immunostaining of differentiated and undifferentiated SHSY5Y cells. 
SHSY5Y cells are shown having undergone differentiation for 10 days with all-trans retinoic acid. 
Cells were viewed on a fluorescent inverted stage microscope. Immunohistochemistry was 
performed using anti-TUJ1 (Green fluorescence), anti-GFAP (Red fluorescence) and DAPI (Blue 
fluorescence).
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Anti-GFAP staining was non-specific in all assays. Both undifferentiated and 
differentiated cells exhibited significant anti-TUJ1 staining. DAPI successfully stained cell 
nuclei. The ‘no primary control’ wells showed no fluorescence with either antibody but 
good nuclear staining with DAPI suggesting that fluorescence in other wells was specific. 
These results suggested that the SHSY5Y cells already had a strongly neuronal 
phenotype prior to any differentiation protocols. 
10.4.3 Differentiation of Y-79 cells
Differentiation of Y-79 cells was not achieved. Despite varying the serum free 
growth media and slowly reducing the serum content of the media, it was not possible 
to culture cells without serum for greater than 3 days. Cell death occurred quickly such 
that after 1 week, less than 0.001% cells remained. Applying the differentiation protocol 
to cells grown in medium containing serum resulted in no changes in cell morphology.
Figure 43 Differentiation of Y79 cells.  
Cells imaged with an inverted stage microscope (10x magnification) after 10 days of culture in 
medium with full serum, in 6 well plates pre-coated with poly-l-lysine, either with or without 
lamanin (20 µg/ml).
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It can be seen that cells cultured in medium containing serum for 10 days had 
similar morphology regardless of lamanin inclusion in the medium. A very small minority 
of cells produce neurite like extensions regardless of alterations in the protocol as 
detailed previously. Interestingly, after 2 vigorous washes of any of these plates the cells 
with neurite like extensions tended to remain in the wells to a great extent than the 
other cells, perhaps due to better adhesion. However, these cells were extremely sparse 
and only 15-20 cells were seen in each well.
In summary, differentiation or a change in morphology was not achieved for this 
cell line.
10.4.4 Relative expression in SHSY5Y and Y-79 cells
To confirm the viability of the delta-delta CT method of analysis for expression 
data, calibration curves were completed for each of the three gene assays (GAPDH and 
ACTB control genes and the FRMD7 gene of interest). Due to low expression of the 
FRMD7 gene, an oligonucleotide template was purchased and serially diluted as for the 
cDNA template used for the other 2 assays.
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Figure 44 Standard curves for the human probe based qPCR assays.  
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Standard curves are presented for GAPDH, ACTB and FRMD7 by plotting CT values against 
template concentration on a log scale. The correlation coefficient (R^2), slope of the curve (M) 
and PCR -efficiency (efficiency) are also presented.
It can be seen in that for all three assays, the PCR efficiency is close to 1 and that 
the R^2 value is greater than 0.99. This confirmed that the assays were very close to 
100% efficient over a broad range in target gene copy number and that the delta-delta 
CT method of analysis was appropriate.
All samples were run by the quantitative PCR methodology detailed previously 
on a series of 4 runs. Water controls and rt- controls were run for all experiments to 
confirm the specificity of the PCR assays. In all runs these controls either showed no 
amplification or amplification  at greater than 4 cycles below the lowest cDNA sample. 
Each tissue/time-point was represented by 2 separately prepared cDNA samples which 
were in turn run in duplicate such that each tissue/time-point was represented by four 
wells. Calculation of the relative expression of FRMD7 was performed by the delta-delta 
CT method described in section 9.2.3. An example of the calculation method is shown in 
Table 13.


















for 1 week GAPDH 18.7
SHSY5Y sample 1
Full media 










for 1 week GAPDH 21.42
SHSY5Y sample 2
Full media 
for 1 week ACTB 25.38
SHSY5Y sample 1 Full media +  FRMD 38.45 17.275 -1.665 0.32
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NGF for 1 
week 7
SHSY5Y sample 1
Full media + 
NGF for 1 
week GAPDH 19.75
SHSY5Y sample 1
Full media + 
NGF for 1 
week ACTB 22.6
SHSY5Y sample 2
Full media + 







Full media + 
NGF for 1 
week GAPDH 20.01
SHSY5Y sample 2
Full media + 
NGF for 1 
week ACTB 21.23
Table 13 An example of the method for analysis of comparative expression levels. 
A sample of the spreadsheet calculation of the relative expression of FRMD7 mRNA in 
the SHSY5Y cell line after 1 week of in vitro culture in medium with/without Nerve 
Growth Factor (βNGF) at 100ng/ml.
Using this method a comparative expression level was calculated for all samples 
relative to that of the SHSY5Y cells following culture in full serum alone media for 1 
week. Results are shown in Figure 45.
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(c) 
Label Cells Description
A SHSY5Y Full FBS media for 1 week
B SHSY5Y 1/2 FBS media for 1 week
C SHSY5Y Neurobasal media for 1 week
D SHSY5Y no FBS media for 3/7
E SHSY5Y Full FBS media + NGF for 1 week
F SHSY5Y Full FBS media +NGF+ FK801 for 1 week
G SHSY5Y Full FBS media +CAMP for 1 week
H SHSY5Y 1/2 FBS media + NGF for 1 week
I SHSY5Y 1/2 FBS media +NGF+FK801 for 1 week
J SHSY5Y 1/2 FBS media + cAMP for 1 week
K SHSY5Y no FBS media + NGF for 3/7
L SHSY5Y no FBS media +NGF+FK801 for 3/7
M SHSY5Y no FBS media cAMP for 3/7
N SHSY5Y with full FBS media + Retinoic acid for 24 hours
O SHSY5Y with full FBS media + Retinoic acid for 48 hours
P SHSY5Y with full FBS media + Retinoic acid for 3/7
Q SHSY5Y with full FBS media + Retinoic acid for 1 week
R SHSY5Y with full FBS media + Retinoic acid for 10/7
S Y79 with full FBS media for 1 week
T HK1 medulla human adult kidney medulla
U HK1 cortex human adult kidney cortex
Figure 45 Relative expression of FRMD7  in 3 tissues.
Relative expression values for FRMD7 mRNA are shown for the SHSY5Y cell line relative to the two 
housekeeping genes GAPDH and ACTB. Results are shown as comparative expression levels to cells grown 
in full standard media for 1 week (a). Relative expression values for FRMD7 mRNA are shown for the Y-79 
cell lines and human adult kidney tissues relative to the SHSY5Y cell line grown in full standard media for 1 
week (b). A key legend is provided for all samples (c). Error bars represent the standard deviation (SD).
The results above demonstrate that the variation in expression levels for FRMD7 
mRNA for the SHSY5Y cell line were very small. Despite a variety of differentiation 
protocols, very little change in the low levels of expression were found. The expression 
pattern for SHSY5Y cells during the all-trans retinoic acid differentiation protocol 
(samples N-R in Figure 45) shows a slow increase until day 10. Expression levels in the Y-
79 cell line were also low. Interestingly, human adult kidney samples show a significantly 
higher expression level in both medulla and cortex samples which can be seen in 
comparison to the SHSY5Y cell line sample in Figure 45b.
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10.5 Discussion
The results presented above show that in all tissues studies thus far, FRMD7 
mRNA expression is low. This is consistent with previous expression work
159. All relative 
expression calculations were therefore based on the comparison of a very low level of 
FRMD7 expression with the significantly higher expression of housekeeping genes. 
Differentiation assays were tested and altered using various parameters but the 
only clear change in cell morphology was achieved using all-trans retinoic acid with the 
SHSY5Y cell line. However, a rigorous morphology assessment was not employed and it 
is conceivable that subtle morphological changes reflecting differentiation of the cells 
may have been overlooked. For example, some groups have employed rigorous 
counting and measuring of neurite number, branching and interconnection
249;255. Others 
have advocated fully automated image capture and analysis using multichannel 
fluorescent immunohistochemical techniques
248. Therefore, it is possible that these 
protocols did induce some differentiation. This is why cells from each differentiation 
assay, regardless of morphological changes, were studied for changes in FRMD7 
expression levels. 
It is apparent that no significant change in FRMD7 expression occurred in either 
cell line during attempted differentiation. All changes in expression level were very small 
and likely within the margin of error for this methodology on a low copy number mRNA. 
Disappointingly, this shows that neither cell line, using the methods described, provides 
a good model for understanding the molecular biology of the FRMD7 gene product due 
to the consistently low copy number of the mRNA.
Interestingly, as illustrated in Figure 45b, the relative expression of FRMD7 is 
significantly higher in the human adult kidney samples. Expression appears to be over 
150 times greater than in either the SHSY5Y or Y-79 cell lines which is in keeping with 
the previous observation that the human adult kidney expresses this gene in higher 
abundance than most other tissues tested
159. However, expression in this tissue was 
calculated relative to the GAPDH and ACTB housekeeping genes and in comparison to 
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expression in the SHSY5Y neuroblastoma cell line. It is important to note that although 
the chosen housekeeping genes have been used extensively in multiple tissues, 
expression can vary between tissue types
261. Therefore, direct comparison of differing 
tissues should be interpreted with caution although averaging 2 housekeeping genes 
reduces this confounding effect.
The work detailed in this chapter has demonstrated that FRMD7 expression is 
low in 2 cell lines which are commonly used for models of neurite growth / extension 
and ocular development. Therefore, neither of these cell lines represents a good 
opportunity for the study of FRMD7 gene function using the current differentiation 
protocols. This work has also confirmed that expression of this gene is significantly 
greater in human adult kidney samples, suggesting a potential role for cells derived from 
these tissues in the study of FRMD7. Assays and protocols for the rapid assessment and 
analysis of expression levels for the FRMD7 mRNA have been optimised and refined 
during this study.
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11 CHAPTER ELEVEN – Final Discussion
11.1 Thesis summary
The work presented in this thesis has contributed to the recent advances in 
understanding Congenital Idiopathic Nystagmus (CIN). My early work in this project 
showed the variability in phenotype and necessity for detailed investigation of CIN 
pedigrees
38;132. Subsequently, I refined the genetic locus for this disease significantly on 
the X chromosome by linkage analysis
38. After collection of a large cohort of CIN cases I 
quantified the contribution of a newly identified nystagmus gene (FRMD7) to CIN, 
identified a novel mutation in this gene and provided the first detailed phenotype 
genotype correlation for a mutation in this gene
239. This work illustrated the small 
contribution of FRMD7 mutations to sporadic cases of CIN and illustrated the likely 
presence of other significant nystagmus genes or parts/regulatory elements of the 
FRMD7 gene.  I also investigated skewed X-inactivation and variable penetrance in 
female carriers of FRMD7 mutations and identified a possible role for skewed X-
inactivation in these families
239. Additionally, I identified a novel mutation in the 
CACNA1A gene which causes apparent isolated congenital nystagmus until the onset of 
subtle cerebellar ataxia after the age of 30
262. This has shown that mutations in this gene 
can cause variable phenotypes and that apparent congenital nystagmus may be a 
prelude to cerebellar disease in some patients. Furthermore, I have performed the first 
detailed study of FRMD7 mRNA expression by RT-PCR in murine brain heart and lung 
during development
263. This work has shown low levels of expression of this gene in all 
tissues tested with a peak at ED18 in brain suggesting a possible role for this gene in 
synapse formation/function and axon growth and guidance. A final preliminary study of 
FRMD7 expression in human tissues has showed the low levels of expression of this 
gene in human neuronal cell lines and no significant changes in expression during 
neurite extension and growth of the SHSY5Y cell line. Furthermore, this study showed 
that human adult kidney samples show the highest levels of FRMD7 expression of any 
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tissue tested so far. This has suggested that kidney derived cells may represent a 
promising opportunity for initial investigations into FRMD7 gene expression and 
function.
This work has been timely and has incorporated many different avenues of 
nystagmus research. It has been completed at a time of renewed interest in 
understanding the underlying pathophysiology of anomalous eye movements. Much of 
my work has been hypothesis-generating and has provided preliminary information 
which is allowing us, and other groups to pursue further work with the common goals of 
understanding the underlying mechanisms of eye movement control and their 
malfunction. Also, to understand the role and pathophysiology of the FRMD7 gene with 
the potential to identify novel treatment and diagnostic modalities in the future.
11.2 Future work
Due to recent advances in the field of nystagmus research, including the 
discovery of the FRMD7 gene in 2006, many new avenues of study have opened up 
during the tenure of this PhD project. The following sections describe some of these 
avenues and illustrate the work which is continuing in our group.
11.2.1 Clinical and genetics studies
 My resent work and that by others has illustrated the necessity of accurate and 
detailed phenotyping of nystagmus patients to allow the study of homogeneous 
subgroups of patients who have the greatest likelihood of similar underlying 
pathophysiologys. In a recent investigation of the phenotype of CIN patients with and 
without FRMD7 mutations, the FRMD7 mutant subgroup had a significantly lower 
number of subjects with pronounced head turn and, correspondingly, had relatively 
smaller nystagmus amplitudes in the primary position of gaze
264. I have also noted 
previously that patients with different classes of FRMD7 mutations seem to exhibit 
greater or lesser penetrance rates in female carriers
265. It is therefore clear that further 
work is needed to investigate the phenotype/genotype correlation between mutations 
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in FRMD7 (and other genes under current investigation) and phenotype to include; 
penetrance in female carriers, X-inactivation, age of onset of the disease and detailed 
clinical characteristics such as head turns and null points. It is likely that this work will 
shed light on possible molecular mechanisms occurring in this disease and also the 
efficacy of diagnostic techniques and genetic counselling. 
The work presented in chapter 6, and that of others has suggested the existence 
of other nystagmus genes and the strong possibility of mutations in other, as yet 
unidentified parts of the FRMD7 gene
159;239;239;265. This is supported by the pedigrees for 
which we (unpublished work) and Tarpey et al have found linkage to the FRMD7 locus 
but no mutations in the currently known exons of that gene. Therefore, if these sites 
were identified and characterised, they would provide strong candidates for the 
identification of additional nystagmus causing mutations. Furthermore, the full extent of 
the contribution of mutations affecting the FRMD7 gene product could be assessed. 
Identification of regulatory sites and potential promoters is complex. Many indicators 
can be used to identify such sequences, for example; CpG islands
266 and evolutionary 
conservation
267. Several papers have associated these conserved regions with regulatory 
sites
268  and generally the assumption seems valid that evolutionary conservation of 
non-coding DNA sequence is due to conservation of regulatory DNA including 
transcription factor binding sites
267. Furthermore, many algorithms have been developed 
to combine multiple factors and motifs to identify sequence which have a high statistical 
chance of containing regulatory sites. Using these tools I have performed a detailed in 
silico bioinformatic mining study of the genetic sequence surrounding the FRMD7 gene 
to highlight any potential regions which contain additional exons, promoters and other 
regulatory elements (unpublished work). This was achieved by annotating the genomic 
sequence of FRMD7 and 5kb of flanking region at the 3 and 5-prime ends. The sequence 
was annotated with information derived from 46 separate algorithms designed to locate 
any one, or combination of features/motifs including; exapted conserved non-exonic 
elements, homology with known regulatory elements in 7 species, transcription factor 
binding sites in 3 species, RNA secondary structure prediction, predicted alternative 
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conserved exons, evolutionary conservation across 28 species, homology with known 
promoter sequences, CpG islands and Predicted Start and stop codon sequences. Known 
FRMD7 exons were identified by multiple algorithms illustrating the power of this 
method of combined data mining (see Figure 46). This work has yielded some very 
exciting preliminary data. I have identified a strong candidate promoter region close to 
the transcription start site of FRMD7 which was identified as putative promoter 
sequence by 18 separate algorithms but could also represent an additional alternatively 
spliced/untranslated exon: 
Figure 46 Annotation of the FRMD7 gene sequence.
A screen shot from SeqBuilder module of the Lasergene 6 DNA & Protein Sequence Analysis 
suite (DNASTAR, Inc., Madison, USA)). An illustration of evidence for exon 1 and for the putative 
promoter region (which includes; conservation, 5 exon prediction algorithms, cross-species 
identification exons , multiple transcription factor binding sites, a predicted conserved 
transcription factor binding site, and a region identified as highly likely of having regulatory 
potential by the ESPERR Regulatory Potential algorithm and cross reference with 7 other 
species).
Similarly, a number of intra-intronic regions were identified which have some 
evidence to suggest that they may contain additional, alternatively spliced/untranslated 
exons. It is hoped that investigation of these regions of the FRMD7 gene will identify 
new sites in which nystagmus causing mutations may occur (thus increasing the yield of 
FRMD7 gene screening in CIN) and provide information about the regulation, 
transcription and alternative splicing of this gene. This work has been planned and it is 
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hoped that it will begin within the next year. We will investigate these regions using 
dual-reporter Luciferase assays and the pGL-3 vector series (Promega) using methods 
which have been previously described
269;270. In brief, we will design PCR primers to 
amplify putative regulatory sequence from genomic DNA in amplimers up to 1kb in 
length. These fragments will be cloned into vectors from the pGL-3 series as follows: the 
pGL3-enhanser vector that lacks an internal promoter and will be used to test for 
promoter activity, the pGL3-promoter vector which lacks an internal enhancer and will 
be used to test sequences for enhancer or silencer activity, the pGL3-control vector that 
contains both internal promoter and enhancer elements which will be used as a positive 
control and an additional test for repressor activity and the pGL3-basic vector with 
neither internal promoter nor internal enhancer element which will be used as a 
negative control and to examine sequence for core promoter activity (when indicated). 
All the vectors will be sequenced to exclude additional point mutations acquired during 
the PCR and cloning process. These vectors will subsequently be co-transfected into a 
number of cell lines available in our laboratory (initially SHSY5Y, PC12 and Y-79 cells) 
with the Renilla luciferase-containing pRL-TK control plasmid (Promega) using the 
FuGENE6 Lipofectamine Reagent (Roche). After 24 hours, cell lysates will be prepared 
from each transfected culture and transferred to 96-well microtiter plates. The firefly 
and Renilla luciferase activities will be analyzed in our 96-well plate luminometer with 
Doc-It
RLS  software (UVP) according to the manufacturer’s protocol. The activity of each 
promoter sequence will be assessed by normalising the firefly luciferase fluorescence to 
that of the renilla luciferase fluorescence for each sample (to control for transfection 
efficiencies) and comparing with control samples. Sequences with evident promoter, or 
other regulatory activity will then be prioritised for further study using the same 
methodologies to identify the functional regulatory elements by serial deletions of the 
initial transfected sequence. Any sequence of a suitable size, with regulatory activity will 
be prioritised for mutation scanning by direct sequencing. 
During the course of this study I have collected and expanded my nystagmus 
cohort significantly. Currently the cohort includes 31 probands which are either sporadic 
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cases or part of an X-linked pedigree, which have not been screened for FRMD7 
mutations. Following the initial studies detailed above we hope to screen all these 
probands for mutations in the FRMD7 gene and the additional promoter/regulatory 
sequences by direct sequencing.
Skewed X-inactivation, (significant deviation away from the expected 50:50 
contribution of each X chromosome in females) has been described in various ocular 
diseases 
186;188 and may explain why X-linked nystagmus pedigrees with FRMD7 
mutations have shown such varied inheritance patterns
38;104;159;178. Many X-linked 
disorders do not fit classical dominant or recessive modes of inheritance and it is known 
that X-linked genes can cause partial cell selection and incompletely skewed X-
inactivation
192. The vast majority of genes on the long arm of the X chromosome are 
subject to X-inactivation, including those immediately flanking FRMD7: MST4, MBNL3 
and RAP2C 
27 and since genes which are subject to, or escape from, X-inactivation tend 
to be clustered into domains, it is very likely that FRMD7 is inactivated. We have tested 
the hypothesis that Skewed X-inactivation is responsible for the variable penetrance in 
X-linked CIN pedigrees by performing 2 X-inactivation assays in a large X-linked CIN 
pedigree (see chapter 7). Results showed a significant overall excess of skewing in this 
pedigree (10 of 16 females including 3 with >95% skewing)
239. Recently, Kaplan et al 
replicated our findings by describing a significantly increased susceptibility to skewed X-
inactivation in affected females in a large CIN pedigree with a missense FRMD7 
mutation
190. This preliminary work has provided the first exciting evidence to suggest 
that X-inactivation contributes to variable phenotype in CIN pedigrees and that more 
detailed studies are warranted. It is hoped that such studies will provide clinically useful 
information and also provide insights into the pathogenic mechanisms of FRMD7 
mutations including gain or loss of function effects. To build on this exciting work we 
would like to contrast X-inactivation patterns in hair and lymphocyte derived DNA, run 3 
different assays to ensure maximum information in 7 pedigrees and design a novel assay 
to look directly at inactivation of the FRMD7 gene. In brief: we would like to extract DNA 
from scalp hair root samples for one pedigree (in the first instance)  because it has been 
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postulated that the X-inactivation pattern in the brain and retina (where FRMD7 is most 
likely expressed) is possibly replicated in hair root follicles due to their common 
ectodermal origin during embryonic
 development
271;272. We would then use 3 X-
inactivation assays, 2 of which we have used before (HUMAR
24 and ZNF261
187) and one 
which utilizes a region closer to the FRMD7 gene than the previous assays (FMR1 
assay
273). These assays will be used to asses the difference in X-inactivation pattern 
between hair follicle and lymphocyte derived DNA in one large family. If differences 
exist, hair follicle samples will be collected from 6 additional families and used for 
further analysis. We hope to identify and characterise the promoter of FRMD7 (as 
detailed above) which will provide the exciting possibility of designing a novel X-
inactivation assay(s) to directly study inactivation of the FRMD7 gene. This novel 
assay(s) will be designed following identification of the FRMD7 promoter and run 
initially to definitively answer the question of whether FRMD7 is inactivated and then to 
assess the precise X-inactivation pattern in affected females and female carriers from all 
7 CIN pedigrees. The resulting data will allow us to: determine whether FRMD7 
undergoes X-inactivation, look for a correlation between X-inactivation and penetrance 
in FRMD7 mutant CIN pedigrees and elucidate the potential role of X-inactivation in the 
pathology of CIN and whether this is dependant on the class of FRMD7 mutation or not.
Mutations in the Ocular Albinism Type 1 gene (OA1, or GPR143, OMIM 300500) 
causes a form of X-linked ocular albinism
274. In many cases the most prominent feature 
of the phenotype is nystagmus. Additional features such as iris transillumination, foveal 
hypoplasia and retinal hypopigmentation are only identified when specifically saught
275. 
Abnormal optic nerve fibre decussation at the optic chiasm is also found in these 
patients but can only be identified by electrophysiological testing with Visual Evoked 
Potentials (VEPs). Many families with OA1 mutations have been described in whom 
nystagmus is the only clinical finding even when extensively examined by slitlamp bio-
microscopy. These families have been described and published as ‘congenital 
nystagmus’ pedigrees with novel OA1 mutations
276;277. However, electrodiagnostic 
testing was not always presented for these cases and it seems likely that crossed 
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asymmetry may have been demonstrated if VEPs had been performed. This illustrates 
two interesting points. Firstly, without any electrodiagnostic testing it is difficult to 
exclude OA1 in male patients with nystagmus.  Secondly, description of these pedigrees 
as ‘Congenital Nystagmus’ is misleading especially when a mutation in the OA1 gene has 
been identified, therefore these families arguably represent a phenotypic variation of 
ocular albinism type 1. Using MRI, Schmitz et al. (2003) found that the abnormal 
decussation at the optic chiasm in OA1 was identical to that found in tyrosinase gene-
related OCA1 (203100) and  P gene(611409)-related OCA2 (203200). He later showed 
that the misrouting was due to changes in cell cycle regulation in the developing retina 
which is in part controlled by melanin
278. Therefore, lack of pigment in the developing 
eye and visual pathways is responsible for the crossed asymmetry in albinism 
irrespective of the causative gene mutation. As has been detailed above, mutations in 
the OA1 gene can cause extremely variable pigmentation levels in the eye. It is possible 
that nystagmus develops independently of the chasmal routing process and therefore 
conceivable that some patients may exist in whom nystagmus has occurred due to an 
OA1 mutation but in whom abnormal chiasmal decussation has not occurred. These 
patients would be likely to be those with the greatest amount of visible ocular 
pigmentation and would therefore be diagnosed as CIN due to a normal clinical and 
electrodiagnostic examination. The OA1 gene is a relatively small, 8 exon gene which is 
therefore quite amenable to direct sequencing on individual patients. Perhaps this gene 
represents a reasonable candidate for an ‘apparent congenital nystagmus’ gene. 
Therefore, it may be fruitful to screen my cohort of clinically and electrophysiological 
examined, FRMD7 negative patients for mutations in this gene. 
Other potential nystagmus genes have been identified by recent work. The 
FRMD7 gene is a member of the protein 4,1 superfamily and contains 2 domains (B41 
and FERM-C) around which all the identified mutations in CIN have clustered
159 (see ). 
Two other members of the protein 4.1 superfamily show significant homology, 
particularly to these domains of the FRMD7 gene. These are FARP1 (FERM, RhoGEF 
(ARHGEF) and pleckstrin domain protein 1 (chondrocyte-derived)) and FARP2 (FERM, 
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RhoGEF and pleckstrin domain protein 2). The FARP1 gene on chromosome 13 is also 
located within the interval identified for a family with an unknown familial vestibulo-
cerebellar disorder
279 with predominant nystagmus phenotype. The FARP2 gene on 
chromosome 2  is also known to alter neurite length and degree of sprouting in rat 
embryonic cortical neurones when over-expressed
184;185 and thus has a function relevant 
to the nystagmus phenotype. Additionally, other potential nystagmus genes are likely to 
be identified by functional studies of FRMD7 including protein-protein interactions and 
co-expression studies. All these genes may be used by future studies to identify novel 
mutations which may cause CIN.
11.2.2 Understanding the function of FRMD7 
In chapters 9 and 10 I have detailed some interesting preliminary studies of 
FRMD7 expression. I now have 3 custom designed FRMD7 monoclonal antibodies which 
have been delivered with the corresponding hybridoma cell lines to allow continued 
antibody production. This exciting resource will allow a more detailed study of spatial 
tissue expression patterns for the FRMD7 transcript and also characterisation of sub-
cellular expression. These antibodies have not been used and will require various 
preliminary test to evaluate their specificity and optimal experimental protocols. 
Initially, we plan to study protein extract from human adult kidney samples by both 
direct Immunostaining at various antibody concentrations and also using a western blot. 
Furthermore, the initial antigen was chosen for its homology between human, rat and 
mouse FRMD7 protein. Therefore, it will be necessary to identify which of these species 
it will be possible to use for these studies. The results of these preliminary experiments 
will largely dictate the subsequent work but it is hoped that we will be able to utilize our 
resource of wax embedded murine embryo samples, human foetal tissue, fresh adult rat 
brain and ocular tissue and human donor eye tissue. We hope to characterise the 
expression of the FRMD7 protein and identify potential binding partners and sites of 
function. These studies will help to; identify where and when the FRMD7 protein is 
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functioning, identify good models for further siRNA knockdown experiments, identify 
novel putative nystagmus genes, unravel some of the details of eye movement control, 
and even identify potential sites of therapeutic intervention. 
An additional resource which is likely to become available within 2 years is an 
FRMD7 knockout mouse. In early 2007 I nominated the murine FRMD7, FARP1 and 
FARP2 genes for knockout via the NIH backed Knockout Mouse Project (KOMP) which 
aims to ‘generate a public resource of mouse embryonic stem (ES) cells containing a null 
mutation in every gene in the mouse genome’ 
(http://www.nih.gov/science/models/mouse/knockout/). Subsequently, the FRMD7 and 
FARP2 genes were selected out of 17,350 genes for priority targeting and the 
development of knockout ES cells is currently underway. The ES cells will be available to 
the authors on completion which is anticipated to be in early 2009. Subsequently, the 
KOMP repository will create mice from the ES cells for individual researchers on request. 
Supply of pups following recovery from cryo-preserved ES cell lines has an anticipated 
cost of approximately £3500 with an estimated 6-9 months production time depending 
on ES implantation and pup generation (information from direct correspondence with 
Dr. Colin Fletcher, Program Director, Knock Out Mouse Program (KOMP)). All 
Experiments will be carried out in accordance with the European Communities Council 
Directive of 24 November 1986 (86/609/EEC) and under a personal animal license 
(No.PIL504b) held by Dr Thompson.
When the KOMP generated FRMD7 mouse knockout is received will use our local 
expertise and experience with organotypic murine brain slice cultures and in vitro 
analysis of brain sections to investigate the anatomical and physiological anomalies in 
these animals. The knockout of any gene is potentially embryologically lethal. It seems 
unlikely that this is the case with FRMD7 as it is not lethal in humans who are 
hemizygous for truncating mutations resulting in no detectable FRMD7 protein 
expression in peripheral blood
159. However, should this be this case, aborted foetuses 
could be studies by similar techniques. Ocular and neuroanatomical comparisons will be 
performed by light microscopy of simple wax embedded whole brain, visual pathway 
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and eye sections from the knockout and control wildtype mice. Similarly, investigation 
of cell type and distribution (as directed by the aforementioned immunohistochemical 
protein expression profiles) will we performed by identification of cell markers by simple 
staining and fluorescent labelled antibody assays used routinely in our laboratory. These 
initial anatomical/histological studies will direct further work. For example, to study 
neuroanatomical changes in more detail, neuronal cell distribution could be determined 
by thionin-staining (a Nissl stain) followed by a more specific investigation of changes in 
synaptic connectivity using antibodies against pre- and post-synaptic proteins, markers 
of axonal and dendrite morphology and specific markers of glutamatergic and 
GABAergic pathways (including vesicular transporter proteins and receptor subunits). 
Organotypic murine brain slice cultures preserve intact neuronal circuitry. This 
feature can be exploited to look for neural pathway anomalies in these animals by 
performing in vitro electrophysiological assessment of the optic pathways and the 
cerebellum. Again,  these investigations will be directed by initial neuro-anatomical 
studies and may include direct techniques such as stimulus evoked inhibition of 
spontaneous purkinje cell firing in the cerebellum.
11.2.3 Summary of future work
This project and the resent work of other groups has provided a broad platform 
for further study in the field of nystagmus research. Many avenues of clinical, genetic 
and molecular biological study have been created and are becoming ever more possible 
with the arrival of specific antibodies and even a mouse knockout model. It is likely that 
within the next 5 years, significant advances in the understanding of the development of 
the oculo-motor control pathways will take place. Along with genotype/phenotype 
correlations, clinical studies and a greater understanding of the contribution of genetics 
to nystagmus it is hoped that novel diagnostic and therapeutic opportunities will be 
found for nystagmus patients. Furthermore, as nystagmus forms a part of many 
different disorders, it is likely that a by-product of this work will be a greater 
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understanding of some of these disorders at the molecular level possibly even the 
development of novel treatments.
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